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SUMMARY 
Thyroid cancer, the most common endocrine malignancy has a rising incidence worldwide. 
Radiation damage is a known aetiological factor in thyroid tumourigenesis, particularly in 
children. Pituitary tumor transforming gene (PTTG) and its binding partner (PTTG binding factor; 
PBF) are overexpressed in thyroid cancers. Critically, PTTG and PBF have been shown to be 
independent markers of poor prognosis in thyroid cancer.  Both PBF and PTTG have been shown 
to be tumourigenic in vivo. PTTG, a human securin, has multifunctional roles in mitotic control, 
DNA repair, apoptosis, cell transformation and genomic instability. PTTG null murine 
embryogenic fibroblasts demonstrate prolonged G2/M transition and aneuploidy. Overexpression 
of PTTG in MG63 osteosarcoma, H1299 lung cancer and HeLa cell lines induces aneuploidy. 
Additionally, PTTG binds and inhibits Ku70, a DNA repair protein involved in double-strand 
DNA breaks. PBF, which has independent tumourigenic and transforming actions, binds to PTTG, 
transports it to the nucleus and facilitates its actions within the nucleus. Taken together, the above 
implicate the functional role of PTTG and PBF in genetic instability. 
This thesis describes the generation of a transgenic murine model of thyroid cancer which 
overexpressed both human PTTG and human PBF in the thyroid gland (BI-Trans). The BI-Trans 
murine model developed goitres from a young age in both genders. Additionally, they develop 
thyroid adenomas at a later age, which had a female preponderance. Unexpectedly, this BI-Trans 
murine model did not develop cancers. We measured the index of genetic instability (GI) in the 
thyroids of our transgenic murine models with fluorescent inter-simple sequence repeat-PCR 
(FISSR-PCR). This technique was refined to measure GI with small quantities of DNA obtained 
from murine thyroids. Additionally, we identified target gene for further evaluation through 
microarray analysis to elucidate the mechanism by which PBF and PTTG induced genetic 
instability. 
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ABBREVIATIONS 
ATM    Ataxia telangiectasia mutated 
ATR pathway  Ataxia telangiectasia and Rad3-related pathway 
BI-Trans   Homozygote for both PBF and PTTG 
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BSA    Bovine serum albumin 
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GI    Genetic instability 
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hPBF    Human PTTG binding factor 
hPTTG   Human pituitary tumor transforming gene 1 
IR-    No radiation treatment 
IR +    Ionising radiation treatment 
PBF    human PTTG binding factor 
PBFHomo-PTTGHet PBF homozygote – PTTG1 heterozygote 
PBFHET-PTTGHET PBF heterozygote – PTTG1 heterozygote 
PBS    Phosphate buffered saline 
PBF-Tg   Homozygote murine model of PBF expression in the thyroid  
PCR    Polymerase chain reaction 
PMTC   Primary murine thyroid culture 
PTC    Papillary thyroid cancer 
PTTG +/-   Heterozygote for PTTG1 
PTTG +/+   Homozygote for PTTG1 
PTTG    Human pituitary tumor transforming gene 1 
Cdk    Cyclin dependent kinase 
MPF    Maturation promoting factor 
   
 
 
SDS    Sodium Dodecyl Sulfate 
SSB    Single strand break 
Trp53    p53 
TSH    Thyroid stimulating hormone 
MSI    Microsatellite instability 
VEGF    Vascular endothelial growth factor 
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1.1 THE THYROID GLAND 
1.1.1 Anatomy and physiology 
The thyroid gland, located in the neck is the largest endocrine organ. Embryologically, the thyroid 
gland originates in the foramen caecum at the junction of the anterior and posterior tongue and 
descends to its adult position by 7 weeks in the embryo (Kay and Goldsmith, 2010). The thyroid gland 
measures approximately 10 -30 g in an adult and increases in size during pregnancy (Dorion and 
Lemaire, 2008). Histologically, the thyroid gland consists of numerous follicles, each of  which is 
comprised of thyroid epithelial cells surrounding a globule of colloid (Krause, 2005).   
The main function of the thyroid gland is the production of thyroid hormone which is essential for 
energy metabolism, growth and maturation of tissue. The secretion of thyroid hormone from the 
thyroid gland is under the influence of thyroid stimulating hormone (TSH) which is produced in the 
anterior pituitary gland and secreted into the bloodstream. Circulating levels of TSH is in turn 
controlled by thyrotropin-releasing hormone (TRH) which is produced in the hypothalamus and 
transported via the superior hypophyseal artery to the anterior pituitary gland. The secretion of TRH 
and TSH is negatively regulated by high levels of circulating thyroid hormone (Yen, 2001). See Figure 
1-1. 
At a molecular level, TSH binds to the TSH receptor on the membrane of thyroid epithelial cells 
which leads to an increase in the stimulation of several thyroid genes including the sodium-iodide 
symporter (NIS), thyroglobulin and thyroid peroxidise which promote the biosynthesis of thyroid 
hormone (Yen, 2001).   
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Figure 1-1  Negative feedback loop of thyroid hormone regulation. 
 
1.1.2 Thyroid hormone biosynthesis 
Iodine, an essential component of thyroid hormone biosynthesis, is concentrated from the bloodstream 
by the thyroid gland. The ability of  thyroid epithelial cells to concentrate iodine lies within the 
sodium-iodide symporter (NIS) which sits on the basolateral membrane of the thyroid cell (Dohan et 
al., 2003). NIS is coupled to the Na-ATPase pump which generates the energy required to concentrate 
iodine against its natural gradient. At the apical part of the thyroid epithelial cell, the transporter 
pendrin drives iodine from the cytoplasm to the colloid. Iodine subsequently binds to the tyrosine 
residue of  thyroglobulin, a protein found within the colloid, in a reaction catalysed by the enzyme 
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thyroid peroxidise (TPO). This reaction produces mono-iodothyrosine (MIT) or di-iodothyrosine 
(DIT).  The combination of MIT with DIT results in the active triiodothyronine (T3) whilst DIT with 
DIT results in thyroxine (T4). See Figure 1.2. The products of the reaction catalysed by TPO, MIT, 
DIT, T3 and T4 are stored in the colloid of the thyroid follicle. During the secretion of thyroid 
hormone, MIT, DIT, T3 and T4 are internalised into the thyroid epithelial cell, undergoes proteolytic 
digestion to recapture MIT and DIT with the release of T3 and T4 into the bloodstream (Yen, 2001). 
 
 
Figure 1-2  The reactions in thyroid hormone biosynthesis catalysed by thyroid peroxidise 
(TPO). 
 
 
1.1.3 Thyroid hormone at the end-organ 
Thyroid hormone in the bloodstream can exist in a free active state or bound to protein such as 
thyroxine binding globulin (TBG) or albumin. It is the free, unbound T3 and T4 that enters target cells 
and generates a biological response. Overall, the ratio of  T3 to T4 in the bloodstream is approximately 
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1:20. The effect of T3  is about four times more potent at the end-organ compared to T4. End-organs 
convert T4 to the more active T3 by the enzyme iodothyronine deiodinase and is actively transported 
across the cell membrane by OATP 1C1, monocarboxylate transporter (MCT) 8 and MCT10 (Visser 
et al., 2011). T3 has a short half-life of 2.5 days compared to the half-life of T4 which is about 6.5 days.  
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1.2 THYROID CANCER 
1.2.1 Classification 
The vast majority of thyroid cancers are of the well-differentiated variety which comprises mainly 
papillary carcinoma (80 %) and follicular carcinoma (10 - 15 %). These well-differentiated tumour 
types arise from thyroid follicular cells. Poorly differentiated thyroid carcinomas such as anaplastic 
(ATC) tumours are rare (1 - 3 %) (Nagaiah et al., 2011) and are thought to arise de-novo or be a de-
differentiation progression of well-differentiated thyroid carcinoma (Smallridge et al., 2009). Hurtle 
cell carcinoma, characterized by the presence of oncocytes rich in mitochondria, is considered a 
subtype of follicular carcinoma of the thyroid gland. 
Medullary carcinoma (5%) of the thyroid, a completely separate aetiological entity, arises from the 
parafollicular C-cells of the thyroid gland. Parafollicular C-cells of the thyroid are involved in the 
secretion of calcitonin, a hormone related to calcium homeostasis. Calcitonin reduces calcium levels 
by reducing resorption of calcium in the kidneys, inhibiting the activity of osteoclasts, stimulating 
osteoblastic activity and inhibits calcium resorption in the intestines. Another type of thyroid cancer, 
primary lymhoma of the thyroid gland, is not common and is associated with Hashimoto’s disease of 
the thyroid (Kato et al., 1985). The molecular mechanism by which primary lymphoma of the thyroid 
gland develops in Hashimoto’s disease of the thyroid is not understood. Hashimoto’s disease is an 
autoimmune condition causing chronic lymphocytic thyroiditis leading to an underactive thyroid 
gland. Patients with this condition may have high autoantibody titres to thyroid peroxidise, 
thyroglobulin or TSH receptor. For the purpose of this thesis, DTC refers to the common papillary and 
follicular carcinomas of the thyroid. 
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1.2.2 Epidemiology 
Thyroid cancer has an incidence of 3.23 cases per 100,000 per year in the the UK. This incidence rate 
is increasing as shown in Figure 1-3 (Cancer Research UK, 2014). The increasing rate of thyroid 
cancer, documented over 30 years across 5 continents, showed an average increase of 67% in females 
and 48% in males (Peterson et al., 2012). This increase has been attributed in part to the early 
detection of small tumours (“incidentalomas”) on neck scanning for other non-thyroid related 
conditions (Leenhardt et al., 2004, American Thyroid Association Guidelines Taskforce on Thyroid et 
al., 2009). The increasing trend in the detection of large advanced thyroid tumours (≥4cm; distant 
spread) does not suggest that the increasing rate of thyroid cancer is solely related to incidentolomas 
and suggests a true increase in the incidence of thyroid cancer (Chen et al., 2009, Sipos and 
Mazzaferri, 2010). The main type of thyroid cancer which is on the increase is papillary carcinoma 
followed by a small increase in follicular carcinoma (Reynolds et al., 2005, Smailyte et al., 2006, 
Mitchell et al., 2007).    
 
Figure 1-3  The rate of thyroid cancer detected in males and females by year in the UK 
(Cancer Research UK, 2014). 
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1.2.3 Risk factors for non-medullary thyroid cancer 
1.2.3.1 Female gender 
There is a predilection for females to develop thyroid cancer compared to males, seen in Figure 1-4. 
The ratio of thyroid cancer between male to female is approximately 1:2.5 (Cancer Research UK, 
2014).  The epidemiological data suggest a link between oestrogen and thyroid cancer. This has been 
supported by further molecular studies demonstrating the stimulatory effect of oestrogen on thyroid 
cell proliferation (Santin and Furlanetto, 2011). However, the mortality rates in males is significantly 
higher compared to females and is largely due to late diagnosis and more advanced disease at the time 
of initial diagnosis (Sipos and Mazzaferri, 2010). 
    
1.2.3.2 Age 
The detection of thyroid cancer peaks in the 4th decade for females and the 6th decade for males in the 
UK as shown in Figure 1-4 (Cancer Research UK, 2014). The sharp increase in the incidence of 
thyroid cancer in females from puberty to the end of the 4th decade closely mirrors the fertility period 
of a female and circulating oestrogen levels.   
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Figure 1-4 Number of cases of thyroid cancer diagnosed per year by age and gender. 
 
1.2.3.3 Ionising radiation 
Previous exposure to radiation is a well recognised risk factor for the pathogenesis of thyroid cancer. 
This association was reported in 1950 where 10 out of 28 children with thyroid cancer had received 
radiation to their thymus gland between the fourth and sixteenth months of life (Duffy and Fitzgerald, 
1950).  Kaplan et al recently described the historic account between thyroid cancer and medical 
radiation (Kaplan et al., 2009). The most convincing evidence for thyroid cancer and radiation came 
following the 1945 nuclear explosion in Hiroshima and Nagasaki. The long term report from the 
atomic bomb survivors described the risk of  thyroid cancer being greatest before the age of 20 years. 
The magnitude of excess risk decreased with increasing age or time since exposure. The majority of 
thyroid cancers from the cohort were mainly papillary carcinomas (Furukawa et al., 2013).  
The Chernobyl nuclear fallout in 1986 exposed a large population in Russia, Ukraine and Belarus to 
radiation. It has been estimated that individuals most exposed, including recovery workers, each 
averaged an effective dose equivalent to 50 years of typical background radiation. This led to a sharp 
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increase in well differentiated thyroid carcinoma (Stsjazhko et al., 1995). Post-Chernobyl thyroid 
cancers were characterised by a predominance of papillary carcinomas (93 – 98 %). Aggressive 
tumour histological characteristics, lymphatic invasion, intrathyroid infiltration and multifocality, were 
described to be dose-dependent (Zablotska et al., 2015). Known and novel gene rearrangements are 
thought to be the oncogenic drive for radiation-induced thyroid cancer (Ricarte-Filho et al., 2013). 
Also, early thyroid cancers that are radiation induced are more likely to have gene rearrangements 
compared to thyroid tumours that occur after a long latency (9 – 12 years) (Nikiforov, 2006). 
 
1.2.3.4 Family history of thyroid cancer 
The cumulative lifetime risk of developing non-medullary thyroid cancer in females and males is 3 
fold and 1.5 fold respectively compared to the normal population if they had a first-degree relative 
with thyroid cancer (Fallah et al., 2013).  
 
1.2.3.5 Other proposed risk factors  
A higher thyroid stimulating hormone (TSH) level, even within the normal range, is associated with 
thyroid cancer (Boelaert et al., 2006, Haymart et al., 2008, Jonklaas et al., 2008, Polyzos et al., 2008, 
Boelaert, 2009, Haymart et al., 2009). The thyroid hormone receptor is dependent on transcription 
factors that regulate apoptosis, cell proliferation and differentiation (Cheng, 2000). The receptor, 
consisting of four binding components (TRα1, TRα2, TRβ1 and TRβ2) is encoded by two genes, 
THRA (chromosome 3) and THRB (chromosome 17). Mutation of TRβ1, the PV mutation, results in 
the inability of the receptor to bind the thyroid hormone T3, causing thyroid hormone resistance 
syndrome in humans (Kamiya et al., 2003, Kaneshige et al., 2000, Suzuki et al., 2003). The transgenic 
murine model harbouring this mutation, known as the TRbetaPV/PV mouse, has high levels of thyroid 
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stimulating hormone and develop follicular thyroid carcinoma (Suzuki et al., 2002) . This murine 
model supports the observation that TSH has a role in thyroid tumourigenesis.    
The association between iodine intake and thyroid cancer in humans is unclear (Blomberg et al., 
2012). However, populations with comparative higher iodine intake have a higher proportion of 
papillary compared to follicular carcinomas of the thyroid. Conversely, there is a higher incidence of 
follicular carcinoma in populations with low iodine intake (Lind et al., 1998, Feldt-Rasmussen, 2001). 
Weight and obesity have been explored by numerous groups as a risk factor for thyroid cancer. 
Systematic reviews did not however prove definitive causation (Peterson et al., 2012, Zhao et al., 
2012).   
Female reproductive factors such as pregnancy, number of children, use of prescription hormones, 
menstrual cycle patterns and menopause were not associated with thyroid cancer in a systematic 
review (Peterson et al., 2012). 
 
1.2.3.6 Association with other hereditary disorders 
Gardner syndrome, a subtype of familial adenomatous polyposis (FAP), is associated with a high risk 
of colon cancer and papillary thyroid cancer. Both conditions are caused by defects in the APC gene 
and is autosomal dominant. Cowden disease, associated with hamartomas, have an increased risk of 
thyroid, uterine and breast cancer. This syndrome is commonly caused by defects in the PTEN gene. 
The Carney complex (Type 1) caused by defects in the PRKAR1A gene have an increased risk of 
papillary and follicular thyroid cancers. Familial non-medullary thyroid carcinoma, with suspect 
defective genes on chromosome 19 and 1 is associated with well-differentiated thyroid cancer. Thus, 
in rare instances, thyroid cancer is associated with other hereditary disorders. 
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1.2.4 Management of non-medullary thyroid cancer 
1.2.4.1 Investigations 
The most common presentation of thyroid cancer to a thyroid specialist is the presence of a lump in 
the thyroid. The investigations for the assessment of the neck lump include neck ultrasonography 
(USS) and fine needle aspiration cytology (FNAC). Features suggestive of cancer on ultrasonography 
include microcalcification, taller rather than wide shape, irregular margins and absence of elasticity of 
the thyroid lump (Remonti et al., 2015). FNAC is now commonly performed under ultrasound 
guidance to accurately sample the area in question. The FNAC result is reported using the 5 main 
categories of the “Thy” classification as shown in Table 1 below. Thyroid cytology reporting can be 
subjective and thus the decision for further management is dependent on the overall estimated risk of 
cancer by the clinician based on thyroid USS, FNAC and clinical history. Patient choice is also taken 
into consideration when the decision is made as to whether further management include repeat USS 
and FNAC or diagnostic surgery. Presently, studies are underway using biomarkers to improve the 
diagnostic accuracy of FNAC to aid the clinician’s decision-making process.     
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DIAGNOSTIC CATEGORY RISK OF MALIGNANCY (%) 
Non-diagnostic for cytological diagnosis 
Thy 1 / Thy 1c 
0  - 10 
Benign 
Thy 2 
0  - 3 
Neoplasm possible / Atypia  
Thy 3a 
5  - 15 
Neoplasm possible / Follicular neoplasm 
Thy 3f 
15 - 30 
Suspicious for malignancy 
Thy 4 
60 - 75 
Malignant 
Thy 5 
97 - 100 
Table 1 The Thy classification of thyroid cytology and the associated risk of malignancy 
(reproduced from the Royal Society of Pathologists, 2009). 
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1.2.4.2 Staging 
Differentiated thyroid cancer is staged according to the Tumour, Node and Metastasis (TNM) 
classification shown in Table 2 below. 
STAGE DESCRIPTION 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1a Tumour ≤ 1 cm in greatest dimension, limited to the thyroid 
T1b Tumour > 1 cm and ≤ 2 cm in greatest dimension, limited to the thyroid 
T2 Tumour > 2 cm and ≤ 4 cm in greatest dimension, limited to the thyroid 
T3 Tumour > 4 cm in greatest dimension, limited to the thyroid or 
any tumour with minimal extrathyroid extension 
T4a Tumour of any size extending beyond the thyroid capsule and invades any of the following: 
subcutaneous soft tissues, larynx, trachea, oesophagus, recurrent laryngeal nerve 
T4b Tumour invades prevertebral fascia, mediastinal vessels, or encases the carotid artery 
Nx Regional nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 Regional lymph node metastasis 
N1a Metastasis in Level VI (pretracheal and paratracheal, including prelaryngeal and Delphian 
lymph nodes) 
N1b Metastasis in other unilateral, bilateral or contralateral cervical or upper/superior 
mediastinal lymph nodes 
cM0 Clinically no distant metastasis 
cM1 Distant metastasis clinically 
Table 2 TNM staging for differentiated thyroid cancer (reproduced from AJCC Cancer 
Staging Manual, 7th edition. 
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1.2.4.3 Treatment 
The most widely offered treatment options for differentiated thyroid cancer include surgery, 
radioiodine and TSH suppression with thyroxine. External beam radiotherapy and chemotherapy 
treatment modalities have largely been reserved for the palliation of thyroid cancer (Perros et al., 
2014). The chemotherapy drug Paclitaxel has been used in the treatment of undifferentiated anaplastic 
thyroid carcinoma (Gomez Saez et al., 2015). Futhermore, targeted therapy with the use of tyrosine 
kinase inhibitors such as vemurafenib, selumetinib, dabrafenib, sorafenib, sunitinib, pazopanib, 
cabozantinib, motesanib, axitinib and vandetanib are currently being evaluated for use in patients with 
advanced or recurrent thyroid cancer refractory to conventional treatments (Ferrari et al., 2015).  
 
1.2.5 Prognosis of differentiated thyroid cancer 
The prognosis of well managed well differentiated thyroid cancer is excellent, with the majority of 
patients diagnosed at an early stage of the disease and having a 5 year survival rate in excess of 95 % 
(Cancer Research UK 2014). Interestingly, mortality rates from thyroid cancer have remained largely 
unchanged despite the improved detection (Chen et al., 2009).  
The worst prognosis arises from anaplastic thyroid tumours. The mortality from anaplastic thyroid 
tumours contributes 14 – 50 % of the overall mortality rates of thyroid cancer despite being 1- 2 % of 
all thyroid cancers. The median survival of anaplastic tumours is between 3 to 5 months (Nagaiah et 
al., 2011). 
 
1.2.6 Molecular genetics 
The main oncogenic pathways investigated and implicated in the aetiology of differentiated thyroid 
cancer are the mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase/Akt 
pathways (PI3K/Akt) which are frequently dysregulated in thyroid cancer. The MAPK and PI3K 
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pathways have upstream common points such as Ras and tyrosine kinase receptor (RTK) illustrated in 
Figure 1-5 below.  
 
 
Figure 1-5 Schematic diagram of the upstream interaction between PI3K/Akt and MAPK 
pathway in thyroid cancer, reproduced from (Xing, 2010). The PI3K/Akt pathway is 
illustrated on the left and the MAPK pathway on the right. The common points of interaction 
include the tyrosine kinase receptor (RTK) and Ras. PTEN inhibits the PI3K/Akt signalling 
pathway.  
 
The most common form of differentiated thyroid cancer, papillary thyroid cancer, is postulated to be 
largely attributed to dysfunctional MAPK signalling. The PI3K/Akt pathway appears to be mainly 
involved in the formation of follicular thyroid cancers and adenomas. However, both pathways can act 
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synergistically in the transformation or dedifferentiation of papillary carcinoma to anaplastic 
carcinoma, as shown in Figure 1-6  (Xing, 2010).  
 
 
 
Figure 1-6 The hypothesized pathways involved in the pathophysiology of  PTC (papillary 
thyroid cancer), FTC (follicular thyroid cancer) and ATC (anaplastic thyroid cancer). 
Reproduced from (Xing, 2010). 
 
The molecular profile of oncogenes causing differentiated thyroid cancer has implications in tumour 
classification as well as prognosis. For example, currently classified papillary thyroid cancers driven 
by  BRAFV600E  or RAS oncogenes have different appearances on histology and response to mitogen-
activated protein kinase (MEK) inhibitors (Cancer Genome Atlas Research, 2014, Ho et al., 2013). In 
PTC, the most frequently encountered gene aberrations include point mutations of BRAF and Ras, and 
the RET/PTC rearrangement (discussed individually in subsequent sections). The profile of abnormal 
genes found in FTC is different, with the PAX8/PPARγ  featuring in 30 %  of follicular carcinomas 
but not being apparent in papillary thyroid carcinoma (Bhaijee and Nikiforov, 2011). The constituent 
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mutation proportions found in follicular thyroid cancer is shown in Figure 1-7 and papillary thyroid 
cancer, Figure 1-8.   
 
 
Figure 1-7 Profile of abnormal genes found in follicular thyroid cancer, reproduced from 
(Bhaijee and Nikiforov, 2011). 
 
 
 
RAS 40% 
PAX8/PPARγ 
30% 
NONE 30% 
Follicular thyroid carcinoma 
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Figure 1-8 Profile of abnormal genes found in papillary thyroid carcinoma adapted from 
(Cancer Genome Atlas Research, 2014). The bar charts in red denote fusions and in blue, 
mutations.  
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1.2.6.1 Mitogen-activated Protein Kinase Pathway  
The mitogen-activated protein kinase (MAPK) pathway regulates cellular functions of proliferation, 
differentiation, migration, growth and apoptosis. MAPKs are highly conserved proteins which belong 
to the serine/threonine family of protein kinases. Conventional MAPK signalling follows a three-tiered 
kinase cascade of MAPKKK → MAPKK → MAPK. MAPKKK is activated via small GTPases, 
belonging to the Ras/Rho family. MAPKKK phosphorylates and activates MAPKK which in turn 
phosphorylates and activates MAPK. Phosphorylated MAPK exerts its effect directly on the nucleus 
which translates to cellular action(s) (Figure 1-9). Dysregulation of this pathway is critical in the 
development and progression of thyroid cancer.  (Pearson et al., 2001, Dhillon et al., 2007).  
 
 
Figure 1-9 Schematic overview of MAPK signalling pathway shown on the extreme left. 
Various known gene interactions are illustrated to the right of the line. Reproduced from  
(Dhillon et al., 2007). 
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1.2.6.2 Phosphatidylinositide 3-kinase/Akt  Pathway 
The lipid kinase phosphoinositide 3-kinase/Akt (PI3K/Akt) pathway is involved in cell growth and 
metabolism. The central gene Akt is activated by the PI3K complex which in itself interacts with the 
upstream tyrosine kinase receptor. Activated Akt phosphorylates several downstream targets which 
lead to cellular actions such as apoptosis, proliferation, DNA repair, growth and survival (Monsalves 
et al., 2014, Vivanco and Sawyers, 2002).  Figure 1-10 describes the PI3K/Akt pathway. 
Dysregulation of this pathway has been implicated in the development of follicular adenomas and 
thyroid carcinoma as described above in section 1.2.6.   
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Figure 1-10 PI3K/AKT signalling pathway adapted from (Vivanco and Sawyers, 2002). 
Activation of class IA phosphatidylinositol 3-kinases (PI3Ks) occurs through stimulation of 
receptor tyrosine kinases (RTKs) and the concomitant assembly of receptor–PI3K complexes. 
These complexes localise at the membrane where receptor-PI3K catalyses the conversion of 
PtdIns(4,5)P2 (PIP2) to PtdIns(3,4,5)P3 (PIP3). PIP3 serves as a second messenger that helps 
activate AKT. Through phosphorylation, activated AKT mediates the activation and inhibition 
of several targets (GSK3β, glycogen synthase kinase-3β; NF-κB, nuclear factor of  κB; 
MDM2; mTOR; FKHR; BAD) resulting in cellular growth, survival and proliferation through 
various mechanisms. 
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1.2.6.3 Point mutations of genes involved in differentiated thyroid 
cancer 
1.2.6.3.1 BRAF 
The RAF family of protein kinases is encoded by the BRAF gene and has 3 isoforms; ARAF, BRAF 
and CRAF. Although all three isoforms play a role in the RAS-RAF cascade, the main activator of the 
MAPK pathway is BRAF. The most prevalent thyroid oncogene found in papillary thyroid carcinoma, 
BRAF, is activated by the V600E substitution (BRAFV600E) (Krause, 2005).  In this mutation the valine 
(V) amino acid is replaced by glutamic acid (E) at codon 600 and this gene remains active, 
independent of upstream cues (Davies et al., 2002). Consequently there is excessive downstream 
signalling of the MAPK pathway, resulting in tumour formation (Hilger et al., 2002, Peyssonnaux and 
Eychene, 2001). 
Papillary thyroid carcinomas with the BRAF V600E mutation are more aggressive tumours as 
demonstrated by extrathyroidal invasion, lymph node metastases and advanced tumour stage at initial 
surgery (Xing et al., 2005, Lee et al., 2007). In a multicentre study involving 16 centres and 2099 
patients, the hazards ratio of developing recurrence in BRAFV600E positive compared to BRAFV600E 
negative thyroid cancers is 1.82, after adjusting for clinicopathologic factors (Xing et al., 2015).  
Murine models of BRAFV600E thyroid knock-in develop goitres and invasive papillary thyroid 
carcinoma which later transition to poorly differentiated carcinoma (Knauf et al., 2005). Thyroid 
cancer initiation via the oncogene BRAFV600E is dependent on TSH signalling (Franco et al., 2011).      
 
1.2.6.3.2 Ras 
The Ras gene encodes for 3 isoforms of the protein; H-, K- and N-Ras. The Ras gene belongs to a 
family of GTP binding proteins that are located in the plasma membrane and has a central role in the 
transduction of signals from tyrosine kinase and G-protein-coupled receptors to effector genes in the 
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MAPK and PI3K/Atk pathways (Dhillon et al., 2007, Xing, 2010). Ras possesses intrinsic GTPase 
activity and in normal cells is mostly in an inactive GDP-bound state. In point mutations of Ras, the 
gene is active by either having an increased affinity for GTP or has losing its intrinsic GTPase activity 
(Howell et al., 2013). Consequently, the MAPK or the PI3K/Atk pathways are aberrantly activated, 
resulting in tumourigenesis.  
Mutation of the Ras gene is interesting because it is found in both papillary and follicular thyroid 
cancers. This probably reflects the ability of mutated Ras to activate both MAPK and PI3K/Akt 
signalling pathways. Numerous Ras point mutations have been identified but the most common Ras 
point mutation in follicular neoplasms of the thyroid involves N-Ras at codon 61 (Vasko et al., 2003, 
Liu et al., 2004). 
Ras mutations are also found in follicular adenomas of the thyroid in up to 48 % of cases. This 
observation suggests that Ras mutations may not be a key oncogene in the malignant transformation of 
thyroid cells to cancer and that additional mutation or epigenetic insult is required for tumourigenesis.    
 
 
1.2.6.4 Tyrosine kinase receptor rearrangements 
1.2.6.4.1 RET/PTC rearrangement 
The RET proto-oncogene, implicated in 15 % of papillary thyroid carcinomas, is located on the long 
arm of chromosome 10 (10q11.2) and encodes a tyrosine kinase receptor (Bhaijee and Nikiforov, 
2011, Ishizaka et al., 1989). The RET receptor has extracellular, transmembrane and intracellular 
domains (Ishizaka et al., 1989, Takahashi et al., 1993). Whilst RET is essential in the development of 
the urogenital and nervous system, its expression is at very low levels in normal thyroid tissue and is 
not required in the development of the thyroid gland (Pachnis et al., 1993, Schuchardt et al., 1994, 
Takaya et al., 1996).  
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The specific type of RET mutation dictates the phenotype. For example, point mutations in the RET 
gene produce medullary thyroid cancer, a tumour arising from the parafollicular c-cells of the thyroid. 
Medullary thyroid cancers with the methionine to threonine substitution at position 918 of the RET 
gene are most aggressive and the RET mutation with the replacement of serine by alanine at position 
891 produces disease less likely to metastasise (Arighi et al., 2005). 
Papillary thyroid cancers are associated with the RET/PTC translocation. To date, 13 different 
oncogenic RET/PTC fusions have been identified. In RET-associated differentiated thyroid cancer, 
RET/PTC1 accounts for 60 %, RET/PTC3 for 30 % and RET/PTC2 10 % of cases. The other 
RET/PTC translocations are very rare in papillary carcinoma of the thyroid (Prescott and Zeiger, 
2015). In support of the oncogenic nature of RET/PTC fusions, thyroid-specific expression of 
RET/PTC1 and of RET/PTC3 in transgenic mice results in the development of papillary thyroid 
cancer (Jhiang et al., 1996, Powell et al., 1998). However, not all RET/PTC fusions result in papillary 
thyroid carcinoma. RET/PTC fusions are also expressed in benign thyroid adenomas and Hashimotos 
thyroiditis (Ishizaka et al., 1991, Rhoden et al., 2006).  
Thyroid cancers arising from radiation exposure in children in the Chernobyl disaster have a high 
prevalence of RET/PTC rearrangements which results in the activation of RET kinase, causing 
papillary carcinomas of the thyroid (Bounacer et al., 1997, Nikiforov et al., 1997, Fugazzola et al., 
1995, Mizuno et al., 2000). The gene loci of RET and PTC lie in close proximity to one another within 
the thyroid nucleus during interphase and are predisposed to recombination after DNA damage from 
ionising radiation (Nikiforova et al., 2000, Roccato et al., 2005). The finding that 20 % of papillary 
thyroid carcinomas have the RET/PTC rearrangement in the general non-irradiated population and up 
to 72 % of papillary thyroid cancers post Chernobyl harboured the RET/PTC fusion suggested that 
exposure to radiation increases the risk of RET/PTC rearrangement (Unger et al., 2004). The exact 
molecular pathway from activation of the RET tyrosine kinase receptor to papillary carcinoma 
tumourigenesis is yet to be fully defined. 
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1.2.6.4.2 PAX8/PPARγ rearrangement 
The PAX8 gene belongs to a family of genes that encode for transcription factors, crucial in the 
development of the thyroid gland and the production of thyroid hormone. The peroxisome proliferator-
activated receptor gamma (PPARγ)  encodes for a Type 2 nuclear receptor. Translocational 
rearrangement of these genes occur between chromosomes 2 and 3 (Wang et al., 2007). The  
PAX8/PPARγ fusion results in an increased expression of the chimeric protein which inhibits the 
tumour suppressor activity of PPAR and deregulates PAX8 function (Kroll et al., 2000, Tallini, 2002, 
Gregory Powell et al., 2004).  
The PAX8/PPARγ rearrangement is found in 30 to 35 % of follicular thyroid carcinomas (French et 
al., 2003, Nikiforova et al., 2003). 2 – 13 % of follicular adenomas and 1 – 5 % of follicular variant of 
papillary carcinomas have this rearrangement (Marques et al., 2002, Nikiforova et al., 2002, Dwight et 
al., 2003). Follicular carcinomas with the PAX8/PPARγ translocation affect younger patients, are 
smaller in size and more likely to exhibit vascular invasion (French et al., 2003, Nikiforova et al., 
2003). The detection of the PAX8/PPARγ fusion in fine needle aspiration cytology for distinguishing 
between benign and malignant follicular lesions has not been particularly helpful (Ferraz et al., 2012, 
Pauzar et al., 2012). 
1.2.6.4.3 TRK rearrangement 
The neurotrophic tyrosine kinase receptor Type 1 (NTRK1) gene encodes a protein that is found on 
the cell surface and has a role in activating other genes or itself through phosphorylation. NTRK1 is 
located on the long arm of chromosome 1 (1q21 – q22).   
Rearrangement of the NTRK1 gene with various activating genes such as TPM3, TPR and TFG in the 
thyroid results in constitutive activation of tyrosine kinase activity leading to the transformation of 
thyroid cells. The NTRK1 rearrangements, also known as TRK, commonly found in papillary thyroid 
cancers are TRK (NTRK1/TPM3 fusion) (Wilton et al., 1995), TRK-T1, TRK-T2 (both 
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NTRK1/different portions of TPR gene fusion) (Greco et al., 1992, Miranda et al., 1994, Greco et al., 
1997) and TRK-T3 (NTRK1/TFG fusion) (Greco et al., 1995). The frequency of TRK rearrangements 
in papillary thyroid cancers is approximately 3 % (Cancer Genome Atlas Research, 2014). The 
frequency of TRK rearrangements in papillary thyroid carcinoma in patients previously exposed to 
radiation was the same as patients who were not exposed to ionising radiation (Rabes et al., 2000). The 
prognostic significance of the TRK rearrangement in papillary thyroid carcinomas remains unclear, 
with the numbers involved in various studies being small  (Bongarzone et al., 1998, Brzezianska et al., 
2006, Musholt et al., 2000). Transgenic murine models expressing TRK-T1 in the thyroid gland 
develop follicular hyperplasia and papillary carcinoma from 7 months onwards. This provides in vivo 
evidence that TRK-T1 supports oncogenesis in the thyroid gland. This oncogenic effect on thyroid 
cells is likely to be downstream in nature because of the incomplete penetrance observed within the 
cohort with an abnormal phenotype (Russell et al., 2000). 
 
 
1.2.7 Other genes involved in thyroid cancer 
1.2.7.1 Trp53 
The Trp53 gene, guardian of the genome, regulates multiple vital cellular functions such as growth, 
proliferation, apoptosis, cell cycle progression and DNA repair. Mutated Trp53, and hence 
dysfunctional Trp53, is found in a variety of human cancers. In the Li-Fraumeni syndrome where there 
is a germline autosomal dominant mutation of Trp53, patients are at high risk of developing sarcomas, 
breast cancer, glioblastomas, adrenocortical carcinoma and haematopoietic malignancies at a young 
age (Li et al., 1988, Malkin et al., 1990).  
Trp53 mutations are uncommon in differentiated thyroid cancer but found in as many as 83 % of 
undifferentiated thyroid carcinoma. It is thought that p53 initiates the progression of well 
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differentiated thyroid cancer to anaplastic cancer (Ito et al., 1992, Dobashi et al., 1993, Donghi et al., 
1993, Fagin et al., 1993, Dobashi et al., 1994).  Murine models of papillary thyroid cancer, 
overexpressing RET/PTC1 in the thyroid gland, developed anaplastic tumours of the thyroid gland 
when crossed with Trp53 null mice suggesting that the lack of functional Trp53 promotes 
dedifferentiation of papillary thyroid cancer (La Perle et al., 2000). 
 
1.2.7.2 PTEN 
PTEN is a tumour suppressor that preferentially dephosphorylates phosphoinositide substrates and 
negatively regulates the PI3K/Akt pathway. In human germline mutations of PTEN, also known as 
Cowden disease, there is an increased risk of thyroid cancer. In a study of 146 patients with Cowden 
disease, 74 different mutations were observed. Approximately 70 % of patients with Cowden disease 
have benign lesions of the thyroid and 17 % develop thyroid cancer. The thyroid cancers observed 
were papillary carcinomas (59 %), follicular carcinomas (27.5 %), hybrid between follicular and 
papillary carcinoma (4.5 %), medullary carcinoma (4.5 %) and oxyphil cell tumour (4.5 %) (Bubien et 
al., 2013).   
The loss of PTEN alone in the thyroid gland in murine models induces goitre and follicular adenomas 
in the presence of normal TSH levels. None of the models developed thyroid cancer by the age of 11 
months, strongly suggesting that the persistent activation of the PI3K/Akt pathway alone is not 
sufficient for malignant transformation within the thyroid gland (Yeager et al., 2007).  
 
1.2.7.3 Mutations to the thyroid hormone receptor  
The murine model harbouring the PV mutation which results in an abnormality of the TRβ1 
component of the thyroid hormone receptor develop follicular thyroid carcinoma with vascular 
invasion and metastases  (Suzuki et al., 2002).  
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Interestingly, two further novel genes have been discovered to be associated with human thyroid 
cancer. Both Pituitary Tumor Transforming Gene (PTTG) and PTTG binding factor (PBF) are 
dysregulated in thyroid cancer (Boelaert et al., 2003, Heaney et al., 2001, Saez et al., 2006, Hsueh et 
al., 2013, Stratford et al., 2005). The next section describes these two genes, PTTG and PBF, in further 
detail.   
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1.3 PITUITARY TUMOR TRANSFORMING GENE (PTTG) 
1.3.1 Identification 
Pituitary tumor transforming gene (PTTG) was first identified and found to be exclusively highly 
expressed in rat pituitary tumour cells but not in normal pituitary cells. Subsequently, it was shown 
that PTTG had transforming abilities where overexpression of PTTG in murine 3T3 fibroblasts 
injected in athymic nude mice resulted in tumourigenesis (Pei and Melmed, 1997).  Human PTTG 
shares 89 % sequence homology with rat PTTG and lies on chromosome 5q33 (Zhang et al., 1999). 
Although two further PTTG homologues have been identified (PTTG2 on chromosome 4p12 (Kakar 
and Jennes, 1999, Prezant et al., 1999) and PTTG3 on chromosome 8q13 (Chen et al., 2000)), PTTG 
(PTTG1) is most widely expressed in tumours. Hence, it is the most extensively studied and for the 
purpose of this thesis, PTTG refers to PTTG1.  
 
1.3.2 Structure and function of PTTG 
PTTG, shown schematically in Figure 1-11, has an open reading frame containing 609 bp which 
encodes for 203 amino acids (Zhang et al., 1999). The structure of PTTG can be divided to the basic 
N-terminal regulatory domain and acidic C-terminal functional domain (Dominguez et al., 1998, 
Kakar and Jennes, 1999, Zhang et al., 1999).  
The regulatory N-terminal domain contain the KEN box (amino acid 9 to 11) and destruction box 
(amino acid 61 to 68) which are targets for the anaphase promoting complex (APC).  APC functions 
by binding to PTTG, resulting in the degradation of PTTG and consequently allowing the progression 
from metaphase to anaphase during mitosis. (Zou et al., 1999, Zur and Brandeis, 2001).  
PTTG has transcriptional abilities as shown by the presence of a DNA binding domain, from amino 
acid 61 to 118, and a transactivation domain further downstream, from amino acids 119 to 164 within 
its structure (Zhang et al., 1999, Pei, 2000, Wang and Melmed, 2000). Although the subcellular 
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localisation of PTTG, either cytoplasmic or nuclear, is dependent on cell type (Mu et al., 2003), in 
order for this gene to be functional, it needs to be within the nucleus (Zou et al., 1999). Interestingly, 
PTTG does not contain a nuclear localisation signal sequence, essential for the ability of a gene to 
cross the nuclear membrane. This led to the discovery of  PTTG binding factor (PBF) which binds to 
PTTG and translocate it to the nucleus (Chien and Pei, 2000). 
 The transactivational and transforming capabilities of PTTG is attributed to the proline-rich region in 
the C-terminal (amino acids 163 to 173). This region contains the highly conserved and putative Src-
homology-3 (SH3) interacting domain (Zhang et al., 1999). The only reported phosphorylation site of 
PTTG, thought to play a role during mitosis, lies at serine residue 165 within the SH3 interacting 
domain (Pei, 2000, Ramos-Morales et al., 2000, Boelaert et al., 2004).     
 
 
Figure 1-11 Schematic representation of human PTTG protein reproduced from (Smith et al., 
2010). The regulatory N-terminal contains the KEN  and destruction boxes. The SH3 
interacting domain and  phosphorylation site lies within the functional C-terminus.  
 
1.3.3 Regulation of PTTG expression 
The first regulator of PTTG to be identified was the hormone oestrogen. Oestrogen was found to 
upregulate PTTG expression in pituitary lactotroph tumours in rats (Heaney et al., 1999). Thyroid 
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stimulating hormone was also found to induce PTTG expression (Heaney et al., 2001). Insulin has 
been demonstrated to upregulate PTTG expresssion but the effect of insulin differed between 
malignant and non-malignant astrocytes suggesting that the response of PTTG to insulin is variable 
depending on tissue type (Chamaon et al., 2005, Thompson and Kakar, 2005).  
The basal levels of PTTG transcription is regulated by the transcription factor SP1 (Clem et al., 2003).  
Oct-1 expression activates the PTTG promoter and increases the expression of PTTG (Zhou et al., 
2008). β-catenin was found to increase PTTG expression in oesophageal cancers (Zhou et al., 2005) 
and colorectal cancers (Hlubek et al., 2006). γ-catenin which exists in conjunction with β-catenin has 
been shown to increase the transcription of PTTG (Pan et al., 2007). The binding of NF-Y to Trp53 is 
thought to inhibit the transcription of PTTG (Zhou et al., 2003).   
The relationship between PTTG expression and growth factors has been extensively studied. The 
epidermal growth factor (EGF) receptor, itself regulated by EGF and transforming growth factor alpha 
(TGF-α), has been demonstrated to upregulate PTTG expression. The promalignant hepatocyte growth 
factor (HGF) increases the expression of PTTG via the c-Met membrane receptor in astrocytic cells 
(Tfelt-Hansen et al., 2004). Insulin-like growth factor (IGF-1) has also been shown to enhance 
transcription of PTTG (Chamaon et al., 2005, Thompson and Kakar, 2005). The relationship between 
the induction of PTTG by fibroblast growth factor-2 (FGF-2) is well established (Chamaon et al., 
2010, Heaney et al., 1999, Tsai et al., 2005). 
A small number of studies have investigated the epigenetic mechanisms involved in the control of 
PTTG expression since no mutations of PTTG and its promoter sequence were found in pituitary 
neoplasms (Zhang et al., 1999, Kanakis et al., 2003). The overexpression of histone acetyltransferase 
(HAT) p300, a transcription co-activator, increased PTTG promoter activity, ultimately resulting in 
increased PTTG mRNA and protein. It was also found that increased PTTG promoter activity with 
p300 was mediated by NF-YA and NF-YB.  (Li et al., 2009).  
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1.3.4 Subcellular localisation of PTTG 
The expression of PTTG is cell cycle dependent and increases from low in S-phase, higher in G2-
phase and peaks at M-phase in HeLa cells (Zou et al., 1999, Ramos-Morales et al., 2000, Yu et al., 
2000b). PTTG was largely localised to the nucleus during interphase, with small amounts in the 
cytoplasm in JEG-3 cells overexpressing PTTG (Yu et al., 2000b). In contrast, earlier studies have 
indicated that PTTG was located primarily in the cytoplasm with only partial nuclear expression in 
Jurkat T lymphoma cells, pituitary adenomas, lung and breast adenocarcinomas (Dominguez et al., 
1998, Saez et al., 1999). It is possible that the difference in localisation of PTTG is cell-specific. The 
function of PTTG requires its presence in the nucleus but it has no nuclear localisation signal within 
its structure. It is thought that PTTG being a small protein of low molecular weight, has the ability to 
diffuse freely across the nuclear membrane. Alternatively, PTTG requires a transport protein to 
facilitate its entry into the nucleus and the discovery of PTTG binding factor (PBF) has supported this 
hypothesis (Chien and Pei, 2000).    
One study observed PTTG expression in the Golgi apparatus and vesicles. Analysis of the culture 
medium detected the presence of PTTG. It was thus suggested that PTTG is a secretory protein that 
may have an autocrine and/or paracrine function in murine pituitary tumour cells and human pituitary 
adenomas (Minematsu et al., 2007). 
PTTG has been observed to co-localise with mitotic spindles during mitosis when its concentration 
within the cell was highest (Yu et al., 2003). These observations are consistent with the role of PTTG 
as the human securin involved in the regulation of mitosis. Furthermore, the observation that PTTG 
phosphorylates during mitosis suggests that PTTG is involved in the regulatory pathway controlling 
cell proliferation (Ramos-Morales et al., 2000).   
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1.3.5 Expression in normal human tissue and cancers 
PTTG is expressed at low levels within the spleen, prostate, ovary, heart, brain, liver, skeletal muscle, 
kidney and pancreas. High levels of PTTG expression are found in the testes, thymus and placenta 
(Dominguez et al., 1998). It is thought that PTTG plays a role in spermatogenesis (Pei, 1999).  
High PTTG expression has been reported in various human cancers including astrocytomas (Tfelt-
Hansen et al., 2004), breast (Puri et al., 2001), oesophagus (Shibata et al., 2002), lung (Kakar and 
Malik, 2006), stomach (Wen et al., 2004), liver (Cho-Rok et al., 2006), colon (Heaney et al., 2000), 
ovary (Puri et al., 2001) and haematopoietic (Dominguez et al., 1998). Interestingly, promoter 
mutation was not found to play an important role in PTTG overexpression in pituitary adenomas 
(Kanakis et al., 2003). Further investigations indicate that neither methylation nor loss of 
heterozygosity are involved in PTTG overexpression, suggesting that the misregulation of PTTG is a 
post-transcriptional event (Hidalgo et al., 2008).  
 
1.3.6 Expression in thyroid cancer  
Of interest to this study is the overexpression of PTTG in thyroid neoplasms (Heaney et al., 2001, 
Boelaert et al., 2003). Heaney et al  initially reported increased PTTG mRNA expression in follicular 
thyroid neoplasms. Our own group has confirmed that PTTG expression is increased at both an mRNA 
and protein level in well differentiated thyroid cancers with no difference between papillary or 
follicular lesions. In addition, thyroids from multinodular goitres or Graves disease did not show a 
significant increase in PTTG. More importantly, high PTTG expression was an independent 
prognostic indicator of early recurrence (Boelaert et al., 2003). Saez et al analysed PTTG expression in 
differentiated thyroid cancers using immunohistochemistry and found a  positive association of high 
PTTG expression with nodal and distant metastases, disease persistence, advanced TNM stage and 
reduced radioiodine uptake  (Saez et al., 2006).  
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Reduced iodine uptake was observed by Heaney et al in FRTL5 cells overexpressing PTTG (Heaney 
et al., 2001). Subsequently, PTTG has been shown to repress the sodium-iodide symporter (NIS) 
responsible for active radioiodine transport into thyroid cells via FGF-2  (Boelaert et al., 2007), 
discussed in section 1.3.11.4. This observation may account for a poorer prognosis in patients with 
thyroid cancer overexpressing PTTG.  
 
1.3.7 Murine models of PTTG overexpression 
To date, there has been a few studies investigating the effect of PTTG overexpression in specific 
organs. In vivo overexpression of PTTG in murine pituitary cells induced abnormal cell proliferation 
and adenomas (Abbud et al., 2005). The overexpression of PTTG in the ovarian surface epithelium of 
transgenic murine models resulted in the formation of pre-cancerous lesions but did not result in 
ovarian tumourigenesis (El-Naggar et al., 2007). Our group has created a transgenic murine model of 
targeted PTTG overexpression in the thyroid gland demonstrating small thyroids with reduced cellular 
proliferation and did not develop thyroid cancer (Lewy et al., 2013).  
 
1.3.8 PTTG and genetic instability 
PTTG, also known as the human securin, inhibits the separation of sister chromatids (Zou et al., 1999). 
The ubiquitination of PTTG by APC/CCdc20 is inhibited by Cdk1 which phosphorylates PTTG (Holt et 
al., 2008). The activation of separase at the metaphase-anaphase transition triggers the release of 
Cdc14 phosphatase which dephosphorylates PTTG, resulting in its ubiquitination, ultimately allowing 
the separation of sister chromatids (Queralt et al., 2006, Stegmeier et al., 2002).    
Defects in chromatid separation result in aneuploidy (Nasmyth, 2002). Hence, it is not surprising that 
overexpression of PTTG results in aneuploidy, a histological observation associated with 
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chromosomal instability (Winnepenninckx et al., 2006, Yu et al., 2000a, Yu et al., 2003, Wang et al., 
2001). The measurement of intrachromosomal instability by fluoresecent intersimple sequence repeat 
PCR in thyroid cancer demonstrated a positive correlation between PTTG expression and genetic 
instability (Kim et al., 2005).  
In keeping with this, PTTG knockout (PTTG -/-) murine embryo fibroblasts had a prolonged G2/M 
phase and exhibited aneuploidy (Wang et al., 2001). PTTG -/- knockout murine models are 
surprisingly viable and fertile, with testicular and splenic hypoplasia, thymic hyperplasia and 
thrombocytopenia (Wang et al., 2001). In addition, PTTG deficient mice developed non autoimmune 
insulin deficiency with pleiotropic beta islet cells (Wang et al., 2003). This was attributed to a 
combination of apoptosis and senescence in beta islet cells secondary to DNA damage (Chesnokova et 
al., 2009). Taken together, the observed PTTG -/- mouse phenotype could be explained by the varying 
importance of PTTG in different organ development. Also, it appears PTTG plays an important role in 
cell cycle progression, albeit not being the only mechanism that regulates sister chromatid separation 
(Mei et al., 2001, Wang et al., 2001).  Overall, murine models of both PTTG knockout and 
overexpression demonstrate that PTTG has a role in genomic stability. 
 
1.3.9 PTTG, Trp53 and apoptosis 
The functions of Trp53 in apoptosis, cell cycle regulation and DNA repair (Levine, 1997, Vousden, 
2000) in response to DNA damage alludes to its importance in the maintenance of genomic stability. 
The importance of Trp53 in tumourigenesis is demonstrated by the fact that it is mutated in over 50 % 
of human cancers (Hollstein et al., 1994). The loss of function of or inability to illicit a normal Trp53 
response to DNA damage can cause malignant transformation (Vousden, 2006). 
PTTG has been demonstrated to cause apoptosis both in a Trp53 dependent and independent manner. 
The same group found that Trp53 was capable of preventing aneuploidy caused by an overexpression 
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of PTTG (Yu et al., 2000a, Yu et al., 2000b). These observations suggests that Trp53 exerts a 
protective effect via apoptosis to ameliorate the chromosomal instability induced by PTTG. PTTG 
upregulates the transcription of Trp53 through the expression of c-myc. Bax, a pro-apoptotic 
downstream gene of the Trp53 signalling pathway is upregulated in the presence of PTTG 
overexpression only when normal functioning Trp53 is present (Hamid and Kakar, 2004). This 
suggests that PTTG-induction of Trp53-dependent apoptosis is at least partially mediated via Bax. 
In vivo and in vitro studies have determined that Trp53 and PTTG interact directly (Bernal et al., 
2002). In contrast to the above findings by other groups, Bernal et al reported that the transcriptional 
ability of Trp53 was inhibited by its interaction with PTTG. In addition, they reported that PTTG 
inhibited the ability of Trp53 to induce apoptosis (Bernal et al., 2002). Other groups have since also 
reported that PTTG negatively regulates the apoptotic function of Trp53 (Cho-Rok et al., 2006, Lai et 
al., 2007).  
The DNA damaging drugs doxorubicin and bleomycin suppressed PTTG only in the presence of 
functional Trp53 with one study proposing that Trp53 suppressed PTTG via the transcription factor 
NF-Y (Zhou et al., 2003). In the study of apoptosis induced by 5-fluorouracil in HCT116 cells, Trp53 
was found to bind directly with the PTTG promoter and repress its expression (Kho et al., 2004).  
PTTG is involved in the DNA damage pathway. In eukaryotic cells, ultraviolet (UV) radiation has 
been found to reduce PTTG protein levels by reducing its synthesis and increasing its degradation, 
independent of Trp53. PTTG was also found to be required for cell cycle arrest following UV 
radiation, with its loss resulting in premature entry into mitosis and increased apoptosis (Romero et al., 
2004).  
 
1.3.10 PTTG, DNA damage and repair 
Further evidence for the role of PTTG in the DNA damage response comes from the interaction 
between PTTG and Ku70 (Romero et al., 2001). Ku70 forms a heterodimer with Ku80 and together 
  General Introduction 
38 
 
with DNA-PK, this complex facilitates non-homologous DNA end-joining repair of double strand 
breaks (Smith and Jackson, 1999, Kharbanda et al., 1998). In the presence of double strand breaks, 
PTTG is phosphorylated by DNA-PK and dissociates from Ku70 allowing for DNA repair to occur 
(Romero et al., 2001). It has been observed that PTTG overexpression inhibits Ku70 DNA binding and 
represses double strand break repair (Kim et al., 2007b). Thus, in the presence of high PTTG 
expression Ku proteins are bound, consequently adversely affecting DNA repair which results in 
genetic instability. 
Overall, the above studies with Trp53 and Ku70 have demonstrated the multifaceted role PTTG plays 
in the DNA damage response which is complex and not fully understood. Certainly, the role of PTTG 
in the context of genetic instability and tumourigenesis in the thyroid remains to be elucidated.  
 
1.3.11 Gene interactions with PTTG 
The observation that PTTG has a domain for DNA binding, acidic transactivation and partial 
localisation in the nucleus, suggests PTTG may transactivate other genes. Deletion of amino acids 124 
to 202 abolished the transactivational abilities of PTTG, suggesting that the C-terminal end of PTTG is 
responsible for this function (Dominguez et al., 1998).   
The acidic C-terminus of PTTG contains multiple glutamic and proline residues which are 
characteristic of transactivation domains (Pei, 2000, Wang and Melmed, 2000). Within this region are 
two PXXP motifs that are SH3-binding sites which are highly conserved regions that govern 
transduction of intracellular signalling pathways. Point mutations in the PXXP motifs resulted in the 
abrogation of its transactivational ability and more importantly, in its in vitro transforming and in vivo 
tumour-inducing activity (Zhang et al., 1999). Furthermore,   a point mutation at a key prolene residue 
disrupted the transactivation and transforming ability of PTTG, suggesting an intrinsic link between its 
transactivation and transforming functions (Wang and Melmed, 2000).  
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1.3.11.1 FGF2, VEGF and PTTG 
PTTG has been shown to interact with growth factors and cytokines that could promote the 
progression of thyroid neoplasms. The established relationship between PTTG, fibroblast growth 
factor 2 (FGF-2) and vascular endothelial growth factor (VEGF) appear to be critical in tumour 
progression through the promotion of growth and angiogenesis. Angiogenesis is an integral part of 
tumour growth and survival; a blood supply is critical in maintaining tumour viability (Folkman, 1972, 
Folkman, 1990, Folkman, 1992, Folkman and Shing, 1992, Hanahan and Folkman, 1996). FGF-2 and 
VEGF act synergistically to modulate tumour angiogenesis and invasion (Bikfalvi et al., 1997, Ferrara 
and Davis-Smyth, 1997, Gospodarowicz et al., 1987, Fujii et al., 2006, Minematsu et al., 2007, Wang 
et al., 2004). 
Stable overexpression of PTTG in NIH3T3 cells resulted in increased FGF-2 mRNA expression 
(Zhang et al., 1999). Interestingly, FGF-2 has been shown to induce PTTG expression in NIH3T3 cells 
(Heaney et al., 1999), suggesting the existence of a regulatory autocrine pathway between FGF-2 and 
PTTG. The expression of VEGF by PTTG is FGF-2 independent (McCabe et al., 2002).  
 
1.3.11.2  c-Myc and PTTG 
The transcription factor c-Myc was found to bind to PTTG. c-Myc is involved with the regulation of 
cellular proliferation and is dysregulated in tumours. PTTG was found to bind to the c-Myc promoter 
with the upstream stimulatory factor (USF1) (Pei, 2001). Furthermore, the modulation of p53 function 
by PTTG is mediated through the expression of c-Myc (Hamid and Kakar, 2004).  
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1.3.11.3 SP1 and PTTG 
The global transcriptional effect of PTTG was assessed using chromatin immunoprecipitation (ChIP)-
on-Chip in JEG-3 cells. PTTG was found to interact with the transcription factor SP1 to induce cyclin 
D3 expression to promote G1- to S-phase transition, independent of p21 (Tong et al., 2007). 
 
1.3.11.4 NIS and PTTG 
The sodium-iodide symporter (NIS) is involved in the active transport of iodine into thyroid cells. This 
has clinical significance in the treatment of thyroid cancers where poor radioiodine uptake correlates 
to a poor prognosis. Heaney et al demonstrated reduced iodine uptake in rat thyroid FRTL5 cells 
transfected with PTTG (Heaney et al., 2001). Subsequently, it was shown that PTTG overexpression 
in thyroid cancers was associated with reduced radioiodine uptake (Saez et al., 2006). Boelaert et al  
investigated the mechanism by which PTTG repressed NIS. PTTG was found to repress NIS via FGF-
2. In addition, it was found that PTTG repressed NIS by binding to the hNUE element within the NIS 
promoter (Boelaert et al., 2007). 
 
 
1.3.11.5 Other interactions 
Pei et al discovered the interaction between the ribosomal protein S10 and the molecular chaperone 
HSJ2 with PTTG in testicular cells (Pei, 1999). PTTG was also found to inhibit the phosphorylation of 
Aurora-A and histone H3 Aurora-A substrate which resulted in abnormally condensed chromatin in 
HCT116 cells (Tong et al., 2008).  
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1.4 PTTG BINDING FACTOR (PBF) 
PTTG binding factor (PBF), mapped to chromosome 21q22.3, contains an open reading frame of 179 
amino acids with a predicted molecular mass of 22 kDa and is also known as C21orf3 (Yaspo et al., 
1998) or PTTG1IP. As a protein, PBF shares no significant homology with other human proteins but is 
highly conserved between species, suggesting unique function and evolutionary importance.   
 
1.4.1 Structure, function and localisation of PBF 
PBF interacts with PTTG at its transactivating domain between amino acids 123 to 154 (Chien and 
Pei, 2000). Based on its structure it was speculated that PBF was a protein involved in cell signalling. 
Initially it was thought PBF was a cell surface protein because of the presence of a N-terminal signal 
peptide, transmembrane domain, endocytosis motif and N-glycosylation sites (Yaspo et al., 1998). 
PBF contains a bipartite nuclear localisation signal between amino acids 149 and 166 at the C-
terminus suggesting it may be a nuclear protein (Chien and Pei, 2000). Subsequently, the nuclear role 
of PBF was confirmed when it was demonstrated to facilitate the entry of PTTG into the nucleus. 
Furthermore, the transcription and hence expression of FGF-2 by PTTG requires the presence of PBF 
(Chien and Pei, 2000). PBF has also been identified in intracellular vesicles where it co-localised with 
the late endosomal marker CD63 (Smith et al., 2009).  
The structure of PBF contains phosphorylation sites for cyclic AMP- and GMP- protein kinase and 
casein kinase II (Chien and Pei, 2000). Recently, our group has reported phosphorylation of PBF at 
residue Y174 by Src, a proto-oncogene tyrosine protein kinase. Phosphorylation of PBF leads to 
reduced ability to bind NIS (Smith et al., 2013). Also, glycosylation sites for N-linked and O-linked 
oligosaccharides were identified. Finally, a cleavable N-terminal signal sequence was detected (Chien 
and Pei, 2000).  
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Recently, PBF has also been found to be a secretory protein in MCF-7 cells and this function is 
encoded in the PBF amino acid region of 29 to 93 (Watkins et al., 2010). The schematic representation 
of PBF is shown in Figure 1-12 below.  
 
Figure 1-12 Schematic representation of PBF reproduced from (Smith et al., 2010). PBF 
contains a bipartite nuclear localisation signal sequence and phosphorylation site (residue 
Y174) at its C-terminus. The N-terminal contains the signal sequence and glycosylation sites 
denoted by Gly.  
 
1.4.2 PBF and NIS 
PBF has been shown to repress the expression of the NIS promoter via the upstream enhancer hNUE 
(Boelaert et al., 2007). Subsequently, it was found that PBF colocalises with NIS, altering its 
subcellular localisation and affecting the efficacy of radioiodine uptake. In the presence of PBF, NIS 
translocates from the membrane of COS-7 cells to the cytoplasm. Since the uptake of iodine is 
dependent on normal NIS function at the membrane, PBF alters the ability of the cell to uptake 
radioiodine (Smith et al., 2009). Hence, PBF impairs the ability of a thyroid epithelial cell to absorb 
iodine by directly repressing the expression of NIS and by altering the subcellular localisation of NIS 
from the membrane to the cytoplasm.  
 
1.4.3 Expression in human tissue 
PBF is a ubiquitious protein that is expressed in more than one hundred different human tissues with 
the highest level of expression in the placenta. PBF was also shown to be overexpressed in colon 
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carcinoma, Wilm’s tumour, parathyroid tumours (Chien and Pei, 2000, Yaspo et al., 1998). The 
finding that PTTG is overexpressed in breast cancer (Ogbagabriel et al., 2005) led to the investigation 
of PBF in breast cancer. PBF was found to correlate with ER-positive breast cancers (Watkins et al., 
2010). Recently PBF was reported to be implicated in the repression of angiogenesis in a mouse model 
of Down’s syndrome (Reynolds et al., 2010).    
 
1.4.4 Expression of PBF in thyroid cancer 
Stable PBF overexpression in NIH3T3 murine fibroblast cells induced significant colony formation 
and the injection of nude mice with NIH3T3 cells stably overexpressing PBF led to tumour formation. 
These observations support the ability of PBF to transform cells in vitro and induce tumours in vivo 
(Stratford et al., 2005). Unsurprisingly, PBF expression was found to be increased in differentiated 
thyroid cancers and PBF mRNA expression was independently associated with tumour recurrence 
(Stratford et al., 2005). A cohort of 153 papillary carcinomas of the thyroid with a follow-up of 11.2 
years was studied in the context of PBF expression. It was found that increased PBF expression was an 
independent predictor of worse prognosis and shorter disease-specific survival. In addition, PBF 
expression was associated with distant metastases at diagnosis, locoregional recurrence and tumour 
multicentricity (Hsueh et al., 2013).    
 
1.4.5 PBF overexpression in murine thyroids 
The human homolog of PBF shares 80 % homology with murine PBF (Chien and Pei, 2000).  Our 
group has generated a transgenic murine model of PBF overexpression in the thyroid gland (PBF-Tg) 
to study the effects of PBF in thyroid tumourigenesis. The human PBF gene was driven by the bovine 
thyroglobulin promoter and tagged with haemagglutinin (HA) (Read et al., 2011).  
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1.4.5.1 PBF and goitre formation 
The PBF-Tg mouse developed goitres by 6 weeks and more than 65 % of mice developed hyperplastic 
lesions by 52 weeks of age. These in vivo thyroid changes were not TSH driven and expression of 
growth factors VEGF, TGFβ, EGF and IGF-1 was unaltered compared to wild-type mice (Read et al., 
2011). Further investigation into the aetiology of thyroid pathology revealed dysregulation of TSHR 
mRNA expression, which was significantly induced by PBF. The mRNA expression of PTTG, 
throglobulin, transcription factor 1 and paired box gene 8 mRNA was found to be unaltered in the 
presence of PBF overexpression in the thyroid of PBF-Tg mice (Read et al., 2011).  
Interestingly, no cancers were induced although close inspection of the nuclei of the hyperplastic 
lesions revealed large nuclei consistent with a proliferating cell. Although Akt mRNA expression was 
normal in PBF-Tg mice, the phosphorylation of Akt was found to be significantly induced by PBF. 
Furthermore, the expression of cyclin D1, a marker of proliferation and downstream target of  
activated Akt, showed an upregulation in PBF goitres. Thus, Akt activation, involved in the PI3K/Akt 
signalling pathway (described in 1.2.6.2), might  be involved in inducing goitre and hyperplastic 
thyroid lesion formation. (Read et al., 2011). The thyroid phenotype observed in the PBF-Tg murine 
model was very similar to the PtenL/L;TPO-Cre mouse in which there is constitutive activation of the 
PI3K/Akt pathway (Yeager et al., 2007). The  PtenL/L;TPO-Cre mouse did not develop thyroid cancers 
but developed metastatic follicular carcinomas when the Kras oncogenic mutation was introduced. On 
its own, the Kras mutation did not cause thyroid cancer (Miller et al., 2009).   
Further to the above finding in PBF-Tg mice thyroids, the expression of PBF in human thyroid goitres 
was examined. PBF mRNA expression was increased in human multinodular goitres (MNG) but 
protein expression of PBF in MNGs were similar to normal thyoid tissue. TSHR protein expression 
was also found to be upregulated in MNGs compared to normal thyroids (Read et al., 2011). The 
above findings implicate PBF, dysregulated TSHR and the PI3K/Akt pathway in goitrogenesis.   
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1.4.5.2 PBF and thyroid hormone  
The absorption of iodine is impaired in the presence of PBF due to reduced expression of the sodium-
iodide symporter (NIS) and altered localisation of NIS, discussed in section 1.4.3 above (Boelaert, 
2007, Smith, 2009). This observation was confirmed in vivo, in the PBF-Tg murine thyroids where 
radioiodide uptake was represssed (Read et al., 2011).  
Subsequently, Smith et al demonstrated that MCT8, a monocarboxylase transporter which mediates 
thyroid hormone secretion, binds and co-localises with PBF, resulting in reduced thyroid hormone 
secretion and an accumulation of thyroid hormone in the thyroid gland of the PBF-Tg mouse (Smith et 
al., 2012).  
 
1.4.6 PBF and genetic instability 
PBF has been shown to be overexpressed in differentiated thyroid cancer and is an independent 
prognostic marker for recurrent disease (Hsueh et al., 2013, Stratford et al., 2005). Genetic instability 
is a hallmark feature of human cancers and a critical protein that governs genetic instability, Trp53, 
mediates crucial cellular responses to DNA damage (Petitjean et al., 2007). Although Trp53 is 
frequently mutated in human cancer, it is rarely mutated in differentiated thyroid cancer. PBF was 
found to increase the ubiquitination of Trp53 via the E3 ligase, Mdm2 (Read et al., 2014a, Read et al., 
2014b). PBF was also found to interfere with the expression of DNA repair genes which may explain 
the genetic instability induced in thyroid cells overexpressing PBF (Read et al., 2014a).   
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1.5 GENETIC INSTABILITY 
1.5.1 Hypotheses of tumourigenesis 
In the 1950s, researchers came to the hypothesis that tumourigenesis is a multistep process (Foulds, 
1958). Calculations by Ashley based on gastric cancers estimated that three to eight mutations are 
required for tumourigenesis (Ashley, 1969). However, a study on retinoblastoma has shown that as 
few as 2 mutations was required for tumour formation (Knudson, 1971).  
It was initially proposed that most neoplasms are monoclonal and that tumour cells are more 
genetically unstable compared to normal cells (Nowell, 1976).  Mutations are a necessary prerequisite 
for cancer formation and progression because they confer a selective growth or survival advantage. 
Mutations in genes that are critical in cell cycle control and DNA repair, that play an important role in 
maintaining genomic stability, play an important role in tumourigenesis, and led to the development of 
the mutator phenotype hypothesis (Tomlinson and Bodmer, 1999, Loeb, 2001). Negrini et al argues 
that the low frequency of mutations in caretaker genes in high-throughput sequencing studies of 
tumours in sporadic cancer does not support the mutator phenotype hypothesis. Furthermore, 
comparing untreated with treated glioblastomas, the mutations of caretaker genes was higher 
following treatment, suggesting that caretaker gene mutation is a late event rather than being essential 
in the initial development of the tumour  (Negrini et al., 2010). It was therefore argued that whilst the 
mutator phenotype hypothesis explained the cause of hereditary tumours, it did not necessarily explain 
sporadic tumour genesis. 
The oncogene-induced DNA replication stress model put forward by Halazonetis et al. attempts to 
address the issue of genetic instability in tumourigenesis (Halazonetis et al., 2008). In this model, 
activated oncogenes induce replicative stress resulting in genetic instability and early cancer 
formation.  
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Overall, tumourigenesis from a normal to a cancerous cell is a complex process that is not fully 
understood. However, genetic instability is a consistent feature within cancers and has close 
association with genes involved in DNA damage and repair. 
   
1.5.2 Genetic instability and cancer 
The hallmark feature of solid tumours is an unstable genome (Rajagopalan et al., 2002, Loeb and 
Monnat, 2008). Genetic instability in cancer reflects an increased rate of mutation which may arise 
either from increased rates of damage or defects in repair ability resulting in reduced genomic integrity 
within cells (Rajagopalan et al., 2002, Loeb and Monnat, 2008). Loss of genetic stability facilitates 
tumour development by generating mutants that can undergo clonal selection (Storchova and Pellman, 
2004). At a molecular level, the accumulation of extra copies of DNA or chromosomes, chromosomal 
translocations, chromosomal inversions, chromosomal deletions, single-strand breaks in DNA, double-
strand breaks in DNA, the intercalation of foreign substances into the DNA double helix or any 
abnormal changes in the DNA tertiary structure resulting in the gain or loss of DNA or the 
misexpression of genes, cause genetic instability. Genetic instability can arise at a nucleotide 
(microsatellite instability) or chromosomal level (chromosomal instability). Microsatellite instability, 
characterised by nucleotide base changes that occur preferentially in repeat sequences, is typically 
caused by a defective repair process whilst chromosomal instability is characterised by aneuploidy 
caused by deletions or amplification of whole / part chromosomes (Fishel et al., 1993, Ionov et al., 
1993, Lengauer et al., 1998). It has been reported that microsatellite instability and chromosomal 
instability are mutually exclusive, suggesting that instability of one variety alone is sufficient for 
driving tumourigenesis (Loeb and Loeb, 1999). Previous studies by Lengauer et al (Lengauer et al., 
1997) and Willenbucher (Willenbucher et al., 1999) suggested that chromosomal instability is more 
dominant in driving tumourigenesis than microsatellite instability, at least in the case of colorectal 
tumours.   
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The role of genetic instability in thyroid cancer has been described previously (Kim et al., 2005, 
Mitmaker et al., 2008, Vaish et al., 2004, Lohrer et al., 2001). In addition, benign thyroid lesions have 
been shown to demonstrate microsatellite instability albeit at a lower level compared to thyroid cancer 
(Mitmaker et al., 2008). However, other studies did not show this (Bauer et al., 2002). 
 
1.5.3 Measuring genetic instability 
Chromosomal instability, characterised by abnormal segregation of chromosomes and aneploidy 
(Rajagopalan et al., 2003), is caused by dysregulation of checkpoint proteins involved in mitosis, 
resulting in the failure to halt cell cycle progression to allow DNA repair to occur (Roschke et al., 
2008). Additionally, apoptosis has an important role to play in removing cells that cannot be repaired 
following DNA damage. Consequently, apoptotic genes when dysregulated can induce chromosomal 
instability. This is confirmed by the observation that loss of p53 and p73 is associated with increased 
aneuploidy in mouse embryonic fibroblasts (Talos et al., 2007, Tomasini et al., 2008).  
Chromosomal instability is predominantly quantified using comparative genomic hybridization (CGH) 
or fluorescent in-situ hybridization (FISH).  The FISH technique uses fluorescent probes to detect and 
localise the presence or absence of specific DNA sequences on chromosomes.  In CGH, differences in 
hybridisation between normal and tumour human DNA can be compared using fluoresecent labelled 
fragments of normal and tumour on a scaffold of human metaphase chromosomes. This technique is 
sensitive for deletions or amplifications between 1 – 10 megabases (Bentz et al., 1998). CGH is an 
improvement of the FISH technique for quantifying chromosomal instability. 
Microsatellite (or simple sequence repeats) are repeat sequences scattered throughout the genome and 
are highly variable from individual to individual. These repeating units consists of 1 to 6 base pairs in 
length (but can be longer) and most commonly in humans, consist of repeat C and A nucleotides. The 
technique of measuring microsatellite instability arose when random oligonucleotide primers used to 
DNA fingerprint colorectal tumours and its adjacent tissue found tumour specific PCR products of 
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altered length encompassing segments with repetitive nucleotide sequences (Peinado et al., 1992). 
Basik et al used the (CA)8RY primer to measure the index of genetic instability in colorectal 
carcinoma and coined the phrase “Inter-simple sequence repeat PCR” for this technique (Basik et al., 
1997). Subsequently, Stoler et al used the same technique of inter-simple sequence repeat PCR to 
determine genetic instability in colorectal polyps and found that genetic instability is an early event in 
colorectal tumour progression and is not a consequence of malignancy (Stoler et al., 1999).  
Initially, microsatellite instability was shown to be caused by a defective Msh2 gene, involved in 
mismatch repair, in colorectal carcinoma (Fishel et al., 1993). The mismatch repair family members 
repair base-base mispairs and larger insertions / deletions (Hakem, 2008). Defective mismatch repair 
results in increased rates of DNA replication errors within the genome causing microsatellite 
instability (MSI). Areas within the genome preferentially affected are genes such as TGFβRII, IGF-2R 
and BAX which contain microsatellites within their coding regions. As such, mismatch repair family 
defects result in incorrect DNA replication which may consequently cause microsatellite instability 
preferentially in the above genes (Loeb and Monnat, 2008). Microsatellite instability can also be 
caused by base excision repair pathway defects (Hakem, 2008, Guo and Loeb, 2003).   
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1.6 THE CELL CYCLE 
Cell cycle dysregulation and consequently genetic instability is found widely in human cancer. Cell 
duplication begins with synthesis of DNA in the S phase and division in the mitosis (M)  phase. In 
between these two phases are the G1 and G2 gaps where the cell “rests” to recover from the preceding 
phase. During G1 the cell may enter a  special G0 phase which can last indefinitely. If the cell 
progresses beyond the end of G1, known as the restriction point, the cell is committed to DNA 
replication (Alberts et al., 2014).  
Cyclins and cyclin-dependent kinases (CDK) determine a cell’s progress through the cell cycle. The 
CDK-cyclin complexes directly involved in driving the cell cycle include the three interphase CDKs 
(CDK2, CDK4, and CDK6), CDK1 and ten cyclins belonging to 4 different classes (A, B, D and E 
cyclins) (Malumbres and Barbacid, 2009).  DNA damage induces cell cycle arrest via the inhibition of 
CDK (Bartek et al., 2004) to allow for DNA repair. Unsuccessful DNA repair results in senescence or 
apoptosis, but if the cell cycle is allowed progress, genetic instability results (Kastan and Bartek, 
2004).   
 
1.6.1 CDK and DNA damage 
The genes ataxia-telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) are 
activated together with checkpoint kinases Chk1 and Chk2 in DNA damage, resulting in increased 
levels of the CDK inhibitor p21 or inhibition of CDK activators such as Cdc25 phosphatases (Bartek 
et al., 2004). This results in cell cycle arrest at G1/S and G2/M allowing for DNA repair to occur.  
Mutations in ATM result in ataxia-telangiectasia and ATR in Seckel syndrome (Cimprich and Cortez, 
2008).    
  General Introduction 
51 
 
There is increasing evidence for the role of CDKs in DNA repair (Yata and Esashi, 2009). 
Homologous recombination repair during S phase and G2 is mediated by CDK1 and CDK2 
phosphorylating Brca2 to modulate its interaction with Rad51 (Esashi et al., 2005).  
 
1.6.2 CDK and chromosomal instability 
The CDK1-cyclin complex regulates the centrosome cycle and the onset of mitosis. The 
phosphorylation of downstream targets to the CDK1-cyclin complex during G2 results in centrosome 
separation, nuclear envelope breakdown and chromosome condensation (Malumbres and Barbacid, 
2005). CDK1 activity is repressed at the metaphase-anaphase interface through the activation of 
separase, to allow sister chromatid separation (Musacchio and Salmon, 2007). Hence, in the 
dysregulation of CDK1, aneuploidy and chromosomal instability results. 
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1.7 ATM/ATR signalling pathway 
The cell is under constant stress and requires coping mechanisms to respond and maintain its integrity. 
Genetic instability arises when the appropriate response mechanism fails. As discussed above, genetic 
instability is related to progressive degeneration, cancer predisposition and sensitivity to various DNA 
damaging agents (Bensimon et al., 2010, Bhatti et al., 2011, Nam and Cortez, 2011, O'Driscoll et al., 
2007, Ruzankina et al., 2007). 
The ATM / ATR signalling pathway, which plays a central role in response to DNA damage is shown 
in Figure 1-13. The ATM (ataxia-telangiectasia mutated) gene belongs to a family of serine/threonine 
kinases which was first discovered in the ataxia-telangiectasia disorder. This autosomal recessive 
condition is characterized by progressive cerebellar neurodegeneration and is predisposed to 
lymphoreticular maliganancies (Lavin, 2008, Perlman et al., 2012). Strikingly, patients with the 
condition of ataxia-telangiectasia are particularly sensitive to ionising radiation (Perlman et al., 2012). 
ATM plays a central role in the coordination of cellular functions such as cell cycle arrest, DNA repair 
and apoptosis in response to DNA damage (Sancar et al., 2004). The general consensus is that the 
ATM response occurs in double strand breaks whilst ATR (shown in Figure 1-14) is more pertinent in 
single strand breaks or stalled replication forks. However there is interplay between the 2 genes where 
ATM can activate ATR (Shiotani and Zou, 2009) or ATR can phosphorylate ATM, rendering it active 
(Dodson and Tibbetts, 2006, Stiff et al., 2006, Yajima et al., 2009, Sirbu et al., 2011).  
Murine ATM knockout models develop leukaemia, in particular thymic lymphoma and sporadic 
intestinal cancer (Ejima et al., 2000). ATM has been shown to phosphorylate and activate Trp53, the 
“guardian of the genome”, in response to DNA damage (Banin et al., 1998, Nakagawa et al., 1999). 
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Figure 1-13 An overview of the ATM molecular pathway demonstrating its role in double-
strand DNA damage (Adapted from SABiosciences.com). The diagram depicts known genes 
that interact with ATM and its downstream functions.   
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Figure 1-14  ATR  signalling pathway adapted from (Shiotani and Zou, 2009).The diagram 
shows the activation and function of ATR in response to single-strand breaks.   
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1.8 HYPOTHESIS AND AIMS 
PTTG has been shown to have transforming and tumourigenic effects in vitro and in vivo. 
Additionally, PTTG causes aneuploidy and genetic instability. PTTG is implicated in DNA damage 
and DNA repair through its known interaction with Trp53 and Ku70. The binding partner of PTTG, 
PBF, transports PTTG to the nucleus for its transcription and securin function. PBF is independently 
transforming in vitro and tumourigenic in vivo. PBF is also known to interact with Trp53 which is 
intimately involved in the response to DNA damage. Important to this investigation is the finding that 
PBF and PTTG are both overexpressed in human differentiated thyroid cancer.   
As both PTTG and PBF are transforming genes which show functional interaction and overexpression 
in thyroid cancer, we hypothesised that PBF and PTTG have dependent and independent roles in 
maintaining genomic stability in the thyroid gland. 
The aims of this investigation were: 
1) The development of a murine model of simultaneous PBF and PTTG overexpression in the 
thyroid gland. Our group had murine models of PTTG or PBF overexpression in the thyroid 
gland. The observation that murine models of PBF overexpression in the thyroid developed 
hyperplastic nodules but not cancer and the murine model of PTTG overexpression in the 
thyroid had small thyroid glands led us to hypothesise that two “hits” might be required for 
thyroid tumourigenesis. Hence, I aimed to create a bi-transgenic murine model of both PBF 
and PTTG overexpression in the thyroid gland. 
2) The use of fluorescent inter-simple sequence repeat PCR (FISSR-PCR) for determining 
genetic instability in our murine models. FISSR-PCR was modified for measuring genetic 
instability with small quantities of DNA obtained from our transgenic models and from 
primary murine thyroid culture. 
3) Establishing key genes involved in the DNA damage / DNA repair pathway in the context of 
PBF and PTTG expression with ionising radiation. This part of the study involved the use of a 
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murine DNA damage PCR microarray to screen for genetic alterations within the DNA 
damage / DNA repair pathway.  
 
 
 
 
 
 
 
 
 
 
 
    
2 Materials and Methods 
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2.1 MURINE THYROID DISSECTION 
Murine models used in the following experiments were euthanized with an intra-peritoneal injection of 
sodium pentobarbital (0.2 mls of Euthatal; 200mg in 1 ml) and confirmed to be dead prior to 
harvesting the thyroid gland. The thyroid gland was removed with the aid of a dissecting microscope 
at 10x magnification. Initially, the mouse was secured to a cork board, exposing the neck. 
Subsequently, the fur and skin were excised and the strap muscles divided inferiorly. Superior 
retraction of the strap muscles revealed the thyroid gland sitting on the trachea as shown in Figure 2-1. 
The thyroid gland was removed with micro forceps and scissors and stored in formalin for histology, 
RNAlater for RNA analysis, liquid nitrogen for protein analysis or phosphate buffer solution (PBS) for 
primary cell culture. 
 
Figure 2-1   View of murine thyroid under 10x magnification during dissection. This view of 
the thyroid gland was obtained following the removal of fur and strap muscles in the neck. 
 
2.2 PRIMARY MURINE THYROID CULTURE (PMTC) 
Murine thyroids were mechanically disrupted in PBS prior to being digested in 0.2 % Type II 
collagenase (Worthington Biochemicals) at 37 °C for 45 minutes on a rotator. Subsequently, thyroid 
culture medium described previously by Ambesi-Impiombato et al  (Ambesi-Impiombato et al., 
THYROID 
GLAND 
TRACHEA 
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1980), was added to inactivate collagenase. The mixture was centrifuged at 700 G for 10 minutes to 
obtain a pellet comprising of single thyroid follicles. The supernatant was discarded and the pellet 
resuspended in 1ml of thyroid culture medium. The resuspended thyroid cells were seeded into 12-
well plates (2 wells for each hPTTG or WT thyroid; 4 wells for each PBF and Bi-Transgenic thyroid) 
in thyroid culture medium, supplemented with thyrotrophin (300 mU/l), insulin (10 mg/ml), 
transferrin (5 mg/ml) [Sigma], hydrocortisone (3.5 ng/ml) [Sigma], somatostatin (10 ng/ml) 
[Sigma], glycyl-L-histidyl-L-lysine acetate (2 ng/ml) [Sigma], penicillin (105 U/l), streptomycin 
(100 mg/l) and 5 % fetal calf serum. After 3 days, the thyroid culture medium was changed with calf 
serum omitted. Experiments were performed at day 10. In experiments involving radiation, primary 
murine cultures were exposed to 15 Gy of radiation on day 9 and harvested 24 hours later. 
 
2.3 DNA EXTRACTION 
DNA was extracted as per the DNA extraction kit protocol (DNeasy 96 Blood & Tissue Kit; Qiagen). 
Briefly, tissue was dissolved in ATL buffer and Protein K at 56°C for 3 hours. RNAse A was added to 
the mixture and left to stand for 2 minutes at room temperature to remove RNA contaminants. AL 
buffer and 100% ethanol were added to the mixture and filtered in a DNeasy Mini spin column. The 
DNA binds to the filter whilst contaminants wash through. The filter was washed twice to ensure a 
clean DNA sample. Finally, the DNA was extracted by elution through adding AE buffer to the filter. 
The amount of DNA was quantified using a spectrophotometer (Nanodrop ND-1000; 
Thermoscientific). 
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2.4 RNA EXTRACTION 
RNA was extracted using the RNAeasy micro extraction kit protocol (RNeasy Micro; Qiagen). 
Thyroid tissue was processed using β-Mercaptoethanol to denature RNAses and buffer RLT 
(proprietary buffer; Qiagen RNAeasy micro extraction kit) to promote RNA binding to the filter. RNA 
was filtered onto the proprietary filter within the RNeasy MinElute spin column and washed several 
times to remove contaminants. RNase-free water to dissolve the purified RNA was used in the final 
step to collect purified RNA. RNA concentration was quantified using spectrophotometry (Nanodrop 
ND-1000; Thermoscientific). To ensure consistent and good RNA quality, the spectral value of 
A260:A230 ratio was greater than 1.7 and A260:A280 ratio, between 1.8 and 2.0. The average amount of 
total RNA obtained in this manner ranged between 220 to 800 ng. 
 
2.5 REVERSE TRANSCRIPTION 
Reverse transcription was carried out using the Promega Reverse Transcription System. Briefly, each 
reaction consisted of 0.5 µg RNA, 2 µl 25 mM MgCl2, 1 µl 10X reverse transcriptase buffer, 1µl 
10mM deoxynucleotide triphosphate, 5 pmol random hexamers, 10 units ribonuclease inhibitor 
(RNAsin) and 7.5 units avian myeloblastosis virus (AMV) reverse transcriptase, in a total reaction 
volume of 10 µl. The reaction was incubated for 10 minutes at room temperature followed by 60 
minutes at 42 °C to allow primer fixation and extension. The reaction was terminated by heating the 
sample for 5 minutes at 95 °C.   
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2.6 QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (qRT-
PCR) 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using TaqMan™ 
chemistry. In this technique, the target gene of interest is amplified through polymerase chain reaction 
(PCR). The probe used within the reaction was specially labelled with a 5’ reporter dye (FAM 6-
carboxy-fluorescein or VIC) and a 3’ quencher dye (TAMRA 6-carboxy-tetramethyl-rhodamine). PCR 
amplification of the target gene released the reporter dye for each cycle of the PCR reaction which was 
read by a laser and CCD camera. The quantity of gene within the known amount of cDNA or DNA 
was thus determined. Pre-optimised specific gene-expression assays for qRT-PCR were purchased 
from Applied Biosystems, UK. All target gene probes were labelled with FAM and housekeeping 
genes (DS-CAM, 18S or β-actin) labelled with VIC.  
These reactions were carried out in 25 µl volumes on 96 well plates. Each reaction comprised of 5 ng 
DNA, 450 nM each target gene forward and reverse primers, 175 nM target gene probe, 450 nM 
housekeeping gene forward and reverse primers, 175 nM housekeeping gene probe and 12.5 µl of 1x 
TaqMan Universal PCR Master Mix (Applied Biosystems). 1x TaqMan Universal PCR Master Mix 
consisted of 3 mM Magnesium Acetate, 200 µM dNTPs, 1.25 units Ampli-Taq Gold polymerase and 
1.25 units AmpErase UNG.  The reaction cycle in the ABI 7500 Sequence Detection System was as 
follows: 50 °C for 2 minutes, 95 °C for 10 minutes followed by 44 cycles of 95 °C for 15 seconds and 
60 °C for 1 minute. 
The cycle number at which a calculated threshold line bisects the logarithmic PCR plot 
determined the Ct value. ΔCt values were calculated by subtracting the Ct of the 
housekeeping gene from Ct of the target gene of interest. The fold change was derived from 
the following formula: 2 –(ΔCt of experimental group – ΔCt of control group).  
  Materials and Methods 
62 
 
Reactions were multiplexed where possible. To determine if the reaction could be multiplexed, qRT-
PCR was performed with cDNA amounts of 1 ng, 3 ng, 10 ng, 30 ng and 100 ng in a multiplexing 
experiment using the target gene of interest and housekeeping gene in question. The logarithmic value 
of cDNA quantity was plotted against the Ct value of each gene in the qRT-PCR experiment (Figure 
2-2A). The ΔCt value, obtained by subtracting the target gene Ct value from the β-actin Ct value was 
plotted in a separate graph shown in Figure 2-2B. The gradient of the best fit linear plot of the 
logarithmic cDNA quantity against the ΔCt value should be between -0.1 and 0.1 if multiplexing was 
possible. Figure 2-2 shows the multiplexing experiment between Trp53 and β-actin, used as an 
example illustrating that these two genes cannot be multiplexed.     
 
 
Figure 2-2  Linear plots of logarithmic cDNA against Ct values (A) and  Δ Ct values (B).  
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2.7 PROTEIN EXTRACTION 
Tissue and cell culture harvested for protein extraction were homogenized in a tube containing a 
cocktail of Radio Immuno Precipitation Assay (RIPA) buffer (329 µl) and  protease inhibitor (21 µl). 
Subsequently, the crude lysate was centrifuged at 13,200 rpm for 10 mins at 4 °C. The supernatant was 
removed and protein concentration quantified using spectrophotometry (Nanodrop ND-1000; 
Thermoscientific). 
 
2.8 WESTERN BLOT 
12 % separating gels were made using 1.875 ml 1.5 M Tris HCl (pH 8.8), 3 mls acrylamide, 75 µl 10 
% SDS, 75 µl 10 % APS and 7.5 µl TEMED. Stacking gels were made using 0.625 ml 0.8 M Tris HCl 
(pH 6.8), 0.3125 ml acrylamide, 50 µl 10 % SDS, 50 µl 10 % APS and 5 µl TEMED. 20 µg of protein 
in 4X Laemmli buffer (0.1075 g DTT: 1 ml Laemmli buffer) was loaded into each well.  
Proteins separated by electrophoresis were transferred to polyvinylidene fluoride (PVDF) membranes, 
incubated in 5 % non-fat milk in Tris-Bufferred Saline Tween-20 (TBST) and subsequently incubated 
overnight at 4 °C with a primary monoclonal antibody. After washing in TBST, membranes were 
incubated in the appropriate secondary antibodies conjugated to horseradish peroxidise. After 
additional washes, antigen-antibody complexes were visualized by the ECL chemiluminescence 
detection system on Kodak BioMax Light film. Actin expression (Anti-βactin; 1:10,000; AC-15; 
Sigma-Aldrich) was also determined to control for differences in protein loading between wells. 
Western blot films were scanned using the CanoScan Flatbed Photo and Document scanner and 
relative protein quantification was determined using Image J software. 
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2.9 IMMUNOFLUORESCENCE 
The cells in each well were fixed with 800 μl fixing solution (20 ml of 0.2 M PBS, 0.8g of 
paraformaldehyde, 0.8 g glucose, 8 ml of 0.1 % sodium azide and 12 ml water) for 20 minutes at room 
temperature. Following rinsing with PBS, the cells were permeabilised in  800 μl of chilled methanol 
for 10 minutes. The cells were rinsed again and blocked with 5 % blocking serum for 20 minutes at 
room temperature diluted in PBS containing 1 % BSA (bovine serum albumin). Subsequently, excess 
blocking serum is aspirated and cells incubated in primary HA antibody (mouse monoclonal anti-
HA.11 (16B12); 1:1000; Covance Research Products) diluted in PBS containing 1% BSA for 1 hour. 
The cells are rinsed again and incubated for 1 hour in a red fluorescent labelled secondary antibody 
diluted in PBS containing 1 % BSA and 1.5 % blocking serum. The cells are then visualised using an 
inverting microscope. DAPI (4',6-diamidino-2-phenylindole; 300 µl of diluted stock solution as per 
manufacturer’s recommendation; ThermoFisher Scientific) staining was used to identify nuclei by 
staining DNA blue. 
 
2.10 STATISTICAL ANALYSIS 
Data was analysed using Sigma Stat and SPSS (SPSS Science Software UK Ltd). The numerical data 
was determined if it had a normal distribution. Student’s t-test was used for comparison between two 
groups of parametric data. Kaplan-Meier survival analysis was determined using XLSTAT add-on to 
Microsoft Excel 2007. Two different statistical tests were used to determine the p-value for survival. 
The p-value derived from the Cox-Mantel or log-rank test is more powerful for detecting late, whilst 
the Wilcoxon test is more powerful for detecting early differences in probabilities for survival. A p 
value ≤ 0.05 was taken to be statistically significant. 
 
 
    
3 Bi-transgenic murine model of human PTTG and PBF 
overexpression in the thyroid gland 
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3.1 INTRODUCTION 
The human securin PTTG was first described in rat pituitary tumours (Pei and Melmed, 1997). The 
role of PTTG in cell transformation and tumourigenesis was subsequently confirmed when murine 
fibroblast 3T3 cells overexpressing PTTG, injected into nude mice developed tumours (Pei and 
Melmed, 1997). Further experiments in vitro showed aneuploidy or chromosomal instability when 
overexpressed (Wang et al., 2001, Winnepenninckx et al., 2006, Yu et al., 2000a, Yu et al., 2003). 
Further evidence for the role of PTTG in tumourigenesis came from the observation that PTTG was 
overexpressed in a variety of tumour types (Cho-Rok et al., 2006, Dominguez et al., 1998, Heaney et 
al., 2000, Kakar and Malik, 2006, Puri et al., 2001, Shibata et al., 2002, Tfelt-Hansen et al., 2004, Wen 
et al., 2004). More importantly, the link between thyroid cancer and PTTG has been well-established 
(Liang et al., 2011, Kim et al., 2007a, Kim et al., 2005, Boelaert et al., 2003, Zatelli et al., 2010).  
The binding factor for PTTG (PBF) was initially discovered by Yaspo et al and its function as a 
transport protein for PTTG was described later on (Chien and Pei, 2000, Yaspo et al., 1998). PTTG 
does not have a nuclear localising signal of its own and yet needs to be within the nucleus for its 
function. The finding that PTTG requires the presence of PBF to upregulate fibroblast growth factor 2 
(FGF-2), a downstream target of PTTG, provides compelling evidence for the need for PBF for its 
actions (Chien and Pei, 2000).  Hence, it was not surprising that the presence of PTTG upregulated the 
expression of PBF (Stratford et al., 2005). Interestingly, our group has shown that PBF has 
transforming and tumourigenic actions independent of PTTG (Stratford et al., 2005). Additionally, 
PBF has been shown to cause genetic instability, is overexpressed in well differentiated thyroid cancer 
and an independent prognostic marker for tumour recurrence (Hsueh et al., 2013, Stratford et al., 
2005).   
PBF and PTTG are widely conserved in the eukaryote species. Human PTTG and PBF share   89 % 
and 93 %  homology respectively with murine PBF and PTTG (Zhang et al., 1999, Chien and Pei, 
2000). Murine models were generated by our group to study the effects of PTTG or PBF 
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overexpression in the thyroid gland. Murine models with thyroglobulin driven human PTTG 
overexpression in the thyroid gland (PTTG +/+) did not demonstrate tumour formation but instead 
developed small thyroids with reduced cellular proliferation (Lewy et al., 2013). Murine models 
overexpressing human PBF (PBF-Tg) in the thyroid exhibited hyperplastic and macrofollicular lesions 
but with no evidence of thyroid tumours (Read et al., 2011). Taken together, PTTG or PBF 
overexpression individually is inadequate for thyroid tumour formation.  
Overall, PBF and PTTG are proto-oncogenes which are overexpressed in human thyroid cancers. PBF 
binds to PTTG, facilitating its entry into the nucleus, and has independent tumourigenic actions. The 
observation that murine models overexpressing PBF or PTTG alone in the thyroid do not develop 
thyroid cancers suggests that PTTG and PBF independently do not induce thyroid tumours in vivo. 
However, given the strong tumourigenic potential of both PBF and PTTG, and that the genes bind to 
each other, a murine model overexpressing both PTTG and PBF in the thyroid gland was hypothesised 
to develop thyroid cancer.  Thus, the aim of this chapter is to describe and characterise a transgenic 
murine model overexpressing both PBF and PTTG in the thyroid gland.  
 
 
 
 
 
 
 
 
 
 
      Bi-transgenic murine model of human PTTG and PBF overexpression in the thyroid gland
  
68 
 
3.2 MATERIALS AND METHODS 
3.2.1 Generation of murine model 
Two FVB/N murine models of targeted human PBF (hPBF) and PTTG (hPTTG) overexpression in the 
thyroid gland were generated by Dr. Martin Read and Dr. Gregory Lewy at the University of 
Birmingham. Very briefly, plasmids containing the gene of interest attached to a bovine thyroglobulin 
promoter and tag were injected into FVB/N embryos. The tags used for the hPBF gene and hPTTG 
gene were HA and FLAG respectively. These embryos were implanted into pseudo-pregnant mice and 
founder lines were obtained from these litters. 
The murine model expressing both human PBF and PTTG  in the thyroid gland was created by mating 
the two lines described above. The first pairing between the two different models created a mouse that 
was heterozygous for both PBF and PTTG (PBFHet-PTTGHet) as depicted in Figure 3-1. The 
subsequent mating genetics was predictably complicated because of random gene insertion(s) within 
the genome for the PBF and PTTG murine models. Consequently, mating of the PBF HET-PTTG 
HET lines had created a colony of transgenic mice with different genotypes, as seen in Figure 3-2. Our 
plan was to perform all our experiments on the murine model homozygous for both PBF and PTTG in 
the thyroid gland (BI-Trans). To achieve the objective of producing BI-Trans mice, we aimed to mate 
BI-Trans with BI-Trans mice, to ensure a continual supply of BI-Trans murine models shown in 
Figure 3-3.     
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Figure 3-1  Mating genetics of PBF and PTTG homozygotes. Mating a PBF homozygote with 
a PTTG homozygote created a colony of PBF heterozygote – PTTG heterozygote (PBFHet-
PTTGHet). 
 
Figure 3-2 Mating genetics of PBFHet-PTTGHet. Mating PBFHet-PTTGHet with PBFHet-
PTTGHet yielded a colony of mixed genotypes illustrated above. The offspring genotype 
pattern is caused by random PBF / PTTG gene insertion in different chromosomes during the 
creation of the murine models.  
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Figure 3-3  Mating genetics of BI-Trans murine models. The mating of BI-Trans models 
creates a colony comprising exclusively of BI-Trans offspring.   
 
A total of 1271 mice were generate for the above study. Comparison data for the individual hPTTG 
and hPBF murine models were provided by Dr. Gregory Lewy and Dr. Martin Read respectively 
(University of Birmingham).   
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3.2.2 Ageing colony 
To study the long term effects of PBF and PTTG overexpression in the thyroid gland, we had a 
separate colony of mice homozygous for PBF and heterozygous for PTTG (PBFHomo-PTTGHet). 
The rationale for choosing this model for this aspect of our investigation is discussed in section 3.3.2 
and 3.4.2. 
 
3.2.3 Tissue DNA extraction 
DNA from ear clippings was obtained from the murine colony and extracted as per protocol described 
in section 2.3. 
 
3.2.4 Zygosity screening 
Zygosity determination was performed using qRT-PCR on the ABI 7500 Sequence Detection System 
which employs TaqMan™ chemistry for quantification of DNA levels, described previously in section 
2.6. In this chapter, the target gene of interest is PBF and PTTG and hence, the appropriate primers 
and probes were used. The housekeeping gene for the qRT-PCR experiments in this chapter was 
DSCAM. The zygosity was determined based on the fold change value of the mice of unknown 
genotype compared to the control mice samples of known genotype. 
 
3.2.5 Murine organ dissection 
Following euthanasia of the murine model, the animal was weighed and organs dissected. Harvested 
organs including the thyroid gland, lungs, heart, kidney, spleen and liver were initially weighed and 
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stored appropriately. Organs for protein experiments were stored in liquid nitrogen and RNA 
experiments, in RNAlater. Microdissection for the thyroid gland was described in section 2.1.  
 
3.2.6 Western blot 
Protein was extracted from harvested murine organs as described in section 2.7 and used for Western 
blot described in section 2.8. The primary antibodies used were against human PTTG at 2 μg/ml 
(Invitrogen, UK) and human PBF at 1:1000 (rabbit polyclonal; manufactured in-house Dr. Turnell, 
University of Birmingham). Subsequent incubation with the appropriate secondary antibody 
conjugated to horseradish peroxidise (mouse anti-rabbit; Dakocytomation, UK) was performed for 1 
hour at room temperature before being developed.  
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3.2.7 Cardiac puncture 
The animal was rendered unconscious by an overdose of Sevofluorane. Cardiac puncture was carried 
out using a 23G needle and approximately 1ml of blood was aspirated. The sample was stored in a 1.5 
ml Eppendorf at 4 °C for 24 hours. The sample was then spun at 13,200 rpm for 20 minutes. The 
extracted supernatant (serum) was transferred to a second 1.5 ml Eppendorf and spun at 13,200 rpm 
for 10 minutes. The serum was extracted again and transferred to the final Eppendorf which was 
stored at -80 °C prior to usage.  
 
3.2.8 Thyroid function test 
Murine thyroid stimulating hormone (TSH) levels were determined by the laboratory of Professor 
Samuel Refetoff at the University of Chicago. Technical details of this assay has been published 
previously (Pohlenz et al., 1999).   
Total T3 and T4 levels were measured using a radioimmunoassay technique (MP Biomedicals thyroid 
radioimmunoassay kit). Briefly, murine serum and radiolabelled tracer solution were added to tubes 
coated with either T3 or T4 antibodies. The analyte and radiolabelled tracer compete for limited 
antibody binding sites. Radioactivity level, inversely proportional to analyte concentration, was 
quantified using a gamma counter. Finally, the concentration of T3 and T4 was determined by 
interpolation from a standard curve of percentage of trace level versus µg/dL T3 or T4. 
 
3.2.9 Histology 
Murine thyroids were fixed in formalin and sent to the Pathology Department at University Hospital 
Birmingham NHS Trust for processing (courtesy of Dr. Adrian Warfield). Tissue samples were 
embedded in paraffin and  sectioned to produce slides. Slides were stained with Haematoxylin and 
Eosin (H&E). 
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3.3 RESULTS 
3.3.1 Validation of the murine model 
We generated a murine model which was homozygous for both PBF and PTTG in the thyroid gland 
only (BI-Trans). We confirmed the overexpression of PBF and PTTG in the thyroid gland of the BI-
Trans model. We compared the expression of PBF and PTTG in the thyroid gland of the various 
murine models used in our experiments; wild-type (WT), PBF (homozygous for PBF), PTTG+/+ 
(homozygous for PTTG) and BI-Trans. The Western blot below (Figure 3-4) confirmed the 
overexpression of hPBF in the PBF and BI-Trans models  and hPTTG in the PTTG+/+ and BI-Trans 
models (n=4). PBF appeared as a band between 25kDa and 37kDa and PTTG was expressed as a band 
around 29 kDa. The overexpression of hPBF did not appear to increase PTTG protein. Conversely, the 
overexpression of hPTTG did not upregulate the protein expression of endogenous PBF as seen in 
Figure 3.4. 
 
 
Figure 3-4 Western blot showing the expression of hPBF and hPTTG in WT, PBF, PTTG+/+ 
and BI-Trans thyroids (n=4 for each genotype; figure shows n=2 for each genotype).  
 
Next, we used the PBFHomo-PTTGHet model (homozygous for PBF and heterozygous for PTTG) to 
determine the expression of our genes of interest, PBF and PTTG, in the thyroid, heart, lung, liver, 
spleen and kidney. The reasons for this is discussed in section 3.3.2 and 3.4.2 below. The murine 
PBFHomo-PTTGHet thyroids overexpressed human PBF and human PTTG in the thyroid gland only 
and not in the lung, liver, spleen and kidney. A β-actin result in the heart was difficult to obtain as 
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demonstrated in Figure 3.5 because of its fibrous nature. This was consistent with our previous 
experience with the heart organ on Western blot (unpublished).  
 
 
Figure 3-5 Western blot showing the expression of hPBF and hPTTG in PBFHomo-PTTGHet 
(*) in various organs (n=1) compared to wild type (WT). 
 
3.3.2 Reduced mortality in founder BI-Trans models 
Seven PBFHet-PTTGHet breeding pairs were set up to create founder lines. Genotype was determined 
from ear-clippings using qRT-PCR, described above. Offspring genotype followed Mendelian genetic 
principles as shown in Figure 3-2, in expected ratios. Early bi-transgenic (BI-Trans) founder members 
homozygous for both PBF and PTTG, were put in breeding pairs.  
Interestingly, early BI-Trans founder members had reduced mortality compared to PBFHomo-
PTTGHet. In a cohort of breeding pairs over a period of 200 days, 64.3% of Bi-Trans mice died or 
were culled due to illness (n=27). In comparison, the mortality rate in the  PBFHomo-PTTGHet 
genotype was 17.9 % over the same period of time (n=5). The Bi-Trans murine model had an average 
lifespan of 150.9 ± 1.0 days (n=53). The average lifespan of a PBFHomo-PTTGHet model was 477.9 
± 2.9 days (n=89). There was a statistically significant difference between the mortality rates of BI-
Trans (Wilcoxon and log-rank p<0.0001) and PBFHomo-PTTGHet (Wilcoxon p=0.041; log-rank 
p=0.021) models compared to wild-type. The Kaplan-Meier survival plot for the different genotypes is 
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illustrated in Figure 3-6. Post-mortem examination did not reveal any macroscopic cause of death. 
Histological examination of the thyroid gland did not reveal any obvious tumours.  
When comparing the mortality rates between various murine models, PBF and PTTG +/- had similar 
survival rates to wild-type. The survival of BI-Trans was significantly worse than PTTG +/+ 
(Wilcoxon p=0.011; log-rank 0.006). PTTG +/+ mortality was worse than PBFHomo-PTTGHet.  
Hence, for further validation work in this chapter, we used the PBFHomo-PTTGHet model for 
demographic data collection. Moreover, the PBFHomo-PTTGHet model overexpressed large amounts 
of both PBF and PTTG in the thyroid gland.  
 
 
Figure 3-6 Kaplan-Meier survival plot of various murine genotypes according to genotype. If 
0.01 < Wilcoxon p-value ≤ 0.05  (*) and Wilcoxon p-value ≤ 0.0001 (****). n=53 (BI-Trans), 
n=89 (PBFHomo-PTTGHet), n=82 (PBF), n=108 (PTTG+/+), n=129 (PTTG+/- ) and n=30 
(WT).  
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3.3.3 Mice overexpressing both PBF and PTTG in the thyroid gland have 
reduced fertility  
A total of 1271 mice of varying genotypes were raised in the colony. We defined fertility by the time 
to breed, litter size and number of litters. The average mating time for wild-type with wild-type 
pairings (WT2) was 173.00 ± 8.40 days (n=9 pairs), PBF with PBF (PBF2) was 166.17 ± 7.55 days 
(n=12 pairs), PBFHomo-PTTGHet with PBFHomo-PTTGHet (PBFHomo-PTTGHet2) was 146.5 ± 
10.82 days (n=10 pairs), PBFHomoPTTGHet with BI-Trans (PBFHomo-PTTGHet x BI-Trans) was 
142.23 ± 22.62 days (n=41 pairs).  There was no statistical difference between the breeding times for 
the various genotypes compared to the WT2 apart from the BI-Trans with BI-trans pairing (BI-Trans2; 
p=0.003; n=2 pairs) which had a reduced breeding time because of increased mortality. The breeding 
time for the various genotype breeding pairings are shown in Figure 3-7. 
 
Figure 3-7 Average mating period by genotype pairing. The breeding time between BI-Trans 
and BI-Trans, (BI-Trans2) was statistically significant (p=0.003; n=2 pairs). The numbers for 
each genotype pairing was as follows; n=9 pairs (WT2), n=12 pairs (PBF2), n=10 pairs 
(PBFHomo-PTTGHet2) and n=41 pairs (PBFHomo-PTTGHet x BI-Trans).   
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Over the duration of their breeding life, approximately 6 months, mice overexpressing both PBF and 
PTTG in the thyroid gland, irrespective of homo- or heterozygosity, have a fewer number of litters 
compared to wild type pairings (WT2). The PBFHomo-PTTGHet and PBFHomo-PTTGHet pairing 
(PBFHomo-PTTGHet2) produced more litters than the PBFHomo-PTTGHet x BI-Trans pairing (1.65 
± 0.20; n=46), shown in Figure 3-8. The average number of litters for the PBFHomo-PTTGHet2 
pairing was 3.39 ± 0.30 (n=23) compared to the wild type-wild type pairing which produced 5.67 ± 
0.33 litters (n=9) and this was statistically significant  (p=0.0002). The PBF mouse pairing (PBF2) had 
a similar number of litters as WT2 producing an average of 5.75 ± 0.30 litters (n=12) over the same 
period.   
 
 
Figure 3-8 Average number of litters by genotype pairing. The WT2 (n=9) and PBF2 (n=12) 
pairing produced similar number of litters over their breeding period. The PBFHomo-
PTTGHet2 pairing (n=23) had fewer number of litters compared WT2 (p=0.0002) but more 
than the PBFHomo-PTTGHet x BI-Trans pairing (n=46; p<0.00001).    
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The average litter size by genotype pairing is illustrated in Fig. 3-9. There was no statistical difference 
between the size of litter in the WT2 (9.31 ± 0.36; n=51), PBF2 (8.91 ± 0.25; n=64) and PBFHomo-
PTTGHet2 (8.69 ± 0.34; n=78) pairings. However, when a BI-Trans was introduced into the mating 
combination (PBFHomo-PTTGHet x BI-Trans), the litter size reduced significantly to 5.53 ± 0.36 
(p<0.00001 compared to both WT2 and PBFHomo-PTTGHet2; n=86).   
 
 
Figure 3-9 Average size of litter by genotype. The litter size for the WT2 (n=51), PBF2 (n=64) 
and PBFHomo-PTTGHet2 (n=78) pairings were comparable. There was a statistically 
significant difference between the litter size from the PBFHomo-PTTGHet x BI-Trans pairing 
compared to WT2 (p<0.00001) and PBFHomo-PTTGHet2 pairings.  
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The average time for the pairing to yield its first litter was 27.22 ± 2.74 days for WT2 (n=9), 23.58 ± 
1.15 days for PBF2 (n=12), 33.64 ± 4.48 days for PBFHomo-PTTGHet2 (n=22) and 33.86 ± 2.37 days 
for PBFHomo-PTTGHet x BI-Trans (n=36) as shown in Figure 3-10. There was no statistical 
difference between WT2 and PBF2 (p=0.194), between WT2 and PBFHomo-PTTGHet2 (p=0.385) and 
between WT2 and PBFHomo-PTTGHet x BI-Trans (p=0.187). 
 
 
Figure 3-10 Average time to yield first litter by genotype pairing. There was no statistical 
difference between all genotype pairings. The numbers for each genotype group include n=9 
for WT2, n=12 for PBF2, n=22 for PBFHomo-PTTGHet2 and n=36 for PBFHomo-PTTGHet 
x BI-Trans. 
 
Overall, the PBF murine model have similar fertility to wild type (WT). The PBFHomo-PTTGHet2 
pairing had reduced litter numbers compared to the WT2 pairing over the same breeding period. When 
the PBFHomo-PTTGHet mouse was bred with the BI-Trans mouse, the combination had reduced litter 
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over a mating period of 87.5 ± 28.5 days (n=2 pairs). When BI-Trans mice were mated with 
PBFHomo-PTTGHet, it was observed that fertility was limited by the presence of a BI-Trans male, 
suggesting that the BI-Trans male is infertile whilst the BI-Trans female is semifertile. Thus, the main 
breeding pairs used to maintain the colony and generate BI-Trans mice were PBFHomo-PTTGHet 
with PBFHomo-PTTGHet (PBFHomo-PTTGHet2) and male PBFHomo-PTTGHet with female BI-
Trans (PBFHomo-PTTGHet x Bi-Trans). 
 
3.3.4 Bi-Trans and PBFHomo-PTTGHet murine models develop goitres 
We commenced thyroid and body weight data collection from 6 weeks, an age when the transgenic 
murine models were considered fully grown. The thyroid from the murine model homozygous for PBF 
and heterozygous for PTTG (PBFHomo-PTTGHet) increased in weight until 12 months, after which, 
the thyroid weight was essentially stable and in males, atrophied slightly (Figure 3-11A). In the wild-
type mice (WT), thyroid weight was essentially stable from 6 weeks as shown in Figure 3-11B. This 
gradual increase in thyroid weight closely mirrors the trend observed in PBF mice seen in Figure 3-
11C. Body weight data revealed an overall increase in murine body weight over time, with males 
being slightly heavier than their female counterparts up to 6 months. After 12 months, female 
PBFHomo-PTTGHet and WT mice were heavier than males (Figure 3.11). 
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Figure 3-11 Graphs for body and thyroid weight by gender and genotype. The thyroid growth 
trend of the PBFHomo-PTTGHet model (C) closely follows the thyroid growth trend of the 
PBF (B) mouse. Body weight data confirmed that male murine models are heavier than their 
female counterparts up to 6 months in WT (A), PBF and PBFHomo-PTTGHet.  
0 
10 
20 
30 
40 
50 
6 WEEKS 10 WEEKS 3 MONTHS 6 MONTHS 12 MONTHS 18 MONTHS 
W
EI
G
H
T 
AGE 
WT 
Female body weight/g 
Male body weight/g 
Female thyroid 
weight/mg 
Male thyroid 
weight/mg 
A 
0 
10 
20 
30 
40 
50 
6 WEEKS 10 WEEKS 3 MONTHS 6 MONTHS 12 MONTHS 18 MONTHS 
W
EI
G
H
T 
AGE 
PBF 
Female body weight/g 
Male body weight/g 
Female thyroid 
weight/mg 
Male thyroid 
weight/mg 
B 
0 
10 
20 
30 
40 
50 
6 WEEKS 10 WEEKS 6 MONTHS 12 MONTHS 18 MONTHS 
W
EI
G
H
T 
AGE 
PBFHomo-PTTGHet 
Female body weight/g 
Male body weight/g 
Female thyroid 
weight/mg 
Male thyroid 
weight/mg 
C 
      Bi-transgenic murine model of human PTTG and PBF overexpression in the thyroid gland
  
83 
 
We next compared the thyroid weights by time across the genotypes. At 6 weeks, shown in Figure 3-
12, the PBFHomo-PTTGHet mean thyroid weight was 3.5 mg (n=1) in females and 3.58 ± 0.35 mg 
(n=8) in males. The PBFHomo-PTTGHet thyroid weight was significantly larger than WT mice where 
the mean thyroid weight was 1.68 ± 0.04 mg (n=42) for females and 1.91 ± 0.06 (n=35) for males 
(p<0.0001 in males) at 6 weeks. The p-value was not calculatable in females because n=1 for 
PBFHomo-PTTGHet at 6 weeks. There was no significant difference between the thyroid weight of 
PBF, females (3.24 ± 0.11 mg; n=46) and males (3.35 ± 0.09; n=40) compared to PBFHomo-
PTTGHet female (non-calculatable p-value) and males (p=0.38 in males). PTTG heterozygotes 
(PTTG+/-), thyroid weights at this timepoints were 1.42 ± 0.10 mg (n=5) in females and 1.79 ± 0.09 
mg (n=20) in males at 6 weeks. 
 
 
Figure 3-12 Thyroid weight by gender and genotype at 6 weeks. **** denotes a p-value of 
<0.0001 and ns denotes p-value > 0.05.  
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PBFHomo-PTTGHet thyroid weights were 4.09 ± 0.20 mg (n=12) in females and 3.33 ± 0.28 mg 
(n=8) in males at 10 weeks (p=0.031 between genders). At 10 weeks, the thyroid weight for WT was 
1.68 ± 0.10 mg (n=8) in females and 2.10 ± 0.10 mg (n=9) in males. Again, there was a statistical 
difference between WT and PBFHomo-PTTGHet thyroid weight at 10 weeks (p<0.0001 females; 
p=0.0005 males) as shown in Figure 3-13. Comparing PBFHomo-PTTGHet with PBF thyroids, PBF 
thyroid weight was significantly larger at 3.35 ± 0.18 mg (n=13; p=0.01) in females but not in males 
(3.93 ± 0.23 mg; n=14; p=0.121) at 10 weeks. No PTTG+/- data was available for this timepoint.  
 
 
Figure 3-13 Thyroid weight at 10 weeks by genotype and gender. PTTG+/- data was not 
available at 10 weeks. p-values are denoted with * if  0.01 < p   ≤ 0.05,  *** if 0.0001 < p ≤ 
0.001,  **** if  p ≤ 0.0001 and ns if p>0.05. 
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The PBFHomo-PTTGHet female (n=6) and male (n=6) thyroid weights were 6.25 ± 0.64 mg and 5.65 
± 1.04 mg respectively at 6 months shown in Figure 3-14. The WT thyroid weight was 2.40 ± 0.15 mg 
(n=3) in females and 3.33 ± 0.09 mg (n=3) in males. There was a statistical difference between the 
female PBFHomo-PTTGHet and WT thyroid weight (p=0.004) but no difference in males (p=0.172). 
PBF thyroid weights were 5.68 ± 0.43 mg (n=6) in females and 6.37 ± 0.35 mg (n=9) in males at 6 
months. These were statistically not significant when compared to PBFHomo-PTTGHet (p=0.477 in 
females and p=0.460 in males). Finally, PTTG+/- thyroid weights at 6 months were 2.4 ± 0.46 mg 
(n=5) in females and 2.65 ± 0.07 mg (n=8) in males.  
 
 
Figure 3-14 Thyroid weights by genotype and gender at 6 month. p-values are denoted with  
** (0.001 < p ≤ 0.01), *** (0.0001 < p ≤ 0.001)  and ns (p>0.05).  
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Thyroid weights at 12 months is shown in Figure 3-15. At 12 months, female PBFHomo-PTTGHet 
thyroids were 9.24 ± 0.74 mg (n=5) and male PBFHomo-PTTGHet thyroids were 8.98 ± 0.93 mg 
(n=6). The PBFHomo-PTTGHet thyroids were significantly larger (p=0.001 females; p<0.0001 males) 
than their WT counterparts in which the thyroid size was 3.3 ± 0.29 mg (n=3) in females and 3.24 ± 
0.17 mg (n=7) in males. PTTG+/- thyroids were 2.9 ± 0.15 mg (n=3) in females and 2.6 mg (n=1; 
standard deviation not calculable) in males at 12 months. PBFHomo-PTTGHet thyroids were similar 
in size to wild-type thyroids at 12 months (p=0.687 females; p=0.138 males). Female PBF thyroids at 
12 months were 8.1 ± 1.43 mg (n=12) and male PBF thyroids were 6.3 ± 1.08 mg (n=13).  
 
 
Figure 3-15  Thyroid weight by gender and genotype at 12 months. p-values are denoted with 
** (0.001 < p ≤ 0.01), **** (p ≤ 0.0001) and ns (p>0.05).  
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Finally, thyroid weights of the different genotypes at 18 months is shown in Figure 3-16. In 
comparison with WT thyroids (female, 3.25 ± 0.30 mg, n=4; male, 3.2 ± 0.24 mg, n=4), PBFHomo-
PTTGHet thyroids were significantly larger (female 10.00 ± 0.58 mg, p<0.0001, n=6; male 8.03 ± 
0.37 mg, p<0.0001, n=6). The size of PBFHomo-PTTGHet thyroids were larger than PBF thyroids 
(female 6.87 ± 0.42 mg, n=9; male 9.3 ± 0.29 mg, n=12) at 18 months. PTTG heterozygote (PTTG+/-) 
thyroids at 18 months were similar in size to WT thyroids, 3.00 mg (n=1; standard error of mean not 
calculatable) in females and 2.85 ± 0.15 (n=2) in males.    
 
Figure 3-16  Thyroid weights at 18 months by gender and genotype. p-values are denoted 
with *** if  0.0001 < p ≤ 0.001 and **** if p ≤ 0.0001. 
 
Overall, mice that were homozygous for PBF and heterozygous for PTTG (PBFHomo-PTTGHet) had 
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3.3.5 Thyroid hormone levels in transgenic murine models 
Next, we determined whether large thyroids (goitre) in the murine model homozygous for PBF and 
heterozygous for PTTG (PBFHomo-PTTGHet) was associated with aberrant thyroid hormone levels. 
High thyroid stimulating hormone (TSH) levels can stimulate thyroid tissue proliferation. Hence, T3, 
T4 and TSH levels were determined for the PBFHomo-PTTGHet model at 6 weeks, 6 months, 12 
months and 18 months.   
T3 levels maintained a constant level throughout the age range, shown in Figure 3-17.  Interestingly 
the mean T3 levels of 6 week PBFHomo-PTTGHet females were 160.19 ± 6.45 ng/dL  (n=6) 
compared to males at 234.66 ± 9.54 ng/dL (n=6). The difference was statistically significant, 
p<0.0001. This statistically significant intergender difference in T3 levels in PBFHomo-PTTGHet was 
again observed at the 6 month time point; female mice showed a mean T3 of 128.85 ± 5.54 ng/dL 
(n=6) compared with males, who showed a mean T3 of 162.45 ± 2.99 ng/dL (n=5). Subsequently, at 
12 and 18 months there was no significant difference in T3 levels between genders. Overall, there was 
little variation in T3 levels over a time period of 18 months. 
 
Figure 3-17  T3 levels in PBFHomo-PTTGHet mice by gender and age. p-values are denoted 
with  *** for 0.0001 < p ≤ 0.001 and ****  for p ≤ 0.0001. 
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T4 levels between male and female PBFHomo-PTTGHet mice at 6 weeks, 6 months, 12 months and 
18 months were similar and not statistically significant. The PBFHomo-PTTGHet T4 levels 
demonstrated an overall increase over an 18 month period. The mean T4 level in the PBFHomo-
PTTGHet female at 6 weeks was 2.08 ± 0.36 µg/dL (n=5) compared to the 18 month female with a 
mean of 6.11 ± 1.19 µg/dL (n=4); p=0.009. There  was a statistical difference in T4 levels (p=0.0007) 
between the 6 week and 18 month PBFHomo-PTTGHet male (2.98 ± 0.32 µg/dL (n=6) and 11.20 ± 
1.83 µg/dL (n=4) respectively) as shown in Figure 3-18.    
   
 
Figure 3-18  T4 levels PBFHomo-PTTGHet by age and gender. p-values are denoted with ** 
for 0.001 < p ≤  0.01 and  ***  for 0.0001 < p ≤ 0.001. 
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We next compared the TSH, T3 and T4 levels across the different genotypes at 6 week and 12 month 
time points. Mean T3 levels for female PBFHomo-PTTGHet at 6 weeks  (160.19 ± 6.45 ng/dL;  n=6) 
were comparable (p=0.23) to wild type (142.34 ± 11.19 ng/dL; n=8. T3 levels in PBFHomo-PTTGHet 
males at 6 weeks (mean 234.66 ± 9.54 ng/dL; n=6)  were significantly higher (p=0.001) than their wild 
type counterparts (mean 166.32 ± 11.44 ng/dL; n=11), as shown in Figure 3-19. 
 
Figure 3-19  T3 levels by genotype and gender at 6 weeks. p-values are denoted with ** 
(0.001 < p  ≤  0.01) and ns (p > 0.05). 
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PBFHomo-PTTGHet T4 levels (female: 2.96 ± 0.92 mcg/dL, n=6 ; male: 2.98 ± 0.41 mcg/dL, n=6) 
were comparable to wild type (female: 3.34 ± 0.50 mcg/dL, n=9 ;  male: 2.59 ± 0.79 mcg/dL, n=11) at 
6 weeks (female p=0.71 ; male p=0.74).  However, PTTG heterozygote (PTTG+/-) mice had increased 
T4 levels at 6 weeks; with mean levels of 5.34 ± 1.45 mcg/dL  (n=6) in females and 5.53 ± 0.78 
mcg/dL (n=6) in males, as shown in Figure 3.20. In comparing PTTG+/- with PBFHomo-PTTGHet, 
the p-value in females was 0.197 and in males 0.016. 
 
Figure 3-20 T4 levels at 6 weeks by genotype and gender. p-values are denoted by ns 
(p>0.05)  and  * (0.01>p≤ 0.05). 
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The TSH values between PBFHomo-PTTGHet and WT at 6 weeks were no different, seen in Figure 
3-21. Female PBFHomo-PTTGHet TSH against WT TSH was 53 ± 20.05 mU/L (n=5) and 24 ± 3.75 
mU/L (n=6), respectively, p=0.15. Male PBFHomo-PTTGHet TSH was 78 ± 12.87 mU/L (n=6) 
compared to male WT TSH 48 ± 13.85 mU/L (n=6), p=0.14.   
 
Figure 3-21 TSH levels at 6 weeks by genotype and gender. p>0.05 denoted by ns. 
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To establish whether thyroid function tests varied with time, we performed thyroid function tests for 
the different genotypes at a 12 month time point. Similar T3 levels (p=0.14) were observed in 
PBFHomo-PTTGHet females (141.85 ± 9.28 ng/dL, n=4) compared to wild type females (180.51 ± 
22.98 ng/dL, n=3) although there was a slight difference in T3 levels in the male PTTGHomo-
PTTGHet (148.34 ± 5.09 ng/dL, n=5) compared to its WT counterpart (173.82 ± 9.05 ng/dL, n=3; 
p=0.03) shown in Figure 3-22.   
 
 
Figure 3-22 T3 levels at 12 months by genotype and gender. p-values are denoted with *  
(0.01 < p   ≤ 0.05) and ns (p>0.05). 
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In contrast, T4 levels at 12 months in the PBFHomo-PTTGHet model were not significantly different 
from their wild-type counterparts (female p=0.56; male p=0.06) (Fig. 3-23).    
 
Figure 3-23 T4 levels at 12 months by genotype and gender. p-value >0.05 is denoted by 
“ns”.  
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Interestingly, TSH levels were significantly different between genders of their various genotypes, 
shown in Figure 3-24. TSH in WT females (28.00 ± 16.52 mU/L n=3) was significantly reduced 
compared to males (118.00 ± 7.24 mU/L n=3; p=0.007).  Similarly, PBF females (52.00 ± 24.62 mU/L 
n=4) and PBF males (185 ± 39.11 mU/L n=2) had significantly different TSH values than WT 
(p=0.039). Finally, there was a significant difference (p=0.026) between PTTG+/- females (25.00 ± 
8.07 mU/L n=3) and PTTG+/- males (90 ± 16.75 mU/L n=3). No TSH values at 12 months were 
available in the PBFHomo-PTTGHet model. 
 
 
Figure 3-24  TSH  levels at 12 months by genotype and gender. p-values are denoted with *  
(0.01 < p   ≤ 0.05) and  ** (0.001 < p ≤ 0.01).  
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the PTTG thyroid are not explained by TSH levels. As such, the goitre observed in PBFHomo-
PTTGHet is less likely to arise from deranged thyroid function tests. 
 
3.3.6 PBF Homo-PTTG Het mice develop adenomas  
The goitres found in the PBFHomo-PTTGHet murine models were examined microscopically. 
Thyroids were rated as normal as depicted in Figure 3-25 or abnormal. Abnormal thyroids had   
hypercellular areas shown in Figure 3-26  or a distinctive lesion as seen in Figure 3-27.  
 
 
Figure 3-25 PBFHomo-PTTGHet thyroid at 5x magnification. 
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Figure 3-26 PBFHomo-PTTGHet thyroid showing hypercellularity at 10x magnification. 
 
 
Figure 3-27 PBFHomo-PTTGHet discrete thyroid lesion at 10x magnification. 
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Figure 3-28 Lesion with hypercellularity in PBFHomo-PTTGHet thyroid at 10x 
magnification. 
 
 
Overall, microscopic lesions defined above did not develop in the PBFHomo-PTTGHet thyroid gland 
before 12 months. Although the sample size was small (n=48), 40% of PBFHomo-PTTGHet females 
developed lesions compared to no lesions in the PBFHomo-PTTGHet males, in the thyroid gland at 12 
months. Some thyroids had both lesions and hypercellular areas and this is recorded appropriately in 
Table 3 below. At 18 months, 83.3 % of PBFHomo-PTTGHet females had an abnormal thyroid gland 
compared to 14.3 % of  PBFHomo-PTTGHet males. Wild-type (WT) mice were not known to develop 
lesions in the thyroid (Dr. Martin Read, University of Birmingham). The number of PBFHomo-
PTTGHet mice that developed lesions. Risk factors for a histologically abnormal PBFHomo-PTTGHet 
thyroid would seem to include female gender and age of 12 months or more. PBFHomo-PTTGHet 
thyroids with discrete lesions can co-exist with areas of hypercellularity or not. Hence, 
hypercellularity may not necessarily precede discrete thyroid lesion formation. 
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AGE GENDER 
TOTAL 
NUMBER NORMAL 
HYPERCELLULAR 
AREAS LESION 
6 WEEKS FEMALE 6 6 0 0 
6 WEEKS MALE 6 6 0 0 
6 MONTHS FEMALE 6 6 0 0 
6 MONTHS MALE 6 6 0 0 
12 MONTHS FEMALE 5 3 2 (40.0 %) 1 (20.0 %) 
12 MONTHS MALE 6 6 0 0 
18 MONTHS FEMALE 6 1 (16.7 %) 3 (50.0 %) 3 (50.0%) 
18 MONTHS MALE 7 6 (85.7 %) 0 1 (14.3 %) 
Table 3 PBFHomo-PTTGHet ageing colony numbers with normal and  abnormal thyroids.  
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3.4 DISCUSSION 
The proto-oncogenes PTTG and its binding factor (PBF) have been implicated in thyroid 
tumourigenesis. Work by other groups and ours have demonstrated the transforming characteristics of 
PBF and PTTG in vivo (Pei and Melmed, 1997, Stratford et al., 2005). The murine model of PBF 
overexpression in the thyroid do not develop thyroid cancers but developed goitres and hyperplastic 
lesions instead (Read et al., 2011), possibly suggesting that thyroid carcinogenesis required a further 
insult in addition to PBF overexpression. The binding partner of PTTG, PBF,  transports PTTG to the 
nucleus for its actions (Chien and Pei, 2000). Hence, we generated a murine model overexpressing 
both PBF and PTTG in the thyroid gland to test our hypothesis.  
 
3.4.1 Creation of bi-transgenic model colony 
The FVB/N murine model has good reproductive performance and its inbred nature eliminates 
ambiguity caused by different genetic backgrounds (Taketo et al., 1991). This model is the basis of 
most scientific experiments involving murine models. We generated a double-hit murine model 
overexpressing both human PBF (hPBF) and human PTTG (hPTTG) to study the in vivo role of PBF 
and PTTG on the thyroid gland.     
Early in the initial characterisation of the hPTTG model, Dr. Gregory Lewy who constructed the 
model reported increased death rates in homozygote mice (PTTG +/+). Interestingly, heterozygote 
hPTTG mice (PTTG +/-) did not exhibit increased mortality compared to wild type. We observed 
reduced mortality in our BI-Trans model, homozygous for both hPBF and hPTTG. Given that 
mortality in the PTTG model appeared to be dependent on PTTG zygosity, we hypothesised that a bi-
transgenic murine model homozygous for PBF and heterozygous for PTTG (PBFHomo-PTTGHet) 
would survive for longer. The improved survival of the PBFHomo-PTTGHet compared to BI-Trans 
was confirmed and shown in section 3.3.2. Hence, we used the PBFHomo-PTTGHet model for our 
long term characterisation study. 
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3.4.2 Reduced mortality 
The reduced mortality observed in the PTTG murine model could be due to one of two reasons or 
both. Firstly, random gene insertion during the creation of the PTTG model may have disrupted 
crucial genes which impact mortality, within the genome. Since reduced mortality was not observed in 
PTTG+/-, it was possible that the organism could cope with a semi disrupted genome. However, in the 
presence of two copies of genes overexpressing hPTTG, as was in the PTTG+/+ model, the 
compensatory mechanism failed or was not existent. Secondly, high levels of hPTTG expression in the 
thyroid might have had a non specific lethal effect. Again, the organism could cope in the presence of 
limited hPTTG overexpression but not in copious amounts.  
The survival probability rank by genotype was observed as follows: WT/PBF/PTTG+/- > PBFHomo-
PTTGHet > PTTG+/+ > BI-Trans. The reduced mortality in PBFHomo-PTTGHet compared to 
PTTG+/- cannot be explained by its PTTG zygosity. Hence, PBF appeared to have a synergistic effect 
with PTTG in reducing mortality in our model.  On its own, however, PBF did not impact on survival 
rates.  
 
3.4.3 Fertility issues 
Overall, the PBFHomo-PTTGHet and BI-Trans models had reduced fertility. Breeding pairs 
consisting of two BI-Transgenic mice did not reproduce. The cause for infertility may lie in the BI-
Transgenic male. Pairings between BI-transgenic females and male PBFHomo-PTTGHets led to 
successful breeding. By contrast, BI-Trans male and PBFHomo-PTTGHet females yielded no 
offspring.  
The PBFHomo-PTTGHet and PBFHomo-PTTGHet pairing yielded more offspring than PBFHomo-
PTTGHet and BI-Transgenic. To maximize yield of the PBFHomo-PTTGHet or BI-Trans model, a 
new breeding strategy was adopted. The pairings and Mendelian genetics shown in Figures 3-29 and 
3-30 were adopted to maintain perpetuity of the breeding colony.  
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Figure 3-29  Genetics of PBFHomo-PTTGHet x PBFHomo-PTTGHet breeding. 
 
 
Figure 3-30  Genetics of PBFHomo-PTTGHet and BI-Trans breeding. 
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3.4.4 Goitre formation in the PBFHomo-PTTGHet murine model 
Goitres found in the PBFHomo-PTTGHet model were comparable in size to the PBF model. This 
suggests that PTTG in the presence of PBF has no additional effect on thyroid size.  
PBFHomo-PTTGHet thyroid weights increased over time in a similar fashion to the PBF model. WT 
and PTTG+/- thyroid weights remained constant over the same period of time. Goitre formation 
appeared to be PBF dependent, even in the presence of PTTG expression.  
There was no gender difference in the corrected thyroid weight of WT and PTTG+/- mice (data not 
shown). Female thyroid weight adjusted for body weight in both PBGHomo-PTTGHet and PBF 
murine models was consistently higher than for male counterparts over the study period (data not 
shown). Hence, it appeared that goitre formation caused by the overexpression of PBF in the thyroid 
had a greater effect in females than males.  
 
3.4.5 Thyroid function tests 
Thyroid function tests are usually interpreted in conjunction with each other. Thyroid hormone 
biosynthesis operates on a negative feedback loop. Thyroid hormone is produced by the thyroid gland 
in the form of T4 and T3. The active component T3 is secreted in small amounts relative to T4. The 
proportion of T4 to T3 in humans is approximately 20:1. High blood thyroid hormone levels inhibit 
the secretion of thyroid stimulating hormone (TSH) from the anterior pituitary gland. Low TSH results 
in reduced thyroid hormone secretion from the thyroid gland. Prolonged and high levels of TSH can 
cause thyroid cell growth in addition to stimulating thyroid production. Hence, the concentration of T3 
and T4 should have an inverse relationship to TSH levels. 
We performed thyroid function tests on the various genotypes at different time points. There was no 
observed correlation between TSH, T3 and T4 levels within each genotype suggesting that the study 
had insufficient power to demonstrate a statistical difference. However, given that we were dealing 
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with a mutant model where changes should be gross, any effect caused by the overexpression of our 
genes of interest should be apparent, even in low numbers. Since there was no gross increase in TSH 
levels, goitre formation in the PBFHomo-PTTGHet and PBF models is not likely to be TSH driven.  
      
3.4.6 Adenoma formation in PBFHomo-PTTGHet 
PBFHomo-PTTGHet thyroids demonstrated areas of hypercellularity and lesion formation 
microscopically. These histological changes were found predominantly in female PBFHomo-
PTTGHet from 12 months onwards. Lesions appeared well-circumscribed with no invasive features 
suggestive of a cancer. The likelihood is that these lesions represent adenomas. Thyroid function tests 
did not reveal hyperthyroidism in the mice with adenomas suggesting these lesions are non-functional.  
It is not possible at this stage to determine if these histological changes are separate entities or 
progression of the same event. Since the above histological changes were similar to PBF thyroids 
microscopically, adenoma formation and hypercellularity are likely an effect of PBF overexpression in 
the thyroid.  
 
3.5 CONCLUSION 
In terms of thyroid changes, the PBFHomo-PTTGHet model appeared phenotypically to be a PBF 
model. The survival characteristics of the PBFHomo-PTTGHet model mirrors the PTTG model. 
Reduced fertility of the PBFHomo-PTTGHet model is likely a PTTG phenotype because the PBF 
murine model had normal fertiility. Unfortunately, we did not have any breeding data for the PTTG 
model to make a direct comparison.    
The PBFHomo-PTTGHet model did not produce any cancers as hypothesized. Hence, we next 
examined whether the PBFHomo-PTTGHet thyroids exhibit genetic instability. 
    
4 Genetic instability in transgenic murine thyroids 
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4.1 INTRODUCTION  
The ability to replicate is a hallmark feature of a living cell. Occasionally, errors of replication result 
in a mutation. Gene mutations that involve cell cycle regulation, DNA repair and the repair of DNA 
damage, which is integral to maintaining genomic stability, can result in mutations that lead to the 
development of tumours. Hence, genetic instability is an integral feature of cancers (Loeb and Monnat, 
2008, Rajagopalan et al., 2002). Furthermore, genetic instability has been demonstrated previously in 
thyroid cancers by multiple groups (Kim et al., 2005, Mitsutake et al., 2005, Saavedra et al., 2000, 
Ward et al., 1998, Wreesmann et al., Tung et al., 1997).  
A technique described by Basik et al, inter-simple sequence repeat PCR (ISSR-PCR), was used for 
measuring genetic instability in colorectal cancers (Basik et al., 1997). In this technique, a primer to 
microsatellite sequences was used in the polymerase chain reaction (PCR) to compare normal and 
tumour samples. Subsequently, Kim et al demonstrated genetic instability in thyroid cancers using the 
modified technique of fluorescent ISSR-PCR (FISSR-PCR) (Kim et al., 2005).  
PBF and PTTG have been shown previously to have independent and dependent effects on 
tumourigenesis (Stratford et al., 2005). PBF expression is increased in thyroid cancer both at a protein 
and mRNA level (Stratford et al., 2005). A high level of PBF expression has been shown to be an 
independent prognostic marker for thyroid cancer recurrence in well-differentiated thyroid cancer 
(Hsueh et al., 2013). Additionally, PTTG expression has been found to be increased in thyroid cancer 
(Boelaert et al., 2003) and has been described to cause genetic instability (Kim et al., 2005). 
Consequently, we aimed to determine if the simultaneous overexpression of PBF and PTTG caused 
genetic instability in murine thyroids. 
Ionising radiation induces DNA damage by causing single and double strand breaks within the DNA. 
Genetic instability results if the surviving cell cannot be repaired adequately. Additionally, ionising 
radiation is a recognised cause of thyroid cancer (Nikiforov, 2006, Nikiforov et al., 1996, Nikiforov et 
al., 1997, Richardson, 2009, Stsjazhko et al., 1995). Since PBF and PTTG overexpression in the 
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thyroid gland have not been shown to cause thyroid cancers, we aimed to observe the effects of 
ionising radiation with a background of PBF and PTTG overexpression independently and 
dependently in the thyroid gland to determine whether our genes of interest affected genomic stability 
of the thyroid cell following radiation.  
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4.2 MATERIAL AND METHODS 
4.2.1 Primary murine thyroid cultures (PMTC) 
Primary murine thyroid culture (PMTC) was developed as a platform for experiments involving 
radiation. Microdissection on 6 week old murine thyroids is described in section 2.2.   
 
4.2.2 Protein extraction and Western blot 
Protein extraction and western blot was performed as described in section 2.7 and 2.8. Primary 
antibodies used were rabbit anti-human PBF-8 polyclonal and anti-human PTTG (Invitrogen, UK) 
used in concentrations of 1:1000 and 2 µg/ml respectively. The secondary antibody used was 
monoclonal anti-β-actin clone AC-15 (Sigma-Aldrich, Poole, UK) in a concentration of 1:10,000. 
 
4.2.3 Immunofluorescence 
PMTC was performed in 6-well plates for immunofluorescence. On Day 10, medium was removed 
from the wells and washed with phosphate buffer solution (PBS). Subsequently, the protocol for 
immunofluorescence was followed as described in section 2.9. 
 
4.2.4 Radioiodine uptake assays 
 Murine primary thyrocytes were grown in 12-well plates in 0.5 ml medium. Thyroid function was 
determined by the ability of the cell to actively absorb 125I from the medium.  A solution containing 
0.05 μCi  125I (Hartmann Analytic, Germany) and 10-9 NaI was added to each well and incubated for 2 
hours as previously described (Eggo et al., 1996, Boelaert et al., 2007). Subsequently, the cell layer 
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was washed with HBSS to remove unincorporated iodide and the cells lysed in 2 % SDS protein lysis 
buffer. Incorporated radioactivity was estimated in a gamma counter. Relative iodide uptake was 
corrected for protein concentration measured by the Bradford assay. 
 
4.2.5 DNA extraction 
DNA was extracted from murine thyroids and primary murine cultures using the same technique 
described for ear clippings in Chapter 2 (DNeasy 96 Blood & Tissue Kit; Qiagen). 
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4.2.6 Polymerase chain reaction (PCR) 
Genomic DNA was subjected to PCR in a Mastercyler® thermal cycler (Eppendorf, Hamburg, 
Germany). Each reaction comprised 50 ng DNA, 1 µl 10 mM dNTP, 2 µl 50 mM MgCl2, 3 µl of 200 
nmol (CA)8RG (R = a 50:50 mix of the purines adenine and guanine; Y = a 50:50 mix of the 
pyrimidines cytosine and thymine) primers labelled with FAM fluorophore (Eurogentec), 1x 
TaqMaster PCR Enhancer (5Prime, Hamburg, Germany), 0.5x NH2 reaction buffer (Bioline), 2.5 U 
Biotaq™ DNA polymerase (Bioline) and nuclease-free water to make up a total volume of 50 µl. 
Initial denaturation of the DNA template took place at 95 °C for 5 minutes before holding at 74 °C. 
Subsequently, DNA polymerase and NH2 reaction buffer was added and the reaction subjected to 35 
cycles of 94°C for 30 seconds, 50 °C for 30 seconds and 72 °C for 60s. The final extension step for 10 
minutes took place at 72 °C. 
 
4.2.7 Agarose gel electrophoresis 
PCR products were initially electrophoresed in 1 % Agarose (Bioline) gel in 1X TAE (Tris-Acetate-
EDTA) buffer (Eppendorf) before being visualized to optimize the PCR reaction for FISSR-PCR 
experiments. 
 
4.2.8 Fluorescent inter-simple sequence repeat-PCR (FISSR-PCR) 
This technique involved a polymerase chain reaction (PCR) using primers labelled with a FAM 
fluorophore targetted to (CA)n microsatellites or simple sequence repeats within the genome. 
Traditionally, the PCR products or fragments were resolved on a PAGE gel and visualised by 
autoradiography. The genetic instability index developed by Basik et al and validated by others (Basik, 
Stoler et al 1997; Viswanathan, Sangiliyandi et al 2003) was determined by dividing the number of 
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altered fragments in the target tissue by the total number of bands in the corresponding tissue and 
multiplied by 100 to form a percentage. 
The modified technique of FISSR-PCR involved performing the fragment analysis in a DNA 
sequencer. PCR reaction products were diluted 20 times in nuclease-free water. 1 µl of diluted PCR 
reaction was added to 8.5 µl Hi-Di Formamide (Applied Biosystems) and 0.5 µl of  Genescan™ 1200 
LIZ® Size Standard (Applied Biosystems) and aliquoted into a 96-well plate. The whole mixture was 
denatured at 95ºC for 5 minutes. The sample was analysed using the ABI 3730 automated DNA 
sequencer (Applied Biosystems) with the microsatellite fragment analysis setting. The “fsa” file 
obtained was subsequently read using Genemapper v3.5 software (Applied Biosystems). The index of 
genetic instability was calculated as follows:- 
GENETIC                         No. of bands lost/gained + No. of different bands        x 100 
INSTABILITY    =                               No. of expected bands 
INDEX                                               
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4.3 RESULTS 
4.3.1 Primary murine thyroid culture 
Primary murine thyroid culture (PMTC) was successfully perfected following several attempts at 
optimisation. Whole thyroid follicles were observed to be settling on the floor of a 12-well plate under 
light microscopy, seen in Figure 4-1. Subsequently, the follicles dispersed over several days, creating a 
sheet of cells with various clusters. Finally, on Day 10 when the cells were ready for experimentation, 
multiple clusters could be observed, shown in Figure 4-2. The cluster pattern tended to be variable, 
comprising between 60 – 70 % of the surface area of the well. Overall, the cultures were viable for up 
to 12 days but were used for experimentation on Day 10. 
 
Figure 4-1 Primary murine thyroid culture under light microscopy depicting whole thyroid 
follicles immediately following processing at Day 0 (10x magnification). 
 
Thyroid follicle 
100 µm 
                                                                         Genetic instability in transgenic murine thyroids
  
113 
 
 
Figure 4-2  Light microscopy of primary murine thyroid culture (10x magnification) showing 
the formation of clusters in a 12-well plate on Day 10. 
 
4.3.2 Immunofluorescence confirmed the presence of thyroid cells 
Having established the technique of PMTC, we next confirmed the purity of our primary cultures. The 
PBF-Tg murine model overexpressing  human PBF tagged to haemagglutinin (PBF-HA) was used for 
immunofluorescence. DAPI, used to stain nuclei which fluoresced in blue, confirmed the presence of 
cells in culture. The presence of thyroid cells was confirmed by red fluorescence, detected using a 
primary HA antibody and a secondary antibody tagged with a red fluorescent dye (Alexa Fluor® 594; 
Life Technologies). The images obtained from the inverting microscope is shown in Figure 4-3. 
Interestingly, the presence of HA and hence, thyroid cells, appeared in clusters. 
 
Thyroid follicle 
100 µm 
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Figure 4-3 Immunofluorescence in PBF-HA primary murine thyroid culture (PMTC) at 10x 
magnification. The nucleus fluoresced in blue (DAPI) and the HA tag fluoresced in red. 
Image A depicts the pattern of cellular growth in PMTCs and image B confirmed the presence 
of  PBF-HA thyroid cells. The composite image C depicts the growth of thyroid cells in 
clusters. 
 
4.3.3 PMTCs overexpress PBF and/or PTTG 
Next, we examined the expression of our genes of interest in each of the PMTC genotypes; wild-type 
(WT; n=4), PBF (n=4), PTTG+/+ (n=4) and BI-Trans (n=4) shown in Figure 4-4 below. The Western 
blot confirms the overexpression of PBF in both PBF and BI-Trans PMTCs and PTTG in both 
PTTG+/+ and BI-Trans PMTCs.   
 
 
 
Figure 4-4 Western blot of PMTCs probed with PTTG (top) and PBF (bottom) antibodies. 
WT, PBF, PTTG and BI-Trans refer to wild-type, PBF, PTTG and BI-Trans PMTCs (n=4 for 
each genotype). 
B C A 
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4.3.4 Primary murine thyroid cultures were functional 
We next confirmed that the thyroid cells in PMTCs were functional. Previous publications by our 
group have shown that thyroid cells overexpressing PBF have reduced uptake of 125I (Boelaert et al., 
2007, Smith et al., 2009, Read et al., 2011).  
A total of 5 WT and 6 PBF thyroids which were age- and sex-matched were used for this study. The 
average adjusted CPM (counts per minute) for WT was 25,210.4 ± 4,819.99 and for PBF 7,400.29 ± 
1,680.58. We observed a 70% reduction of radioiodine uptake in PBF derived cultures compared to 
WT cultures at 10 days (p=0.0004), as shown in Figure 4-5. Taken together, these data confirmed that 
primary murine thyroid culture techniques were appropriate, consistent with previous data and 
functional in that significant reduction in 125I was demonstrated. 
 
Figure 4-5 Relative 125I uptake in WT and PBF primary murine thyroid cultures. The uptake 
of  125I is significantly repressed (p=0.0004) in PBF (n=6) compared to WT (n=5). 
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4.3.5 PCR optimisation 
The technique of FISSR-PCR used in measuring the index of genetic instability (GI) is dependent on 
PCR fragments obtained using the (CA)8RY primer which binds to  microsatellite segments within the 
genome. The quantity of DNA obtained from PMTC is small and hence, it was important to ensure 
optimal PCR conditions to obtain maximal PCR products that can be subsequently resolved 
successfully.     
Several optimisation experiments were performed to determine the optimal conditions for the PCR 
reaction for FISSR. The aim of optimisation was to obtain clear fragments from the PCR reaction and 
to determine the length of products obtained. Initially, we resolved the PCR products on 1 % Agarose 
gel to compare various PCR reactions. The amount of MgCl2 and NH4SO4 buffer in each reaction was 
altered and the reaction which yielded the optimal number of clear fragments is shown in Figure 4.6 
below. Interestingly, the PCR reaction yielded fragments mainly between 200 to 1000 base pairs. 
 
Figure 4-6  DNA PCR products resolved on 1% Agarose gel, extracted from wild type 
(WT)(n=3) and PBF (n=3) primary murine thyroid cultures. The PCR conditions for this run 
were deemed optimal and used for subsequent FISSR experiments. PCR products ranged 
between 200 and 1000 base pairs. 
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4.3.6 Modified FISSR-PCR 
The technique of FISSR-PCR described by Kim et al involved the use of PAGE-gel and 
autoradiography (Kim et al., 2005). This method of resolving PCR products is cumbersome and would 
require a moderate amount of DNA which our primary murine thyroid cultures do not yield. The DNA 
sequencer (ABI 3730; Applied Biosystems) is a sensitive and efficient way of resolving PCR products. 
Hence, the FISSR-PCR technique was modified using the ABI 3730 DNA sequencing machine to 
resolve PCR products. 
Figure 4-7 shows PCR products being resolved within each capillary tube in the ABI 3730 automated 
DNA sequencer. The files obtained from the sequencer are read using Genemapper software which 
express data in numerical (shown in Figure 4-8) or graphical format (shown in Figure 4-9).  
Interpretation of results was challenging because of the huge volume of data present for each sample. 
A difference is defined as a change of more than 500 units in peak area and a band height difference of 
more than 3 fold. The estimated GI index from the same species within the same PCR run had a 
variation of less than 10 % using these criteria. 
 
Figure 4-7 An example of PCR products resolved on ABI Genemapper sequencer. Arrows 
indicate individual sequencing capillaries. Yellow/Orange colour represent the GeneScan LIZ 
Size Standard (ThermoFisher Scientific). The blue colour arises from the FAM fluorophore 
attached to the primer used in the polymerase chain reaction (PCR). 
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Figure 4-8 Resolved PCR products in Genemapper (Applied Biosystems) represented in 
numerical form. The product size for each capillary run is identified. The quantity, defined by 
height and area, is also provided as illustrated above. The FAM marker refers to the 
fluorophore attached to the (CA)8RG primer used in the PCR. 
 
 
Figure 4-9 Graphical representation of PCR products resolved by sequencing on 
Genemapper (Applied Biosystems) showing gross differences (encircled) between WT  and 
PBF genotypes, used in calculating the index of genetic instability. 
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4.3.7 BI-Trans thyroids demonstrated significant genetic instability 
We compared the 4 different murine thyroid genotypes; wild type (WT), PBF, PTTG+/+ and BI-Trans 
(homozygous for both PBF and PTTG) using FISSR-PCR. A mean total of 154 unique fragments were 
found in the WT sample (n=5). PBF (n=5) did not have any unique fragments compared to WT 
resulting in a GI index of 0.00. PTTG+/+ (n=5) had an average of 3 unique fragments resulting in a 
genetic instability (GI) index of 1.95 ± 0.96 (p=0.78). Bi-trans (n=4) had a GI index of 3.73 ± 1.28 
(p=0.01) as shown in Figure 4-10.  
These results suggest that in vivo, PBF or PTTG+/+ overexpression in the thyroid gland independently 
do not cause genetic instability. However, when PBF and PTTG are overexpressed together within the 
thyroid gland, the effect is one of increased genetic instability. 
 
 
Figure 4-10 GI index comparison according to genotype in vivo. PBF (n=5) and PTTG+/+ 
(n=5) thyroids appear to have no statistically significant genetic instability compared to WT 
(n=5). However, BI-Trans (n=4) thyroids had a GI index which was statistically significant 
compared to WT (p=0.01, denoted with *). 
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4.3.8 PBF, PTTG and BI-Trans PMTCs exhibited genetic instability 
We next quantified the index of genetic instability (GI) PMTCs for all four genotypes as a control for 
our experiments with ionising radiation. DNA was extracted from PMTCs on day 10. As shown in 
Figure 4-11 PBF (n=4), PTTG+/+ (n=5) and BI-Trans (n=5) PMTCs exhibited detectable genetic 
instability compared to wild type (WT) (n=5). The mean total number of unique fragments in this PCR 
run for WT was 128. The GI index for PBF, PTTG+/+ and BI-Trans was 18.75 ± 1.78 (p<0.0001 
compared to WT), 7.19 ± 1.55 (p=0.002 compared to WT) and 35.78 ± 2.56 (p<0.0001 compared to 
WT) respectively. Interestingly, PBF PMTC had a higher GI index compared to PTTG+/+ which was 
statistically significant (p=0.002). BI-Trans PMTCs exhibited marked genetic instability compared to 
PBF (p=0.001) or PTTG (p<0.0001) PMTC, similar to that observed in murine thyroids. 
 
 
Figure 4-11 GI index in primary murine thyroid cultures by genotype. All 3 genotypes of PBF 
(n=4), PTTG+/+ (n=5) and BI-Trans (n=5) exhibit genetic instability compared to WT. p-
values are denoted with ** (0.001 < p ≤ 0.01) and **** (p ≤ 0.0001). 
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4.3.9 PBF is associated with reduced genetic instability in cultured thyroid 
cells following exposure to ionising radiation 
PMTCs which underwent radiation were exposed to ionising radiation (IR+) on day 9 and harvested 
on day 10. The dose of ionising radiation, 25 Gy was determined to be optimal, without causing cell 
culture death and sufficient to demonstrate changes (experimental work by Dr. Robert Seed, 
University of Birmingham). Following irradiation of PMTCs, all genotypes exhibited a statistically 
significant change in the index of GI as shown in Figure 4-12. In comparison with WT PMTCs 
without irradiation (WT IR-), WT PMTCs following exposure to ionising radiation (WT IR+) had a GI 
index of 17.19 ± 2.34 (p<0.0001; n=2). Although the GI index of PBF IR+ was significantly increased 
(7.65 ± 1.63; p=0.002; n=5) it had a protective effect on thyroid cells compared to the GI index of WT 
IR+. PTTG+/+ IR+ (n=5) had a GI index of 29.53 ± 1.51 which was significantly higher than WT 
(p<0.0001) and WT IR+ (p=0.007). The GI index for BI-Trans IR+ was significantly elevated (11.09 ± 
2.35; p=0.001; n=5)  but this was not significant when compared to PBF IR+ (p=0.26). PTTG+/+ IR+ 
had a significantly elevated GI index compared to BI-Trans IR+ (p=0.0002) and PBF IR+ (p<0.0001).  
Overall, PBF had a protective effect whilst PTTG+/+ had the opposite effect, augmenting DNA 
damage following radiation exposure. However, when both PBF and PTTG were overexpressed 
together in primary murine thyroid cultures, the damaging effects of PTTG appeared to be partially 
ameliorated by PBF. 
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Figure 4-12 Genetic instability (GI) index of WT, PBF, PTTG+/+  and BI-Trans following 
ionising radiation. WT IR+ (n=2), PBF IR+ (n=5), PTTG+/+ IR+ (n=5) and BI-Trans IR+ 
(n=5).  p-values are denoted with ns for p>0.05, *  (0.01 < p   ≤ 0.05),  ** (0.001 < p ≤ 0.01), 
***  (0.0001 < p ≤ 0.001) and **** (p ≤ 0.0001). 
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4.3.10 GI index before and after ionising radiation by genotype 
When the data was assimilated across the treatment groups shown in Figure 4-13, there was a 
significant change before and after ionising radiation treatment to PMTCs, as expected. Cells 
overexpressing PTTG after irradiation (PTTG+/+IR+) exhibit more DNA damage than PTTG+/+ 
without irradiation (p,0.0001). Interestingly, PBF appeared to have a protective effect after exposure to 
radiation and the difference between PBF IR- and PBF IR+ was statistically significant (p=0.003). 
This effect was also observed in the BI-Trans model where both PBF and PTTG are overexpressed 
together (p=0.001). However, PBF independently without radiation appeared to cause more DNA 
damage than PTTG+/+ in PMTC. 
 
 
Figure 4-13 Genetic instability (GI) index with and without ionising radiation by genotype. 
PMTCs were exposed to 25 Gy of ionising radiation and the GI index measured using FISSR-
PCR. p-values are denoted with ** (0.001 < p ≤ 0.01), ***  (0.0001 < p ≤ 0.001) and **** (p 
≤ 0.0001). 
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4.4 DISCUSSION 
4.4.1 Primary murine thyroid culture 
Human primary thyroid culture has been described and used extensively by various groups previously 
(Eggo et al., 1996, Boelaert et al., 2007). PMTC has been described much less frequently than human 
primary thyroid culture and is a technically challenging exercise because of the diminutive size of the 
murine thyroid gland, which only weighs 2 mg on average. Before the technique was finally optimised 
and described above, several attempts at the technique were performed.  
Growth of murine thyroid cells was confirmed with light microscopy. PMTC was viable for 
approximately 14 days. However, the optimum period for maximal cell coverage was around 10 days. 
The cultures were heterogenous in appearance. We established that thyroid epithelial cells arose from 
follicles and appeared to disperse on the plate resulting in a cluster pattern when viewed under the 
microscope. Immunofluorescence had revealed a second type of cell which was not typical of a 
thyroid epithelial cell. These cells were generally one cell thick on the plate, had a fusiform 
morphology and connected thyroid epithelial cell clusters, and were most likely fibroblast cells arising 
from murine thyroids. The area of well coverage was approximately 60 – 70 % at day 10 when 
experimentation occurred. Furthermore, radioiodine uptake studies were useful in confirming that 
PMTCs were functioning thyroid cells, suitable for experimentation. Overall, we established the 
technique of PMTC in our laboratory as a functional assay which was suitable for our hypotheses 
relating to the induction of genetic instability. 
 
4.4.2 FISSR-PCR 
An established technique for measuring genetic instability in our group is fluorescent inter-simple 
sequence repeat PCR (FISSR-PCR) (Kim et al 2005). The modification of the technique using a DNA 
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sequencer (ABI 3730, Applied Biosystems) to resolve PCR products was necessary for measuring 
genetic instability in murine thyroids and PMTC.  
Several optimisation experiments were carried out. Whilst the sequencing step in FISSR-PCR was 
consistent and reliable, it appeared that the PCR step was not always consistent in yielding the same 
result. As such, a control for the base denominator of the GI index equation is required each time the 
genetic instability index was quantified. Different PCR runs could not therefore be compared with 
each other. 
Unequal loading of sample or reagent during the PCR phase or fragment analysis stage could result in 
different areas under each peak. To control for this, we determined the total fluorescence of a sample 
on the ABI 3730 and adjusted it to an arbitrary value of 2,000,000 relative fluorescent units.  
Using the sequencer to resolve PCR products yielded a huge volume of data. Typically, PCR products 
ranged between 80 and 900 base pairs in length. The Genemapper software detects all fragments and 
quantifies these by using the height or area under each peak. We defined a difference as a change of 
more than 500 units in peak area and a band height difference of more than 3 fold. The estimated GI 
index from the same species within the same PCR run had a variation of less than 10 % using these 
criteria. 
The yield of DNA from a whole murine thyroid is far greater than can be obtained from PMTC. This 
did not prove to be a limiting factor because of the sensitivity of the FISSR sequencing technology. 
 
4.4.3 Index of genetic instability  
PTTG, the human securin regulates mitosis and is known to be overexpressed in thyroid cancers 
(Smith et al., 2010). The relationship between PTTG and genetic instability in the thyroid has been 
reported previously by our group (Kim et al., 2005). The binding factor of PTTG, PBF, shuttles PTTG 
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to the nucleus for its actions. Furthermore, PBF binds to and negatively regulates Trp53 which has a 
key role in maintaining genomic stability in a cell (Read et al., 2014a, Read et al., 2014b). 
Thyroid cancers have been demonstrated to exhibit genomic instability (Bauer et al., 2002, Kim et al., 
2005, Mitsutake et al., 2005, Saavedra et al., 2000, Ward et al., 1998). The relationship between 
genetic instability and tumour formation is not fully understood. However, ionising radiation which 
induces DNA damage and causes genetic instability is a recognised cause of thyroid cancer.  
In stable thyroid tissue, PBF and PTTG expression independently did not result in genetic instability. 
However, when both PBF and PTTG (BI-Trans) were overexpressed in murine thyroids, there was an 
increase in the index of genetic instability suggesting a synergistic effect of PBF and PTTG. PBF 
independently caused more genetic instability than PTTG in primary murine thyroid cultures 
(PMTCs). This observation suggests that PBF plays an important role compared to PTTG in causing 
genetic instability in cells that are growing or being cultured in an environment that encourages 
proliferation.  
Interestingly, it was observed that PBF had a protective effect whilst PTTG had a synergistic effect 
with ionising radiation in increasing the index of genetic instability. This protective effect was further 
confirmed when BI-Trans PMTCs following radiation exposure had a lower GI index compared to BI-
Trans without irradiation. This observation may be a result of PBF enhancing repair following DNA 
damage. 
 
4.5 CONCLUSION 
The relationship between PBF, PTTG and ionising radiation is complex and we aimed to understand 
the mechanism by which these two genes cause genetic instability by exploring the expression of 
genes related to DNA damage and repair pathways next. 
    
5 The effect of genotype on DNA damage and repair genes 
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5.1 INTRODUCTION 
5.1.1  Background 
Cancer formation is a result of uncontrolled cellular proliferation. The process of cellular proliferation 
is a tightly regulated process controlled by a variety of genes. A faulty replication process results in 
genetic mutation and genetic instability. The association between high levels of PBF and PTTG 
expression with thyroid cancer has been demonstrated previously (Boelaert et al., 2003, Heaney et al., 
2001, Hsueh et al., 2013, Stratford et al., 2005).  
PTTG overexpression inhibits Ku70 which facilitates non-homologous DNA end-joining repair of 
double strand breaks (Kharbanda et al., 1998, Kim et al., 2007b, Romero et al., 2001, Smith and 
Jackson, 1999). Additionally, PTTG regulates mitosis at the metaphase-anaphase interface.  
The binding partner of PTTG, PBF, transports PTTG to the nucleus and facilitates it’s action. PBF has 
been shown to interact with and negatively regulate a critical gene involved in maintaining genomic 
stability, Trp53 (Read et al., 2014a, Read et al., 2014b). PBF has also been shown to be transforming 
in vitro and tumourigenic in vivo, independent of PTTG. 
Taken together, the above indicate that PBF and PTTG have roles in maintaining genomic stability of 
a cell dependently and independently. Furthermore, work in this investigation outlined in the previous 
chapter, demonstrated the effect of PBF and PTTG on the index of genetic instability in thyroid cells. 
We next studied key genes intimately involved in DNA damage and repair in association with our 
genes of interest to establish the mechanism by which PBF and PTTG affect genomic stability in a 
dependent and independent manner. Microarrays based on the key DNA damage and repair pathway, 
the ATM/ATR signalling pathway, were used for this purpose. 
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5.2 MATERIALS AND METHODS 
5.2.1 Primary murine thyroid cultures 
Primary murine thyroid culture (PMTC) was performed on the 4 different genotypes (WT, PBF, PTTG 
+/+ and BI-Trans), using 3 males in each genotype group as discussed in section 2.2. 
 
5.2.2 RNA extraction 
RNA was harvested from PMTCs on day 10 using the micro RNeasy kit (QIAGEN), specifically 
designed for small samples. PMTCs were harvested using buffer RLT (QIAGEN) to lyse cells. The 
lysate was subsequently subjected to the QIAshredder homogenizer (QIAGEN) to improve the quality 
of RNA yield. Next, 70 % ethanol was added to the lysate to provide optimum binding conditions to 
the silica membrane. The sample was subsequently transferred to a RNeasy MinElute spin column and 
spun at high speed. This step allowed for binding of the RNA to the silica membrane present in the 
MinElute spun column. The spin column was washed twice with Buffer RW1 (proprietary solution in 
RNeasy kit). The third wash was with Buffer RPE to remove traces of salts left by Buffer RW1. The 
fourth wash was with 80 % ethanol. The final step was the addition of 14 µl of RNAse-free water to 
dissolve the RNA bound to the silica membrane. The dissolved RNA was collected in an Eppendorf 
and the RNA concentration measured using the Nanodrop (ThermoScientific). 
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5.2.3 Reverse transcription 
Reverse transcription was performed as described in section 2.5. 
 
5.2.4 RT2 ProfilerTM PCR Arrays 
RT2 ProfilerTM PCR Arrays (SABiosciences) were used for gene expression detection. Each array 
consisted of a panel of 84 genes relevant to the pathway investigated. The array chosen was the mouse 
DNA Damage Signalling array (PAMM-029E). Each plate contained 384 wells. Measurements were 
carried out in duplicate for each sample. 
Each reaction consisted of 1 µl of cDNA, 5.5 µl of RT2 qPCR Master Mix (PA-012-8 SABiosciences), 
containing SYBR Green and ROX, diluted to a total volume of 10 µl in nuclease-free water. The plate 
was initially heated to 95 °C for 10 minutes. Subsequently, the plate was subjected to 40 cycles of 95 
°C for 15 seconds and 60 °C for 1 minute in the ABI 7900HT Real-Time PCR System.  
 The baseline was manually defined using the log view of the amplification plot. Data were  expressed 
as Ct values and used to determine ∆Ct values by subtracting the Ct of the housekeeping gene from the 
Ct of the target gene. The fold change of mRNA was calculated using the following equation: 
  Fold change = 2-(∆Ct of the experimental group - ∆Ct of the control group) 
where the experimental group refers to PMTC genotype e.g. WT, PBF, PTTG+/+, BI-Trans and the 
control group the housekeeping genes on the array e.g. β-actin. Results were expressed as fold change 
relative to the standard, wild type PMTC without radiation. Fold changes which were more than twice 
or less than half the mRNA expression apparent in wild-type (WT) PMTCs were considered 
significant during data analysis.   
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5.3 RESULTS 
The data from the microarray study in this chapter was analysed initially by identifying the overall 
pattern of mRNA gene expression on the microarray according to PMTC genotype. Subsequently, 
mRNA gene expression was analysed by functional grouping as follows: genes involved with 
apoptosis, cell cycle arrest, cell cycle checkpoint, damaged DNA binding, base excision repair, 
nucleotide excision repair and double strand break repair.  
 
5.3.1 Expression of DNA damage signalling genes in PBF PMTCs 
The overall mRNA gene expression in PBF PMTCs compared with wild type (WT) was 
predominantly repressive, as shown in Figure 5-1. This pattern suggests an inhibitory effect on genes 
that might play an important role in DNA repair. 
The Transient receptor potential cation channel, subfamily C, member 2 (Trpc2) gene displayed the 
most suppression in PBF primary murine thyroid cultures (PMTCs), approximately 0.21 fold of WT 
PMTCs (n=3). Trpc2 is involved in intracellular calcium signalling. The rise of intracellular calcium 
has been shown to increase apoptosis. It is recognised that the process of apoptosis is intimately 
related to the influx of Ca2+ controlled by Trpc2 and the loss of endoplasmic reticulum Ca2+ (Pigozzi et 
al., 2004).  
The expression of X-ray repair complementing defective repair in Chinese hamster cells 3, Xrcc3 was 
0.38 fold in PBF PMTCs relative to WT PMTCs (n=3). Xrcc3 is a member of the Rad51 group of 
genes that maintain chromosome stability and repair DNA damage by participating in homologous 
recombination.  
Both mutYHomolog (Mutyh) and Rad9b had reduced expression at 0.47 fold in PBF PMTC (n=3). 
Mutyh is involved in oxidative DNA damage repair. This enzyme cleaves adenine bases from the 
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DNA backbone when adenine is paired incorrectly with guanine, cytosine or 8-oxo-7,8-
dihydroguanine. Rad9b is a homolog of DNA Repair Exonuclease Rad9.  
 
 
Figure 5-1 DNA damage gene mRNA expression changes in PBF PMTC compared with wild 
type (n=3) on the RT2 ProfilerTM PCR Arrays that is less than half. No genes on the array was 
expressed more than twice. Statistical p-values are represented by ** if 0.001 < p ≤ 0.01. IR- 
refers to without ionising radiation. 
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5.3.2 Expression of DNA damage signalling genes in PTTG PMTCs 
In contrast to PBF PMTCs, PMTCs from homozygote PTTG mice (PTTG+/+) resulted in significant 
mRNA expression alterations (defined by an expression of more than twice or less than half) in DNA 
damage signalling genes compared with wild type (WT) PMTCs as illustrated in Figure 5-2. 
The genes most significantly upregulated in the presence of  PTTG overexpression in the thyroid were 
Polk (3.08 x), Rad9 (3.05 x) and Tdg (3.07 x).  This was followed by Ube2a (2.24 x), Hus1 (2.12 x), 
Nthl1 (2.06x) and Pms1 (2.03); (n=3).  
Equally, a wide array of DNA damage / DNA repair genes were suppressed in the presence of PTTG. 
These suppressed genes included Exo1 (0.11 x), Brca1 (0.15 x), Rad51 (0.23 x), Chek1 (0.23 x), Pole 
(0.29 x), Fen1 (0.31 x) Chaf1a (0.36 x), Rad18 (0.37 x), Fancg (0.38 x), Fancc (0.38 x), Pms2 (0.42 x), 
Mbd4 (0.43 x), Trex 1 (0.44 x), Xpa (0.46 x) and Rad51l1 (0.47 x); (n=3).   
 
                                                           The effect of genotype on DNA damage and repair genes  
134 
 
 
 
Figure 5-2  DNA damage / DNA repair gene mRNA expression in PTTG+/+ PMTC. The 
genes that were expressed by more than twice (B) or less than half (A) compared to WT IR- 
PMTC (n=3) were considered significant. However, statistical p-values are also shown. If  
0.01 < p   ≤ 0.05  (*) and 0.001 < p ≤ 0.01 (**). IR- refers to without ionising radiation. 
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5.3.3 Expression of DNA damage signalling genes in BI-Trans PMTCs 
Targetted overexpression of both PBF and PTTG in transgenic murine thyroids (BI-Trans) resulted in 
an interesting pattern on the DNA damage signalling pathway microarray seen in Figure 5-3. Genes 
such as Polk, Rad9, Tdg, Ube2a, Hus1, Nthl1 and Pms1 were no longer stimulated to a significant 
extent as they have been in PTTG+/+ and PBF transgenic models. The genes inhibited in the BI-Trans 
PMTCs by more than twice included Trpc2 (0.27 x), Pms2 (0.38 x), Brca1 (0.38 x), Ung (0.38 x), 
Chek1 (0.39 x), Mbd4 (0.39 x), Exo1 (0.43 x), Fen1 (0.44 x), Fancg (0.45 x), Chaf1a (0.45 x) and 
Rad51 (0.5 x); (n=3). Genes which were significantly repressed in PTTG PMTCs but not significantly 
repressed in BI-Trans included Fancc (0.59 x), Pole (0.51 x), Rad18 (0.63 x), Rad51l1 (0.67 x), Trex1 
(0.56 x) and Xpa (0.65 x); (n=3). The genes of Muyth, Rad9b and Xrcc3 were significantly repressed 
in PBF PMTCs but is no longer significantly repressed in cells co-expressing PTTG. Brca1 (0.38 x), 
Chaf1a (0.45 x), Chek1 (0.39 x), Fen 1 (0.44 x) and Rad51 (0.5 x) repressed in PTTG PMTCs were 
still suppressed in the presence of PBF but to a lesser extent (n=3). The genes that was repressed in BI-
Trans PMTCs, Trpc2 (3.68 x), was not repressed as much in the presence of both PBF and PTTG 
compared to PBF alone.The only unique gene inhibited when both PBF and PTTG were 
overexpressed in PMTCs was Ung. The profile of genes repressed in BI-Trans where fewer genes 
were suppressed compared to PTTG alone, suggests a more stable cell when compared to PTTG but 
more unstable compared to PBF. 
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Figure 5-3  DNA damage / DNA repair gene expression in BI-Trans PMTC without 
irradiation (n=3) compared with wild type without irradiation (WT IR-).  If  0.01 < p   ≤ 0.05  
(*) and 0.001 < p ≤ 0.01 (**). Fold changes were considered significant if expressed by  less 
than half. No genes were expressed by more than twice. IR- refers to without ionising 
radiation. 
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5.3.4 Affect upon apoptotic genes 
We next examined the microarray mRNA gene expression profile by functional grouping. Brca1 (0.15 
fold)  and Mbd4 (0.43 fold) were repressed by PTTG shown in Figure 5-4. The repression of Brca1 
was partially ameliorated by the additional presence of PBF. In BI-Trans, Brca1 expression was 0.38 
fold (Figure 4.4). In comparison, Mbd4 repression in BI-Trans remained unaffected by the presence of 
PBF. Taken together, PTTG suppressed the apoptotic genes Brca1 and Mbd4 but this effect was 
reduced in the presence of PBF. PBF on its own did not have a significant effect on any of the genes 
involved with apoptosis in the array. 
 
 
Figure 5-4  Expression of genes involved in apoptosis according to genotype (n=3). 
Statistical significance is represented by * if  0.01 < p   ≤ 0.05 and ** if 0.001 < p ≤ 0.01.IR- 
denotes without ionising radiation. 
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5.3.5 Affect upon genes involved in cell cycle arrest 
PBF did not have any significant effect on the expression of any of the cell cycle arrest genes 
investigated, illustrated in Figure 5-5. In PTTG+/+ (thyroids homozygous for PTTG) PMTCs, the 
expression of Hus1 was 2.11 fold and Chek1 0.23 fold relative to wild type (WT) PMTCs (n=3). Hus1 
is a gene involved in cell cycle arrest following DNA damage. Interestingly, Chek1, a gene involved 
in cell cycle arrest in response to DNA damage and serves to integrate signals from ATM and ATR, 
was suppressed in PTTG+/+ PMTCs. In BI-Trans PMTCs, only Chek1 was suppressed (0.39 fold).  
Taken together, PTTG overexpression was associated with cell cycle arrest via the overexpression of 
Hus1, but when PBF was concurrently overexpressed with PTTG, the overexpression of Hus1 was 
ameliorated.  
 
Figure 5-5  Cell cycle arrest gene expression by genotype (n=3). If  0.01 < p   ≤ 0.05  (*), 
0.001 < p ≤ 0.01 (**) and  0.0001 < p ≤ 0.001 (***). IR- denotes without ionising radiation. 
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5.3.6 Affect upon cell cycle checkpoint genes 
PBF PMTCs which overexpressed PBF in thyroid cells did not show any significant expression 
changes in cell cycle checkpoint genes shown in Figure 5-6. PTTG+/+ PMTCs overexpressed Rad9, a 
cell cycle checkpoint protein required for cell cycle arrest and DNA damage repair, by 3.05 times. Bi-
Trans PMTCs did not show any significant gene expression changes.  
 
 
Figure 5-6  Expression of genes involved in cell cycle checkpoint by genotype (n=3). The p-
value is represented by * if  0.01 < p   ≤ 0.05. IR- denotes without ionising radiation. 
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5.3.7 Affect upon other genes related to the cell cycle  
Figure 5-7 shows the affect of our 4 genotypes WT, PTTG+/+, PBF and BI-Trans on further genes 
related to the cell cycle. PTTG and BI-Trans PMTCs showed a repression of Chaf1a, with expressions 
of 0.36 and 0.45 fold compared to WT PMTCs, respectively. PBF did not appear to affect the other 
genes involved in the cell cycle. Chaf1a is a core component of CAF-1 complex, a complex thought to 
mediate chromatin assembly in DNA repair.  
 
 
Figure 5-7  Expression of further genes related to the cell cycle (n=3). p-values are denoted 
by * if  0.01 < p   ≤ 0.05  (*) and ** if  0.001 < p ≤ 0.01 (**). IR- denotes without ionising 
radiation.  
 
 
 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
1.40 
1.60 
Atm Chaf1a Smc3 Rad17 Rad21 Terf1 Tlk1 
FO
LD
 C
H
A
N
G
E 
GENE 
WT IR- 
PBF IR- 
PTTG+/+ IR- 
BI-Trans IR- 
* 
** 
** 
* 
* 
                                                           The effect of genotype on DNA damage and repair genes  
141 
 
5.3.8 Affect upon genes involved in damaged DNA binding 
The expression of Trpc2 and Xrcc3 was reduced in PBF PMTC, with expression levels of 0.21 and 
0.38 fold respectively compared to WT PMTCs, seen in Figure 5-8. Trpc2 and Xrcc3 remained 
suppressed to a lesser extent (0.27 and 0.55 fold respectively) in BI-Trans PMTCs. Additional 
suppressed genes in BI-Trans included Brca1 (0.38 fold) and Rad51 (0.50 fold). The profile of 
suppressed genes in PTTG PMTCs were similar to BI-Trans albeit to a more pronounced extent, with 
the expression of Brca1 0.15 fold and Rad51 0.23 fold relative to WT PMTCs in PTTG PMTCs. 
Additional genes reduced in PTTG PMTCs include Rad51l1 (0.47 fold) and Xpa (0.46 fold). The 
results suggest a general suppression of genes involved in DNA damage binding. Although not 
defined as significant, PTTG PMTCs demonstrated an increase in Rad1 by 1.77 times and Trpc2 by 
1.88 times.  
 
 
Figure 5-8  Damaged DNA Binding gene expression by genotype. p-values are denoted by * if  
0.01 < p   ≤ 0.05  (*) and ** if  0.001 < p ≤ 0.01 (**). IR- denotes without ionising radiation.  
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5.3.9 Affect upon genes involved in base excision repair 
PTTG increased the relative expression of Nthl1 by 2.05 fold and reduced the expression of Mbd4 by 
2.34 fold. The expression of Mutyh was 0.77 fold in PBF primary murine thyroid cultures (PMTCs) 
compared to WT PMTCs. The expression of both PBF and PTTG simultaneously resulted in a relative 
reduction in Mbd4 at 0.43 fold, shown in Figure 5-9. 
 
 
Figure 5-9  Base excision repair gene expression by genotype (n=3). p-values are denoted by 
* if  0.01 < p   ≤ 0.05  (*) and ** if  0.001 < p ≤ 0.01 (**). IR- denotes without ionising 
radiation.  
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5.3.10  Affect upon genes involved in nucleotide excision repair 
Figure 5-10 represents mRNA gene expression involved in nucleotide excision repair. The only gene 
that appeared to have any effect on genes involved in nucleotide excision repair is PTTG. Targetted 
thyroid overexpression of PTTG was associated with increased expression of Nthl1 (2.05 fold) and 
reduced expression of Fancc (0.38 fold) and Xpa (0.46 fold). PBF did not appear to have any effect on 
investigated genes involved in nucleotide excision repair. However, when both PBF and PTTG were 
overexpressed together in murine thyroid cells, the effect of PTTG on nucleotide excision repair genes 
was completely ameliorated. 
 
 
Figure 5-10  Genes involved with nucleotide excision repair by genotype. p-values are 
denoted by * if  0.01 < p   ≤ 0.05  (*) and ** if  0.001 < p ≤ 0.01 (**). IR- denotes without 
ionising radiation.  
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5.3.11  Affect upon genes involved in double strand break repair 
The expression of genes involved in double strand break repair was unchanged in PBF, PTTG and BI-
Trans PMTCs, shown in Figure 5-11. We defined a significant change in mRNA expression as more 
than twice or less than half compared with wild type without ionising radiation (WT IR-). 
 
 
Figure 5-11  Double strand break repair gene expression by genotype. p-values are denoted 
by * if  0.01 < p   ≤ 0.05  (*) and ** if  0.001 < p ≤ 0.01 (**). IR- denotes without ionising 
radiation.  
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5.3.12   Affect upon genes involved in mismatch repair 
PBF did not have discernible effect on the expression of the mismatch repair genes included in the 
microarray (Figure 5-12). PTTG caused the increased expression of Pms1 (2.03 fold) and the 
suppression of Pms2 (0.42 fold) and Trex1 (0.44 fold) relative to WT PMTCs. In BI-Trans PMTCs, 
Pms2 remains suppressed (0.38 fold) but Pms1 is no longer overexpressed and Trex1 not significantly 
suppressed.  
 
 
Figure 5-12  The mRNA expression of genes involved in mismatch repair. p-values are 
denoted by * if  0.01 < p   ≤ 0.05  (*) and ** if  0.001 < p ≤ 0.01 (**). IR- denotes without 
ionising radiation.  
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5.3.13  Affect on other genes related to DNA repair  
Figure 5-13 is shown in 3 separate bar charts for the same functional grouping of other genes related to 
DNA repair on the microarray. PBF suppressed the expression of Rad9b (0.47 fold) whilst PTTG 
increased the expression of Polk (3.08 fold), Tdg (3.07 fold), Rad9 (3.05 fold) and Ube2a (2.24 fold). 
The expression of Fancg (0.38 fold), Rad18 (0.37 fold), Chaf1a (0.36 fold), Fen1 (0.31 fold), Pole 
(0.29 fold) and Exo1 (0.11 fold) was reduced in PTTG PMTCs. The genes that are suppressed in BI-
Trans included Chaf1a (0.45 fold), Fancg (0.45 fold), Fen1 (0.44 fold), Exo1 (0.43 fold) and Ung 
(0.38 fold).  
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Figure 5-13 Expression of other genes related to DNA repair by genotype (n=3). If  0.01 < p   
≤ 0.05  (*), 0.001 < p ≤ 0.01 (**) and  0.0001 < p ≤ 0.001 (***). IR- denotes without ionising 
radiation. 
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5.4 DISCUSSION 
5.4.1 Murine DNA Damage Signalling Microarray studies 
The ability to develop tumours is intimately related to the sophisticated regulation of genes associated 
with DNA damage and DNA repair.  
The Mouse DNA Damage Signalling RT2 Profiler PCR Array profiles 84 genes involved in murine 
DNA damage signalling and DNA repair pathways. The featured genes are associated with the 
ATR/ATM signalling pathways and transcriptional targets of DNA damage response. The ATM 
pathway is primarily activated by double-strand DNA breaks whereas ATR responds to a much 
broader spectrum of DNA damage, including DSBs and many types of DNA damage that interfere 
with DNA replication. ATR stabilises the genome during DNA replication which is essential for 
maintaining genomic stability. 
The interpretation of the microarray data is complex because of the sophisticated gene expression 
relationships with each other which may or may not have been completely delineated. In order to 
interpret microarray gene changes, we considered genes which were relatively overexpressed by more 
than 2 times or genes that were reduced by more than half. Overall, PBF overexpression in the murine 
thyroid had the effect of gene suppression. In contrast, PTTG had a combination of gene mRNA 
upregulation and downregulation. The BI-Trans murine thyroid which overexpressed both PBF and 
PTTG had a gene expression profile similar to PBF.   
 
5.4.2 The effect of PTTG on DNA damage/DNA repair genes 
The relationship between Trp53 and PTTG is complex and ill-defined. Apoptosis involving PTTG can 
be Trp53 dependent and independent (Yu et al., 2000a, Yu et al., 2000b). Interestingly, the transgenic 
overexpression of PTTG was associated with the suppression of  the genes Brca1 and Mbd4 involved 
in apoptosis but had no significant effect on Trp53.  
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Previous studies have shown the interaction between PTTG overexpression and the inhibition of Ku70 
involved in non-homologous end-joining DNA repair (Kim et al., 2007b), leading to our hypothesis 
that PTTG has an effect on DNA repair. Using the microarray, we have screened for genes involved in 
DNA damage and DNA repair. PTTG increased the expression of Hus1 and Rad9 but simultaneously 
reduced the expression of Chek1 and Chaf1a. Hus1, Rad9 and Rad1 form the 9-1-1 ring-shaped 
trimeric complex which is formed in response to DNA damage. Together with Rad17, they act as a 
checkpoint sensor to activate ATM or ATR (ATM and Rad3 related protein) protein kinase. The 9-1-1 
complex interacts and stimulates DNA repair enzymes involved in base excision repair, nucleotide 
excision repair and mismatch repair. Expression changes in PTTG PMTCs may have encouraged the 
production of 9-1-1 complex which then caused a plethora of changes in gene groups on the 
microarray representing suppression of damaged DNA binding (suggesting no damaged DNA 
involved), equivocal changes in base excision repair, nucleotide excision repair and mismatch repair 
and no change in double strand break repair. There was a variety of suppression and enhancement of 
the expression of genes involved more widely in DNA repair. It is conceivable that PTTG affects the 
DNA repair pathway by way of encouraging the formation of the 9-1-1 complex.   
In contrast, a marked suppression was observed in Chek1, a serine/threonine protein kinase, required 
for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of 
DNA damage or unreplicated DNA. Chek1 also binds to and phosphorylates RAD51 at Thr-309 which 
promotes the release of Rad51 from BRCA2 and enhances the association of Rad51 with chromatin, 
thereby promoting DNA repair by homologous recombination. The PTTG suppression of Chek1 
suggests cells may be allowed to progress in the cell cycle.  
Apoptosis is discouraged by the suppression of Brca1 and Mbd4. The expression of Trp53 was not 
significantly increased. Chek1 is known to phosphorylate multiple sites within the C-terminus of 
Trp53, promoting cell cycle arrest and suppression of cellular proliferation. Hence, although the 
expression of Trp53 was not significantly enhanced, it is still possible to that Trp53 is activated by 
phosphorylation via Chek1, in the presence of PTTG. This hypothesis needs to be investigated further 
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at a protein level. The above would strongly suggest that PTTG suppresses apoptosis, preferring to 
repair the defect within the genome. Further studies are required to delineate the action of PTTG and 
p53 dependent apoptosis.   
The above suggests that the presence of PTTG caused more cellular stress from a DNA damage and 
DNA repair perspective, necessitating the stimulation and suppression of various genes in order to 
maintain genomic stability. 
 
5.4.3 The effect of PBF on DNA damage/DNA repair genes 
The overexpression of PBF in PMTCs did not appear to increase the expression of DNA damage 
genes in the microarray. PBF appeared to suppress the genes Trpc2 and Xrcc3 involved in DNA 
damage binding and Mutyh in base excision repair to a significant extent, defined by our criteria. The 
other gene suppressed is Rad9b which again is involved in DNA repair. Overall, it appeared that PBF 
predominantly suppressed several genes associated with DNA repair but the effect is not entirely clear.  
PBF is recognised to bind to and negatively regulate Trp53 (Read et al., 2014a, Read et al., 2014b). 
The mRNA expression of Trp53 in murine thyroids overexpressing PBF was not significantly altered 
on the microarray suggesting that the interaction between PBF and Trp53 mostly occurred at a protein 
level in our models. 
 
5.4.4 The effect of both PBF and PTTG on DNA damage/DNA repair genes 
Most genes involved in DNA repair were inhibited in BI-Trans PMTCs with the exception of 
nucleotide excision repair and double strand break genes, which remain unaffected. When both PBF 
and PTTG were co-expressed in PMTCs, the general trend observed was the amelioration of over or 
under expression of DNA damage / DNA repair genes observed in PTTG PMTCs. This effect is 
interesting because PBF is a protein that transports the mainly cytoplasmic PTTG to the nucleus. This 
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microarray observation is in contrast to the hypothesis that PBF enhances the genetic instability caused 
by PTTG. However, further studies are required to establish this. 
 
 
5.5 CONCLUSION 
The changes observed in the microarray show that PTTG caused more disruption to the DNA damage/ 
DNA repair gene expression profile than PBF alone. The study of both genes being expressed together 
suggested that PBF partially ameliorates the instability introduced by PTTG. Ultimately, the gene 
expression profile is important in establishing a background of genes affected by genotype before we 
study the effect of genotype following real DNA damage.  
    
6 The effect of radiation on genotype in DNA damage and 
repair genes 
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6.1 INTRODUCTION 
6.1.1  Background 
PBF and PTTG have been shown independently to alter genomic stability (Read et al., 2014a, Kim et 
al., 2005). Thyroid cancers, particularly of the variety with poor prognosis overexpress PTTG and PBF 
(Stratford et al., 2005, Boelaert et al., 2003, Hsueh et al., 2013). Moreover, ionising radiation which 
induces DNA damage is a known aetiological factor for thyroid carcinoma. PTTG has roles in mitosis 
and can impair DNA repair via the inhibition of Ku70, involved in double strand break repair (Kim et 
al., 2007b). PTTG has a binding partner PBF which facilitates its entry into the nucleus for its 
functions (Chien and Pei, 2000).  
To study the effects of PBF and PTTG in the context of thyroid cancer, we have created transgenic 
murine models that overexpress our genes of interest in the thyroid gland. To study the effects of 
ionising radiation, we established the technique of primary murine thyroid culture (PMTC) which 
overexpress PBF and/or PTTG in a uniform manner in a Petri dish.  
We previously studied the expression of genes associated with the DNA damage and repair pathways 
in the context of PBF and PTTG overexpression in the thyroid gland, described in the last chapter. We 
next investigated the effect of external genomic stress, in the form of ionising radiation to determine 
the expression of the same gene before, in a background of PBF and PTTG overexpression. We 
hypothesised that thyroid cells overexpressing PBF and PTTG will respond differently in the presence 
of DNA damage, resulting in reduced genomic stability compared to wild type PMTCs.  
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6.2 MATERIALS AND METHODS 
6.2.1 Primary murine thyroid cultures 
Primary murine thyroid culture (PMTC) was performed on the 4 different genotypes, WT, PBF, PTTG 
+/+ and BI-Trans, using 3 males in each genotype group. Details of the technique can be found in 
section 2.2.   
6.2.2 RNA extraction 
RNA was harvested from PMTCs on day 10 using the micro RNeasy kit (QIAGEN) as 
described in section 2.4. 
6.2.3 Reverse transcription 
Reverse transcription was performed using the Promega Reverse Transcription system as 
described in section 2.5. 
6.2.4 RT2 ProfilerTM PCR Arrays 
The RT2 ProfilerTM PCR Arrays (SABiosciences) were used for gene expression detection as described 
in Chapter 5. Interpretation of data was based arbitrarily on a fold change relative to WT IR- of more 
than 2 or less than 0.5. Values between 0.5 and 2 were deemed as insignificant for the purpose of this 
analysis. The n value for each genotype category was 3 (e.g. WT IR- (n=3) and WT IR+ (n=3)). 
Although p values were calculated and incorporated within the chapter, the emphasis was more on 
trend rather than the actual p-values because the sample size was small for each genotype, and the aim 
was to identify robust gene expression changes which could be further investigated in subsequent 
chapters. 
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6.3 RESULTS 
6.3.1 The effect of radiation on WT PMTCs 
Gene expression changes in wild type primary murine thyroid cultures of less than 0.5 fold and more 
than two fold following ionising radiation (WT IR+ PMTCs) is shown in Figure 6-1. The most striking 
change affected by radiation in the WT IR+ PMTC is a reduction of Brca1 to 0.35 fold (p=0.004; n=3) 
relative to WT IR-. Brca1 together with Rad51 and γ-H2AX, is usually recruited to areas requiring 
repair following damage (Krum et al., 2010, Feng and Zhang, 2012).  Expression of Mgmt, associated 
with alkalyting injuries (Aquilina et al., 1992, Xiao and Samson, 1993, Hegi et al., 2005), was noted to 
be increased by 2.05 fold (p=0.003; n=3). The expression of genes involved with DNA repair such as 
Brca1, Mbd4 (0.50 fold, p=0.072, n=3), Exo1 (0.30 fold, p=0.006, n=3), Pole (0.37 fold, p=0.002, 
n=3), Lig1 (0.43 fold, p=0.013, n=3) and Ung (0.50 fold, p=0.085, n=3) were reduced on the 
microarray compared to WT IR-. Interestingly, endogenous PTTG was reduced at 0.41 fold in WT 
IR+ PMTCs (p=0.162, n=3). 
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Figure 6-1  Gene expression changes in WT PMTC following irradiation (WT IR+) that were 
less than 0.5 fold (A) and more than 2 fold (B). Fold changes are expressed relative to WT 
PMTC without irradiation (WT IR-). p-values are denoted with *  (0.01 < p   ≤ 0.05) and  ** 
(0.001 < p ≤ 0.01).  
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6.3.2 The effect of radiation on PBF PMTCs 
Significant gene expression changes found on the microarray for PBF primary murine thyroid cultures 
(PMTC) following ionising irradiation (PBF IR+) is shown in Figure 6-2. In PBF IR+ PMTCs, the 
observed pattern was primarily gene suppression on the microarray relative to WT IR-. The observed 
suppression of Exo1 (0.15 fold, p=0.098, n=3), Brca1 (0.23 fold, p=0.130, n=3), Pole (0.26 fold, 
p=0.512, n=3), Pttg1 (0.28 fold, p=0.386, n=3), Ung (0.41 fold, p=0.142, n=3) and Mbd4 (0.45 fold, 
p=0.056, n=3) probably reflected the effect of radiation as a similar pattern of suppression in the same 
genes was observed in WT IR+ (Figure 6-1A).  The expression changes in the genes Xrcc3 (0.31 fold, 
p=0.009, n=3), Mutyh (0.36 fold, p=0.003, n=3), Rad9b (0.46 fold, p=0.052, n=3) and Trpc2 (0.49 
fold, p=0.004) observed in PBF IR+ were also observed to be expressed less than 0.5 fold in PBF IR- 
PMTCs (Figure 5-1), suggesting that the reduced expression of these genes were likely the effect of 
the PBF genotype. The gene expression in PBF IR+, Chaf1a (0.39 fold, p=0.064, n=3), Chek1 (0.18 
fold, p=0.077, n=3), Terf1 (0.35 fold, p=0.032, n=3), Rad51 (0.10 fold, p=0.658, n=3), Rad51l1 (0.32 
fold, p=0.336, n=3), Rad51c (0.35 fold, p=0.015, n=3), Lig1 (0.36 fold, p=0.129, n=3), Parp1 (0.46 
fold, p=0.149, n=3) and Xrcc2 (0.49 fold, p=0.167, n=3) were exclusively the effect of radiation on 
PBF PMTCs because these gene expression changes were not found in PBF IR- or  WT IR+ PMTCs. 
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Figure 6-2  DNA damage / DNA repair gene expression changes in PBF PMTC following 
exposure to radiation. All values are relative to WT IR-. p-values are denoted with *  (0.01 < 
p   ≤ 0.05),  ** (0.001 < p ≤ 0.01) and ***  (0.0001 < p ≤ 0.001). There were no genes on the 
RT2 Profiler™ PCR Array that were expressed more than twice in PBF IR+ PMTCs. 
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6.3.3 The effect of radiation on PTTG+/+ IR+ PMTCs 
The significant gene expression changes on the microarray for PTTG primary murine thyroid cultures 
(PMTCs) with ionising radiation (PTTG+/+ IR+) is shown in Figure 6-3. The genes suppressed in 
PTTG+/+ IR+ PMTCs, also observed in WT IR+ PMTCs were as follows; Exo1 (0.13 fold, p=0.010, 
n=3), Brca1 (0.16 fold, p=0.003, n=3), Pole (0.19 fold, p=0.003, n=3) and Mbd4 (0.39 fold, p=0.058, 
n=3). The genes which were suppressed in WT IR+ but not in PTTG IR+ were Lig1, Pttg1 and Ung. 
The gene Mgmt increased by 2.05 in WT IR+ but was not elevated by more than 2 fold in PTTG+/+ 
IR+. The genes suppressed to less than 0.5 fold compared to WT IR- in both PTTG+/+ IR- and 
PTTG+/+ IR+ included Chek1 (0.14 fold, p=0.013, n=3), Rad51 (0.15 fold, p=0.036, n=3), Fen1 (0.22 
fold, p=0.002, n=3), Chaf1a (0.30 fold, p=0.022, n=3), Rad18 (0.31 fold, p=0.001, n=3), Fancc (0.31 
fold, p=0.023, n=3), Trex1 (0.37 fold, p=0.012, n=3), Fancg (0.40 fold, p=0.032, n=3), Pms2 (0.48 
fold, p=0.071, n=3) and Xpa (0.48 fold, p=0.060, n=3). The genes expressed by more than 2 fold in 
PTTG+/+  IR+ were Hus1 (2.04 fold, p=0.011, n=3), Nthl1 (2.10 fold, p=0.020, n=3), Ube2a (2.46 
fold, p=0.018, n=3), Trpc2 (2.79 fold, p=0.025, n=3), Tdg (2.81 fold, p=0.090, n=3), Rad9 (3.23 fold, 
p=0.011, n=3) and Polk (4.97 fold, p=0.004, n=3), were also expressed by more than twice in 
PTTG+/+ IR-. The genes that were significantly altered in PTTG+/+ IR- but not in PTTG+/+ IR+ 
were Rad51l1, Pttg1 and Pms1. The genes exclusively suppressed in PTTG+/+ IR+ but not in 
PTTG+/+ IR- were Pold1 (0.44 fold, p=0.004, n=3) and Wrn (0.48 fold, p=0.264, n=3). 
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Figure 6-3  DNA damage / DNA repair gene expression changes in PTTG+/+ IR+ PMTC 
less than 0.5 (A) and more than 2 (B) fold. p-values are denoted with *  (0.01 < p   ≤ 0.05) 
and  ** (0.001 < p ≤ 0.01). 
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6.3.4 The effect of radiation on BI-Trans PMTCs 
The significant gene expression changes on the microarray for murine models overexpressing both 
PBF and PTTG in the thyroid gland (BI-Trans) following radiation exposure is shown in Figure 6-4. 
The genes of Exo1 (0.09 fold, p=0.001, n=3), Brca1 (0.14 fold, p<0.000, n=3), Pole (0.15 fold, 
p=0.002, n=3), Ung (0.26 fold, p=0.009, n=3), Lig1 (0.43 fold, p=0.002, n=3) and Mbd4 (0.44 fold, 
p=0.021, n=3) were suppressed  in BI-Trans following ionising radiation (BI-Trans IR+) PMTCs. 
These genes were altered in all genotypes following exposure to ionising radiation and is likely the 
effect of radiation. The expression of genes altered in BI-Trans IR+ which were most likely to be due 
to the effect of PBF and radiation included Rad51l1 (0.33 fold, p=0.088, n=3) and Rad51c (0.40 fold, 
p=0.016, n=3). The altered genes Fen1 (0.33 fold, p=0.001, n=3), Rad18 (0.47 fold, p=0.001, n=3), 
Trex1 (0.50 fold, p=0.064, n=3) and Polk (2.01 fold, p=0.009, n=3) in BI-Trans IR+ PMTCs were 
likely the effect of PTTG because these genes were also altered in PTTG+/+ PMTCs. The genes Fancg 
and Pinx1, suppressed to a significant degree in BI-Trans IR-, were no longer suppressed significantly 
in BI-Trans IR+. Finally, genes which were significantly altered in BI-Trans IR+ and in PBF IR+, 
PTTG+/+ IR-, PTTG+/+IR+ and BI-Trans IR- were Chek1 (0.14 fold, p<0, n=3), Rad51 (0.15 fold, 
p=0.034, n=3) and Chaf1a (0.42 fold, p=0.019, n=3).  
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Figure 6-4  DNA damage and DNA repair gene expression changes in BI-Trans IR+ PMTCs 
of less than 0.5 (A) and more than 2 (B) fold.  Fold expression is relative to WT IR-. p-values 
are denoted with *  (0.01 < p   ≤ 0.05),  ** (0.001 < p ≤ 0.01) and ***  (0.0001 < p ≤ 0.001). 
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6.3.5 PBF, PTTG and radiation reduced the expression of Brca1 and Mbd4,  
genes involved with apoptosis. 
To make sense of the enormous amount of data generated by these studies, we next examined gene 
expression by functional grouping to interpret the mouse DNA Damage Signalling Pathway RT2 
ProfilerTM PCR Array findings in a meaningful manner. Thus, in the following sections, data have 
been grouped according to biological pathway. For apoptosis, the expression of Brca1 (0.35 fold, 
p=0.004; n=3), Mbd4 (0.50 fold, p=0.072, n=3) and Mgmt (2.05 fold, p=0.003; n=3) was altered in 
wild type primary murine thyroid cultures (PMTCs) following treatment with ionising radiation (WT 
IR+) shown in Figure 6-5. Brca1 (0.23 fold, p=0.130, n=3) and Mbd4 (0.45, p=0.056, n=3) were 
suppressed by more than 0.5 fold in PBF IR+ compared to WT IR-. This represented a further 
suppression of these genes when comparing PBF IR+ with PBF IR-. In PTTG IR+ PMTCs, both 
Brca1 (0.16 fold, p=0.003, n=3) and Mbd4 (0.39 fold, p=0.058, n=3) were reduced relative to WT IR-. 
The pattern of suppression in both genes was fairly similar in PTTG IR-. As expected, Brca1 (0.14 
fold p<0.000 n=3) and Mbd4 (0.44 fold p=0.021 n=3) had reduced expression in BI-Trans IR+ 
PMTCs. It appeared that radiation increased the suppression of Brca1 in BI-Trans IR+ PMTCs but 
radiation did not appear to increase the suppression of Mbd4.  
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Figure 6-5  Expression of genes involved in apoptosis by genotype. Top figure (A) denotes 
PMTC genotype with irradiation (IR+) and bottom figure (B) denotes PMTC genotype 
without irradiation (IR-). Fold expression is relative to WT PMTC without irradiation (WT 
IR-). p-values are denoted with *  (0.01 < p   ≤ 0.05) and  ** (0.001 < p ≤ 0.01). 
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6.3.6 Radiation and PTTG reduced the expression of Chek1, a gene 
involved in cell cycle arrest. 
Radiation did not cause any significant expression changes to genes involved in cell cycle arrest in 
WT IR+ PMTCs as shown in Figure 6-6. The genes Chek1 (0.14 fold, p=0.013, n=3) and Hus1 (2.04 
fold,  p=0.011,  n=3) had altered expression in PTTG IR+ compared to WT IR- PMTCs. This observed 
trend was also found in PTTG IR- PMTCs, suggesting the increased expression of Hus1 and reduced 
expression of Chek1 was likely an effect of PTTG genotype on PMTCs. The expression of Chek1 
(0.14 fold, p<0.000, n=3) was significantly reduced in BI-Trans IR+ compared to WT IR- PMTCs. 
The expression of Chek1 was more reduced in BI-Trans IR+ compared to BI-Trans IR-. 
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Figure 6-6  Cell cycle arrest gene expression by genotype. Top figure (A) denotes PMTC 
genotype with irradiation (IR+) and bottom figure (B) denotes PMTC genotype without 
irradiation (IR-). Fold expression is relative to WT PMTC without irradiation (WT IR-). p-
values are denoted with *  (0.01 < p   ≤ 0.05),  ** (0.001 < p ≤ 0.01), ***  (0.0001 < p ≤ 
0.001) and **** (p≤0.0001). 
0 
0.5 
1 
1.5 
2 
2.5 
Chek1 Gadd45a Hus1 Msh2 
FO
LD
 C
H
A
N
G
E 
R
EL
A
TI
V
E 
TO
 W
T 
IR
- 
GENE 
WT IR+ 
PBF IR+ 
PTTG+/+ IR+ 
BI-Trans IR+ 
A 
** 
* **** 
* 
* 
0 
0.5 
1 
1.5 
2 
2.5 
Chek1 Gadd45a Hus1 Msh2 
FO
LD
 C
H
A
N
G
E 
GENE 
WT IR- 
PBF IR- 
PTTG+/+ IR- 
BI-Trans IR- 
* 
** 
** 
*** 
B 
                                        The effect of radiation on genotype in DNA damage and repair genes
  
167 
 
6.3.7 Genes involved in cell cycle checkpoint remained unchanged 
following irradiation regardless of genotype  
Radiation did not appear to impact on the expression of genes involved in cell cycle checkpoint to a 
significant degree, seen in Figure 6-7. The effect of genotype on the microarray genes remained 
essentially unaltered following irradiation. The high expression of Rad9 (3.23 fold, p=0.011, n=3)  in 
PTTG IR+ PMTC appeared to be essentially an effect of the PTTG genotype.  
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Figure 6-7  Expression of cell cycle checkpoint genes by genotype. Chart A denotes PMTC 
genotype with irradiation (IR+) and chart B denotes PMTC genotype without irradiation (IR-
). Fold expression is relative to WT PMTC without irradiation (WT IR-). p-values are denoted 
with *  if 0.01 < p   ≤ 0.05.  
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6.3.8 Reduced Chaf1a expression in PBF and PTTG genotypes was further 
suppressed by radiation   
In the functional grouping of other genes involved in cell cycle regulation on the microarray, gene 
expression was not significantly altered following radiation in WT PMTCs. Chaf1a (0.39 fold, 
p=0.064, n=3) and Terf1 (0.35 fold, p=0.032, n=3) was significantly reduced in PBF PMTCs 
following radiation. The reduced expression of these genes were exaggerated by radiation (see Figure 
6-8). Chaf1a was significantly reduced in PTTG IR- PMTCs. The reduction in Chaf1a (0.30 fold, 
p=0.022, n=3) expression in PTTG IR+ PMTCs was increased by radiation. A similar trend was 
observed in Chaf1a (0.42 fold, p=0.019, n=3) expression in BI-Trans IR+ where Chaf1a expression 
was reduced in BI-Trans IR- but the effect of decreased expression was more profound following 
radiation exposure. 
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Figure 6-8  Other genes related to cell cycle following DNA damage, gene expression by 
genotype. Top figure (A) denotes PMTC genotype with irradiation (IR+) and bottom figure 
(B) denotes PMTC genotype without irradiation (IR-). Fold expression is relative to WT 
PMTC without irradiation (WT IR-). p-values are denoted with *  (0.01 < p   ≤ 0.05) and  ** 
(0.001 < p ≤ 0.01). 
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6.3.9 Genes involved in damaged DNA binding 
Of those genes involved in damaged DNA binding, Brca1 (0.35 fold, p=0.004, n=3) was the only gene 
significantly repressed following radiation, shown in Figure 6-9. PBF PMTCs showed repressed 
expression of Xrcc3 (0.31 fold, p=0.009, n=3), Trpc2 (0.49 fold, p=0.004), Rad51 (0.10 fold, p=0.658, 
n=3), Rad51c (0.35 fold, p=0.015, n=3) and Xrcc2 (0.49 fold, p=0.167, n=3) following treatment with 
ionising radiation. The gene repression in PBF IR+ PMTCs was enhanced following radiation induced 
damage seen in Figure 6-9. In PMTCs overexpressing PTTG, Brca1 (0.16 fold, p=0.003, n=3), Rad51 
(0.15 fold, p=0.036, n=3), Xpa (0.48 fold, p=0.060, n=3) and Trpc2 (2.79 fold, p=0.025, n=3) had 
altered expression following irradiation. The gene expression changes following radiation were 
consistent with PTTG genotype related changes. The expression of Brca1 (0.14 fold p<0.000 n=3), 
Rad51 (0.15 fold p=0.034 n=3), Rad51c (0.40 fold p=0.016 n=3) and Rad51l1 (0.33 fold, p=0.088, 
n=3) in BI-Trans were significantly reduced following radiation. The only exception was the 
expression of Trpc2 (0.53 fold, p=0.171, n=3) in BI-Trans IR+ which showed reduced suppression 
when compared to BI-Trans IR- PMTC.  
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Figure 6-9  Expression of genes involved in DNA binding by genotype. The top chart (A) 
denotes PMTC genotype with irradiation (IR+) and bottom chart (B)  denotes PMTC 
genotype without irradiation (IR-). Fold expression is relative to WT PMTC without 
irradiation (WT IR-). p-values are denoted with *  (0.01 < p   ≤ 0.05),  ** (0.001 < p ≤ 0.01) 
and ***  (0.0001 < p ≤ 0.001). 
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6.3.10  Genes involved in base excision repair 
The expression of Mbd4 (0.50 fold, p=0.072, n=3) was reduced in WT PMTC following radiation as 
shown in Figure 6-10. In PBF IR+ PMTCs, Mutyh  (0.36 fold p=0.003 n=3), Mbd4 (0.45 fold, 
p=0.056, n=3) and Parp1 (0.46 fold, p=0.149, n=3) had reduced expression. The gene Mbd4 (0.44 fold 
p=0.021 n=3) was suppressed and Nthl1 (2.10 fold p=0.020 n=3) increased in PTTG IR+ PMTCs. 
This pattern of expression was comparable to PTTG IR- PMTCs. Mbd4 expression (0.44 fold, 
p=0.021, n=3) was reduced in BI-Trans IR+, similar to BI-Trans IR-. 
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Figure 6-10  Expression of genes involved in base excision repair by genotype. Top figure 
denotes PMTC genotype with irradiation (IR+) and bottom figure denotes PMTC genotype 
without irradiation (IR-). Fold expression is relative to WT PMTC without irradiation (WT 
IR-). p-values are denoted with *  (0.01 < p   ≤ 0.05) and  ** (0.001 < p ≤ 0.01). 
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6.3.11  Genes involved in nucleotide excision repair 
Radiation did not appear to have a significant effect on nucleotide excision repair genes in WT, PBF 
and BI-Trans PMTCs (Figure 6-11). Fancc (0.31 fold p=0.023 n=3) and Xpa (0.48 fold, p=0.060, n=3) 
had reduced expression in PTTG IR+ compared to WT IR-. The expression of Fancc and Xpa were 
similar in PTTG IR- and PTTG IR+ PMTCs.  
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Figure 6-11 Expression of genes involved in nucleotide excision repair by genotype. Top 
chart (A) denotes PMTC genotype with irradiation (IR+) and bottom chart (B) denotes PMTC 
genotype without irradiation (IR-). Fold expression is relative to WT PMTC without 
irradiation (WT IR-). p-values are denoted with *  (0.01 < p   ≤ 0.05) and  ** (0.001 < p ≤ 
0.01). 
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6.3.12  Genes involved in double strand break repair 
No genes involved in double strand break repair appeared to be expressed more than 2 or less than 0.5 
fold in all genotypes 24 hours following radiation as shown in Figure 6-12. The gene expression 
changes in all genotypes between IR- and IR+ was similar. 
 
 
Figure 6-12  Expression of genes involved in double break strand repair by genotype. Top 
figure (A) denotes PMTC genotype with irradiation (IR+) and bottom figure (B) denotes 
PMTC genotype without irradiation (IR-). Fold expression is relative to WT PMTC without 
irradiation (WT IR-). p-values are denoted with *  (0.01 < p   ≤ 0.05) and  ** (0.001 < p ≤ 
0.01). 
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6.3.13   Genes involved in mismatch repair 
Genes involved in mismatch repair did not appear to be altered significantly in WT and PBF PMTCs 
following radiation. The gene expression changes in WT IR- compared with WT IR+ and PBF WT 
IR- compared with WT IR+ were essentially similar (Figure 6-13). The altered expression of genes in 
PTTG IR+ PMTCs, Pms1 (1.95 fold, p=0.014, n=3), Pms2 (0.48 fold, p=0.071, n=3) and Trex1 (0.37 
fold, p=0.012, n=3) compared to WT IR- had similar expression levels in PTTG IR- PMTCs. Trex1 
(0.50 fold, p=0.064, n=3) had reduced expression in BI-Trans IR+ PMTCs. The level of suppression in 
BI-Trans IR+ PMTCs were comparable to BI-Trans IR- PMTCs.  
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Figure 6-13  Expression of genes involved in mismatch repair by genotype. Top chart (A) 
denotes PMTC genotype with irradiation (IR+) and bottom chart (B) denotes PMTC genotype 
without irradiation (IR-). Fold expression is relative to WT PMTC without irradiation (WT 
IR-). p-values are denoted with *  (0.01 < p   ≤ 0.05),  ** (0.001 < p ≤ 0.01), and ***  
(0.0001 < p ≤ 0.001). 
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6.3.14  Expression of other genes related to DNA repair  
We next examined genes that are involved in DNA repair but do not specifically and umabigiously 
belong to any of the categories described above (Figure 6-14). WT IR+ PMTCs show altered 
expression in Exo1 (0.3 fold p=0.006 n=3), Lig1 (0.43 fold p=0.013 n=3), Mgmt (2.05 fold, p=0.003, 
n=3), Pole (0.37 fold, p=0.002, n=3), Pttg1 (0.41 fold, p=0.162, n=3) and Ung (0.50 fold, p=0.085, 
n=3) relative to WT IR-. PBF+/+ IR+ PMTCs had reduced expression of Exo1 (0.13 fold, p=0.010, 
n=3), Pole (0.19 fold, p=0.003, n=3), Pttg1 (0.28 fold, p=0.386, n=3), Chaf1a (0.30 fold, p=0.022, 
n=3), Pold1 (0.44 fold, p=0.004, n=3), Lig1 (0.36 fold, p=0.129, n=3), Ung (0.41 fold, p=0.142, n=3) 
and Rad9b (0.46 fold, p=0.052, n=3). The genes suppressed to a significant extent in PBF IR+ was 
similarly suppressed in PBF IR- albeit not less than 0.5 fold with the exception of Rad9b. The 
expression of Chaf1a (0.30 fold, p=0.022, n=3), Exo1 (0.13 fold, p=0.010, n=3), Fancg (0.40 fold, 
p=0.032, n=3), Fen1 (0.22 fold, p=0.002, n=3), Pold1 (0.44 fold, p=0.004, n=3), Pole (0.19 fold, 
p=0.003, n=3), Polk (4.97 fold, p=0.004, n=3), Rad18 (0.31 fold, p=0.001, n=3),  Rad9 (3.23 fold, 
p=0.011, n=3), Tdg (2.81 fold, p=0.090, n=3), Ube2a (2.46 fold, p=0.018, n=3) and Wrn (0.48 fold, 
p=0.264, n=3). The genes that were also significantly repressed in PTTG IR- PMTCs included Chaf1a, 
Exo1, Fancg, Fen1, Pole, Polk, Rad18, Rad9, Tdg and Ube2a. Genes that had reduced expression in 
BI-Trans IR+ included Chaf1a (0.42 fold, p=0.019, n=3), Exo1 (0.09 fold, p=0.001, n=3), Fen1 (0.33 
fold, p=0.001, n=3), Lig1 (0.43 fold, p=0.002, n=3), Pole (0.15 fold, p=0.002, n=3), Polk (2.01 fold, 
p=0.009, n=3), Rad18 (0.47 fold, p=0.001, n=3) and Ung (0.26 fold, p=0.009, n=3). The expression of 
Chaf1a, Exo1, Fen1 and Ung was altered in BI-Trans IR-.  
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Figure 6-14  Expression of genes related to DNA repair by genotype. Top figure (A) denotes 
PMTC genotype with irradiation (IR+) and bottom figure (B) denotes PMTC genotype 
without irradiation (IR-). Fold expression is relative to WT PMTC without irradiation (WT 
IR-). p-values are denoted with *  (0.01 < p   ≤ 0.05),  ** (0.001 < p ≤ 0.01) and ***  (0.0001 
< p ≤ 0.001). 
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6.4 DISCUSSION 
6.4.1 Study on gene expression changes following radiation damage in 
PMTCs 
The purpose of this chapter has been to appraise in detail the influence of genotype and ionising 
radiation on a panel of 84 genes involved in DNA damage and DNA repair in order to screen for 
candidate genes to appraise in detail in subsequent chapters. The above study performed on PMTCs 
was interpreted based on the expression changes of more than 2 or less than 0.5 fold relative to WT 
IR- PMTCs. Although statistical significance was expressed in the above findings, the trend was more 
important at this stage than the actual p-values in determining the relevance of the gene identified. 
This assumption will be challenged when validation studies were performed to determine the 
reproducibility of the microarray findings.  
DNA repair following DNA damage is an evolving process that activates and suppresses various genes 
at different stages. This experiment was performed at 24 hours following ionising radiation, 
considered a relatively late time point in DNA damage studies, but allowing time for all 84 genes to 
putatively show expression changes. 
 
6.4.2 PBF IR+ PMTCs and DNA damage / DNA repair gene changes 
In DNA damage, PBF responds to ionising radiation in a similar fashion to WT PMTCs by the 
suppression of downstream gene targets of Chek1 and Chaf1a. Chek1 is a cell cycle checkpoint 
protein and Chaf1a is involved in mediating chromatin assembly in DNA repair. The only difference 
the genotype PBF makes is the suppression of Terf1, a gene involved in telomerase nucleoprotein 
complex. The inhibition of this gene should increase telomerase activity which adds DNA sequence 
repeats to the 3’ end of DNA strands. 
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The RAD51 family of proteins appeared to be suppressed to a significant degree by PBF following 
irradiation. The proteins encoded by this family of genes are involved in DSBs and homologous 
recombination (Krejci et al., 2012). The significance of this is not entirely clear but the ability to repair 
double stranded breaks is crucial in protecting a cell from ionising radiation.        
 
6.4.3 PTTG IR+ PMTCs and DNA damage / DNA repair gene changes 
As described previously, PTTG independently encouraged the expression of gene products necessary 
for the formation of the 9-1-1 complex. However, the expression of ATR, the gene required in 
conjuction with the 9-1-1 complex to activate the ATR pathway, remained largely unaltered. 
The observed microarray changes in PBF IR+ PMTCs seems to indicate that the Rad51 system of 
DNA damage genes is more suppressed than in WT IR+. The changes observed in reduced Trpc2, 
Xrcc3, Mutyh, Lig1 and Rad9b appeared to be similar to the pattern of changes observed as a result of 
PBF overexpression in PMTCs. The additional suppression of genes such as Exo1, Pole, Pttg1 and 
Ung appeared to be exaggerated in PBF PMTCs. Although this effect was similar to WT IR+, the 
response was more marked when PBF was overexpressed in follicular thyroid epithelial cells. 
 
6.4.4 The effect of both PBF and PTTG on DNA damage and DNA repair 
genes in PMTCs  
The microarray gene expression changes indicated that the changes observed in BI-Trans IR+ PMTCs 
was a unique combination in PBF and PTTG overexpression and radiation. Rad51l1 and Rad51c 
expression was reminiscent of PBF IR+ PMTCs, whilst the altered expressions of Fen1, Rad18, Trex1 
and Polk were also observed in PTTG+/+ IR. 
The PBR IR+ effect is dominant mainly in the upstream genes of the Rad51 family involved in 
homologous recombination. Several downstream genes are suppressed apart from Polk. Polk functions 
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by encouraging the replication fork to continue through a DNA lesion which might stall the replication 
process (Haracska et al., 2002). As such, we hypothesize that an increase in Polk levels might increase 
genetic instability by permitting mutations within the genome.   
 
6.5 CONCLUSION 
The increased expression of Hus1, Rad1 and Rad9 involved in the formation of the 9-1-1 complex in 
the ATR signalling pathway is primarily PTTG related. Radiation did not appear to affect the 
expression of these genes. However, PBF appeared to attenuate the increased expression of the genes 
involved in the 9-1-1 complex. PBF PMTC response to radiation included the suppression of the 
Rad51 family proteins and its functionally related Xrcc proteins. In PMTCs overexpressing both PBF 
and PTTG, and treated with ionising radiation, the gene expression changes were a combination of 
PBF IR+ and PTTG IR+. 
    
7 Evaluation of shortlisted genes within the DNA Damage / 
DNA Repair pathway 
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7.1 INTRODUCTION 
7.1.1  Background 
PBF and PTTG each cause genetic instability independently in the thyroid (Kim et al., 2007b, Kim et 
al., 2005, Read et al., 2014a). To study the effects of our genes of interest on thyroid tumourigenesis, 
the McCabe group created transgenic knock-in murine models of PBF, PTTG and both PBF and 
PTTG overexpression in the thyroid gland. The persistent level of expression of our genes of interest 
in thyroid cells within a physiological environment mirrors that in thyroid neoplasia and is ideal for 
further studies involving PBF, PTTG and their interacting genes (Kim and Zhu, 2009, Read et al., 
2011). 
Primary murine thyroid culture (PMTC) is a technique established in our group. PMTCs have been 
validated to be functional and to exhibit overexpression of our knock-in genes in culture. The presence 
of functional thyroid cells in culture overexpressing our genes of interest in a uniform manner makes it 
a flexible platform for further studies.  
On the background of PBF and PTTG affecting genomic stability, we studied the interaction of our 
genes of interest in the context of DNA damage and DNA repair genes. Microarray studies on the 
effects of PBF, PTTG and both genes together have established a pattern of gene mRNA expression 
and suppression within the ATR/ATM signalling network. 
This chapter aimed to validate the findings of genes identified and shortlisted from the microarray 
studies. mRNA expression of genes identified on the Mouse DNA Damage Signalling RT2 ProfilerTM 
PCR Arrays (SABiosciences) were validated by Taqman real-time qRT-PCR and protein expression 
on Western blotting.      
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7.2 MATERIALS AND METHODS 
7.2.1 Primary murine thyroid cultures 
PMTC was performed on the 4 different genotypes, WT, PBF, PTTG +/+ and BI-Trans as described 
previously in section 2.2.  PMTCs were harvested at day 10. For studies involving radiation, cells were 
exposed to 25 Gy ionising radiation on day 9 and harvested 24 hours later.  
   
7.2.2 RNA extraction and reverse transcription 
RNA was harvested from PMTCs on day 10 using the micro RNeasy kit (QIAGEN) and 
complementary DNA (cDNA) was obtained using the Promega Reverse Transcription system. Both 
methods were described in section 2.4 and 2.5 respectively.  
 
7.2.3 Real-time quantitative polymerase chain reaction (qRT-PCR) 
These experiments were performed using the ABI PRISM 7500 Sequence Detection System, which 
employs TaqMan TM  chemistry for highly accurate quantification of mRNA levels (Wang and Brown, 
1999) described in section 2.6. We performed singleplexed experiments because none of our 
shortlisted genes could be multiplexed with β-actin, our housekeeping gene. The housekeeping gene 
was selected based on the microarray data that suggested  β-actin was the most reliable housekeeping 
gene.  
 
7.2.4 Western blotting 
The resolution of protein on SDS-gel has been described previously in section 2.8. Primary antibodies 
used in this chapter included rabbit polyclonal antibody to Rad51 at a concentration of 1:500 (Product 
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code: ab63801; Abcam®), Rabbit DO-1 (courtesy of Dr. A Turnell, University of Birmingham) at a 
concentration of 1:100, monoclonal anti-β-actin (clone AC-15, Sigma-Aldrich, Poole, UK) at a 
concentration of 1:10,000 and γ-H2AX antibody at a concentration of 1:10,000 (NEWENGLAND 
Biolabs, MA, USA).   
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7.3 RESULTS 
7.3.1 The presence of γ-H2AX in PMTCs confirmed the presence of DNA 
damage following ionising radiation 
We assessed the protein expression of γ-H2AX in primary murine thyroid cultures (PMTCs) to 
determine whether there was DNA damage following irradiation. The expression of γ-H2AX has been 
used as a reliable indicator of DNA damage and its expression is linear with time following exposure 
to ionising radiation (Kuo and Yang, 2008, Sharma et al., 2012). On Western blot, γ-H2AX appeared 
as a band at approximately 15 kDa, shown in Figure 7-1.  
Relative fold protein expression of γ-H2AX to WT IR- (n=6) was 2.3 ± 0.5 fold (n=7, p=0.034) in WT 
IR+, 1.01 ± 0.26 fold (n=7, p=0.976) in PBF IR-, 0.96 ± 0.29 fold (n=8, p=0.902) in PBF IR+, 2.14 ± 
0.59 fold (n=7, p=0.099), 3.39 ± 0.86 fold (n=7, p=0.019) in PTTG IR+, 2.03 ± 0.51 (n=8, p=0.075) in 
BI-Trans IR- and 2.42 ± 0.34 (n=8, p=0.023) in BI-Trans IR+ on  on densitometry studies, shown in 
Figure 7.1. This crucial experiment confirmed the presence of DNA damage in our PMTCs following 
exposure to ionising radiation, providing confirmation that the dose of ionising radiation and time 
point used in our experiments were adequate to demonstrate gene expression changes on the 
microarray and validation studies. Interestingly, PBF PMTCs following treatment with ionising 
radiation (PBF IR+) did not demonstrate a statistically significant change compared to WT IR-. 
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Figure 7-1  Western blot and densitometry study of γ-H2AX in PMTCs by genotype with and 
without irradiation.WT IR- (n=6), WT IR+ (n=7), PBF IR- (n=7), PBF IR+ (n=8), PTTG+/+  
IR-(n=7), PTTG+/+ IR+ (n=7), BI-Trans IR- (n=8) and BI-Trans IR+ (n=8). p-values are 
denoted with *  (0.01 < p   ≤ 0.05). 
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7.3.2 The mRNA expression of Brca1 was reduced by PTTG expression 
and ionising radiation 
Brca1 maintains genomic stability via its roles in DNA repair, cell cycle checkpoint control, 
transcriptional regulation, apoptosis and mRNA splicing. Brca1 deficient cells have been observed to 
exhibit chromosomal translocations with large deletions and/or amplifications that involve multiple, 
non homologous chromosomes (Deng and Scott, 2000).  
PTTG but not PBF appeared to inhibit the expression of Brca1 significantly on the microarray. We 
also observed a reduction in Brca1 in all PMTCs following radiation on our microarray (Figure 7-2A). 
Hence, we decided to study this gene in greater detail. 
The relative fold expression of Brca1 on Taqman qRT-PCR relative to WT IR- was 0.58 ± 0.03 
(p=0.018, n=4) in WT IR+,  0.92 ± 0.08 (p=0.655, n=4) in PBF IR-, 0.32 ± 0.08 (p=0.002, n=4) in 
PBR IR+, 0.37 ± 0.10 (p=0.005, n=4) in PTTG+/+ IR-, 0.31 ± 0.15 (p=0.009, n=4), 0.35 ± 0.14 
(p=0.004, n=4) in BI-Trans IR- and 0.20 ± 0.11 (p=0.003, n=4) in BI-Trans IR+, shown in Figure 7-
2B. The findings on Taqman qRT-PCR thus closely followed the pattern of changes observed on the 
microarray, validating our screening approach. This therefore suggests that the results obtained on the 
microarray closely reflects the situation in reality.  
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Figure 7-2  Brca1 mRNA expression in PMTCs by genotype before and after irradiation on 
the microarray  (A) and Taqman qRT-PCR (B). n=4 PMTCs all genotypes. p-values obtained 
by comparing with WT IR- are denoted with *  (0.01 < p   ≤ 0.05),  ** (0.001 < p ≤ 0.01) and  
***  (0.0001 < p ≤ 0.001). 
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7.3.3 The mRNA expression of Chek1 was inhibited by PTTG and ionising 
radiation 
Chek1 is a serine/threonine kinase that plays an important role in the activation of S and G2/M phase 
checkpoints. It regulates these checkpoints by altering the inhibitory phosphorylation of cyclin-
dependent kinases which drive cell cycle progression. ATR and other intermediate proteins such as 
replication protein A, Claspin, Rad17, Tim/Tipin, TopBP1 involved in DNA replication are necessary 
for Chek1 activation. Other functions of Chek1 include stabilization of replication forks (Feijoo et al., 
2001), the promotion of DNA repair  and coordinating homologous recombination repair (Sorensen et 
al., 2005). 
This upstream gene is crucial in the DNA response to damage and its mRNA expression was observed 
to be independently affected by PBF, PTTG and ionising radiation damage.  The expression of Chek1 
on our Taqman qRT-PCR shown in Figure 7-3 was 0.54 ± 0.004 (p=0.038, n=4) in WT IR+, 0.67 ± 
0.09 (p=0.059, n=4) in PBF IR-, 0.18 ± 0.03 (p<0.000, n=4) in PBF IR+, 0.38 ± 0.11 (p=0.015, n=4) 
in PTTG+/+ IR-, 0.25 ± 0.10 (p=0.020, n=4) in PTTG+/+ IR+, 0.22 ± 0.07 (p=0.003, n=4) in BI-Trans 
IR- and 0.08 ± 0.02 (p=0.001, n=4) in BI-Trans IR+. Hence, it would appear that ionising radiation 
and overexpression of PBF and PTTG would increase genetic instability through the repression of 
Chek1.  
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Figure 7-3  Chek1 mRNA expression in PMTCs before and after irradiation on the 
microarray (A) and Taqman qRT-PCR (B). n=4 for PMTCs all genotypes. p-values shown, 
compared to WT IR-, are denoted with *  (0.01 < p   ≤ 0.05),  ** (0.001 < p ≤ 0.01), ***  
(0.0001 < p ≤ 0.001) and **** (p ≤ 0.0001). 
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
FO
LD
 C
H
A
N
G
E 
Chek1 (Microarray) 
* 
* 
** 
**** 
** 
A 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
FO
LD
 C
H
A
N
G
E 
Chek1 (Taqman) 
* 
**** 
* 
* 
** 
*** 
B 
                       Evaluation of shortlisted genes within the DNA Damage/ DNA Repair pathway  
197 
 
7.3.4 The mRNA expression of Exo1 was repressed by PTTG and radiation 
Exo1 interacts with Msh2 and is involved in mismatch repair and recombination. Exo1 was repressed 
following ionising radiation and in the presence of PTTG overexpression. The expression of Exo1 was 
not significantly altered in the presence of PBF. The expression of Exo1 was 0.31 ± 0.05 fold 
(p=0.132, n=4) in WT IR+, 0.97 ± 0.09 fold (p=0.966, n=4) in PBF IR-, 0.19 ± 0.05 fold (p=0.061, 
n=4) in PBF IR+, 0.22 ± 0.02 fold (p=0.073, n=4) in PTTG+/+ IR-, 0.13 ± 0.03 fold (p=0.047, n=4) in 
PTTG+/+ IR+, 0.24 ± 0.06 fold (p=0.128, n=4) in BI-Trans IR-, 0.08 ± 0.03 fold (p=0.049, n=4) in BI-
Trans IR+ PMTCs relative to WT IR- PMTCs as shown in Figure 7-4. Hence, it appears that mismatch 
repair and recombination mediated by Exo1 is reduced following ionising radiation and in the 
presence of PTTG overexpression.  
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Figure 7-4 Exo1 mRNA expression in PMTCs before and after irradiation on the microarray 
(A) and Taqman qRT-PCR (B). n=4 for PMTCs all genotypes. p-values obtained by 
comparing to WT IR- are denoted with *  (0.01 < p   ≤ 0.05),  ** (0.001 < p ≤ 0.01) and ***  
(0.0001 < p ≤ 0.001). 
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7.3.5 The mRNA expression of Mgmt was increased by radiation 
Naturally occurring DNA damage in the form of methylated guanine bases is repaired by Mgmt. This 
methylation is directly reversed by Mgmt in a suicide reaction (Sharma et al., 2009).  
In the Taqman validation experiment, Mgmt had increased expression, compared to WT IR-, in WT 
(2.77 ± 0.07 fold, p=0.001, n=4), PBF (1.45 ± 0.15, p=0.032, n=4), PTTG (1.43 ± 0.57, p=0.373, n=4) 
and BI-Trans (1.89 ± 0.18, p=0.022, n=4) PMTCs following irradiation. The expression of Mgmt was 
reduced by the PBF (PBF IR-, 0.76 ± 0.06 fold, p=0.171, n=4) and PTTG (PTTG+/+ IR- 0.69 ± 0.38 
fold, p=0.430, n=4) genotype. Interestingly, the expression of Mgmt in BI-Trans IR- (1.02 ± 0.12 fold, 
p=0.906, n=4) was similar to WT IR- (Figure 7-5). The upregulation of Mgmt mRNA following 
treatment with ionising radiation was attenuated in the presence of PBF and PTTG overexpression in 
the thyroid, representing a less effective response following radiation induced damage.  
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Figure 7-5 Mgmt mRNA expression in PMTCs before and after irradiation on the microarray 
(A) and Taqman qRT-PCR (B). n=4 for PMTCs all genotypes. p-values obtained by 
comparing to WT IR- are denoted with *  (0.01 < p   ≤ 0.05) and  ** (0.001 < p ≤ 0.01). 
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7.3.6 The mRNA expression of Rad51 was reduced by PTTG and radiation 
The Rad51 family of proteins participates in homologous recombination to maintain chromosomal 
stability and DNA repair following damage.  
Ionising radiation inhibited the expression of Rad51 in the Taqman qRT-PCR to a significant degree 
in PBF IR+ (0.24  ± 0.03 fold, p=0.258, n=4), PTTG+/+ IR+ (0.22 ± 0.06 fold, p=0.173, n=4) and BI-
Trans IR+ (0.14 ± 0.06 fold, p=0.016, n=4) PMTCs shown in Figure 7-6. The expression of Rad51 in 
WT IR- PMTCs (0.55 ± 0.02 fold, p=0.275, n=3) was reduced but not less than 0.50 fold and hence, 
not described as significant. PTTG overexpression independently repressed Rad51. The expression of 
Rad51 in PTTG+/+ IR- and BI-Trans IR- PMTCs was 0.32 ± 0.02 fold (p<0.000, n=4) and 0.32 ± 0.11 
fold (p=0.141, n=4) respectively. PBF overexpression did not repress Rad51. The expression of Rad51 
was 0.78 ± 0.07 fold (p=0.120, n=4) in PBF IR- PMTCs. Overall, the expression pattern of the various 
genotypes was similar in both the Taqman and the Mouse DNA Damage Signalling RT2 ProfilerTM 
PCR Arrays (SABiosciences). More importantly, the marked repression of Rad51 by PBF and PTTG 
following exposure to ionising radiation could result in increased genetic instability.  
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Figure 7-6 Rad51 mRNA expression in PMTCs before and after irradiation on the microarray 
(A) and Taqman qRT-PCR (B). n=4 for PMTCs all genotypes. p-values obtained by 
comparing to WT IR- are denoted with *  (0.01 < p   ≤ 0.05) and ***  (0.0001 < p ≤ 0.001). 
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7.3.7 The mRNA expression of Tdg remained unchanged 
Tdg is a downstream gene involved with DNA repair and has a major role in DNA demethylation 
(GeneCards®; www.genecards.org). The Mouse DNA Damage Signalling RT2 ProfilerTM PCR Arrays 
(SABiosciences) showed an increased expression of Tdg particularly with the PTTG genotype. The 
expression of Tdg was unchanged in all PMTC genotypes with or without irradiation on Taqman qRT-
PCR. The relative expression of Tdg to WT IR- PMTCs in the Taqman validation was 1.02 ± 0.10 fold 
(p=0.976, n=4) in WT IR-, 1.34 ± 0.09 fold (p=0.645, n=4) in PBF IR-, 1.36 ± 0.17 fold (p=0.619, 
n=4) in PBF IR+, 1.55 ± 0.67 fold (p=0.596, n=4) in PTTG+/+ IR-, 1.52 ± 0.57 fold (p=0.611, n=4) in 
PTTG+/+ IR+, 1.45 ± 0.25 fold (p=0.549, n=4) in BI-Trans IR- and 1.21 ± 0.16 fold (p=0.779, n=4) in 
BI-Trans IR+ PMTCs (Figure 7-7). Thus, the Taqman did not validate a role for Tdg in the context of 
genetic instability with PBF and PTTG overexpression. 
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Figure 7-7 Tdg mRNA expression in PMTCs before and after irradiation on the microarray 
(A) and Taqman qRT-PCR (B). n=4 for PMTCs all genotypes. p-values obtained by 
comparing to WT IR- are not denoted because all values were statistically insignificant ie. 
p>0.05. 
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7.3.8 The mRNA expression of Trp53 was unchanged by PBF, PTTG or 
radiation 
Both PBF and PTTG interact with Trp53 (Bernal et al., 2002, Read et al., 2014a, Read et al., 2014b). 
Trp53 has multiple roles follow in DNA repair following DNA damage (Efeyan and Serrano, 2007). 
The mRNA expression of Trp53 was relatively unchanged in the various genotypes with and without 
irradiation. The expression of Trp53 on Taqman qRT-PCR was 1.00 ± 0.13 fold (p=0.992, n=4) in WT 
IR+, 1.74 ± 0.21 fold (p=0.100, n=4) in PBF IR-, 1.62 ± 0.10 fold (p=0.112, n=4) in PBF IR+, 1.26 ± 
0.32 fold (p=0.461, n=4) in PTTG+/+ IR-, 1.19 ± 0.36 fold (p=0.574, n=4) in PTTG+/+ IR+, 1.08 ± 
0.55 fold (p=0.769, n=4) in BI-Trans IR-, and 0.96 ± 0.54 fold (p=0.901, n=4) in BI-Trans IR+ 
PMTCs shown in Figure 7-8. The results suggest that the interaction between Trp53 and our genes of 
interest (PBF and PTTG) overexpressed in the thyroid may occur at a protein rather than mRNA level.  
 
 
 
 
 
 
 
                       Evaluation of shortlisted genes within the DNA Damage/ DNA Repair pathway  
206 
 
 
 
Figure 7-8 Trp53 mRNA expression in PMTCs before and after irradiation on the microarray 
(A) and Taqman qRT-PCR (B). n=4 for PMTCs all genotypes. p-values obtained by 
comparing to WT IR- are not denoted because all values were statistically insignificant ie. 
p>0.05. 
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7.3.9 Rad 51 expression was not significantly altered on Western blot. 
Following the Taqman validation assays, we selected genes to be examined at a protein level. These 
experiments involved small quantities of protein obtained from PMTC. Rad51 mRNA levels were 
reduced following radiation and was significantly repressed by the presence of PTTG compared to WT 
IR- and may represent a potential candidate for inducing genetic instability. We studied the protein 
levels of Rad51 to determine whether this trend was observed further downstream, at a protein level. 
Unfortunately, Western blot of Rad51 on the various genotypes did not demonstrate a consistent 
pattern of expression (n=4), Figure 7-9.  
 
 
 
 
 
Figure 7-9  The expression of Rad51 on Western blot by genotype, with and without 
irradiation in 4 separate experiments. 
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7.3.10 Trp53 appeared to be stabilised following radiation 
The mRNA expression of Trp53 was not significantly elevated  following radiation damage in 
PMTCs. However, there is an established interaction between PBF (Read et al., 2014a) and and PTTG 
((Hamid and Kakar, 2004) with Trp53. Since mRNA expression may not tell the entire story, we next 
quantified relative Trp53 protein expression on Western blot. 
Trp53 protein levels were increased in the presence of PTTG and both PTTG and PBF. PBF on its 
own did not exert a significant effect on Trp53 levels. The relative fold expression of Trp53 in PMTCs 
to WT IR- was 1.50 ± 0.50 fold in PBF IR- (p=0.422, n=3), 2.63 ± 0.35 fold in PTTG+/+ IR- 
(p=0.021, n=3) and 2.91 ± 0.51 fold in BI-Trans IR- (p=0.029, n=3).  Radiation had the effect of 
increasing further the protein levels of Trp53 but this was not significant in PBF IR+ PMTCs. The 
densitometry study of Trp53 Western blot confirmed the increased expression of Trp53 at a protein 
level at 3.39 ± 0.64 fold in WT IR+ (p=0.026, n=3), 1.95 ± 0.43 fold in PBF IR+ (p=0.134, n=3), 2.53 
± 0.98 fold in PTTG+/+ IR+ (p=0.206, n=3) and 5.80 ± 0.18 fold in BI-Trans (p<0.000, n=3), shown 
in Figure 7-10.   
Added to the γ-H2AX results, Trp53 stabilisation shows that a sufficient ionising radiation dose was 
used in these studies. Interestingly, PBF and PTTG both attenuated Trp53 stabilisation in response to 
ionising radiation. However, overexpression of both proto-oncogenes was associated with increased 
basal Trp53 levels, and a restoration of Trp53 stabilisation in response to ionising radiation.  
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Figure 7-10 Western blot and densitometry study of Trp53 expression by genotype, before and 
after irradiation (n=3). p-values obtained by comparing to WT IR- are denoted with *  (0.01 
< p   ≤ 0.05) and ***  (0.0001 < p ≤ 0.001). 
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7.4 DISCUSSION 
7.4.1 Validation of cDNA array gene changes 
A wide array of gene changes was observed on the Mouse DNA Damage Signalling RT2 ProfilerTM 
PCR Arrays. We carefully selected genes which were altered in the WT IR+ PMTCs because these 
genes represented endogenous baseline behaviour of PMTCs at 24 hours after 15 Gy radiation 
exposure. The genes Brca1, Chek1, Exo1 and Mgmt were hence selected. Trp53 is a gene that has 
known interaction with our genes of interest, PBF and PTTG, and despite not having a gross change 
on the microarray, we felt it was prudent that it remained on our shortlist. Tdg was selected because it 
was the only gene that was affected by PTTG and not by PBF on the array. The inhibition of Rad51 
appeared on the microarray to be affected by PTTG and to a lesser extent PBF. However, in response 
to irradiation, the expression of Rad51 in PBF PMTCs was significantly repressed, to levels observed 
in PTTG+/+ IR+ PMTCs. 
 
7.4.2 Taqman qRT-PCR validated the gene expression pattern on the 
microarray  
Taqman qRT-PCR is a technique that is accurate and is widely recognised for studying the expression 
of mRNA. The experiments above showed an almost identical expression pattern of the gene of 
interest on both Taqman qRT-PCR and  Mouse DNA Damage Signalling RT2 ProfilerTM PCR Arrays.  
The lack of statistical significance was most likely related to the low n numbers. However, the pattern 
of gene expression on the microarray appeared to be a good representation of gene expression and 
could be used for further analysis. 
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7.4.3 DNA damage was present in PMTCs following irradiation 
The gene H2AX (H2AFX) encodes for histones which are basic nuclear proteins that are responsible 
for the nucleosome structure of the chromosomal fibre in eukaryotes. In response to double strand 
DNA breaks, ATM and PRKDC phosphorylate H2AX at serine-139, forming the protein γ-H2AX. 
The quantity of γ-H2AX is proportional to the amount of double strand breaks present (Kuo and Yang, 
2008). 
Western blotting confirmed the presence of γ-H2AX in WT IR+, PTTG+/+ IR+ and BI-Trans IR+ 
PMTCs following irradiation. Interestingly, PBF IR+ PMTCs did not show an increase in γ-H2AX at 
24 hours as demonstrated in the other PMTCs. This raises the possibility that the phosphorylation of 
H2AX following DNA damage in PMTCs is ameliorated by the overexpression of PBF in PMTCs, or 
that PBF exerts a protective effect on the genome. Further mechanistic studies would be required to 
establish the likely situation. 
 
7.4.4 The relationship between γ-H2AX and Brca1 
Brca1 and γ-H2AX form a physical complex on chromatin following DNA damage. Brca1 is normally 
present in small quantities on chromatin (Krum et al., 2010). Following DNA damage, Brca1 and γ-
H2AX interact with each other, catalysed by the phophorylation by ATM or ATR (Krum et al., 2010). 
It was proposed in the same study that Brca1 serves to decrease the level of  γ-H2AX as a mechanism 
of signalling an end to early DNA damage events (Krum et al., 2010). Our observation on the 
microarray that Brca1 is suppressed suggests that the PMTCs were in a later stage of DNA 
damage/repair. 
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7.4.5 Rad51 
Rad51 mRNA was suppressed to less than 0.5 fold in response to PBF and PTTG overexpression and 
radiation. The suppression of Rad51 in PMTCs by radiation seems to suggest that the role of Rad51 
may be diminished at 24 hours. Futher work with Rad51 at various time points would be needed to 
clarify the situation. 
Brca1 and Rad51 are recruited to areas of replication fork stalling and collapsed DNA replication 
forks (Cousineau et al., 2005). Our study found similar mRNA expression patterns in both Brca1 and 
Rad51. We used a commercial antibody for the Western blot of Rad51 which unfortunately did not 
show any pattern of change in multiple experiments. This may be a reflection of the sensitivity and 
specificity of the antibody. Alternatively, it may suggest that mRNA levels does not reflect protein 
concentration. 
 
7.4.6 The relationship between Chek1 and Rad51 
Chek1-mediated phosphorylation of the homologous recombination proteins Brca2 and Rad51 
modulates their interaction (Bahassi et al., 2008). The inhibition of Chek1 following DNA damage 
leads to an increase in both the total burden and the persistence of double strand breaks (Sorensen et 
al., 2005). Interestingly, the inhibition of Chek1 mRNA was observed in murine thyroid cells 
overexpressing PBF and PTTG. The expression at a protein level needs to be established by Western 
blot to determine if the mRNA expression pattern is translated to protein. Unfortunately, time was a 
limiting factor in this investigation and Chek1 was not studied further. 
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7.4.7 The relationship between Trp53 and PBF/PTTG 
The association between Trp53 with PBF (Read et al., 2014a, Read et al., 2014b) and PTTG (Hamid 
and Kakar, 2004) have been described previously. The expression of Trp53 on Taqman validation 
assays remained essentially unchanged for all genotypes before and after irradiation. Interestingly, the 
densitometry study of Trp53 demonstrated an increase in all genotypes following radiation and in 
PTTG PMTC without irradiation. This observation correlates with the stabilisation of Trp53 following 
radiation and in PTTG overexpression. 
 
7.4.8 Exo1, Tdg and Mgmt 
Tdg had an interesting pattern of expression on the Mouse DNA Damage Signalling RT2 ProfilerTM 
PCR Arrays because it only appeared to be affected by the PTTG genotype. The Taqman assay did not 
reveal a change of less than 0.5 or more than 2 fold in all PMTCs before and after irradiation. Hence, 
we did not pursue the investigation of this gene. 
Mgmt had increased mRNA expression in our Taqman validation experiment following  exposure to 
ionising radiation. The overexpression of PBF and PTTG only attenuated this response slightly. We 
felt this observation did not differentiate the effect of PBF or PTTG  on the gene and hence had a 
lower priority on further investigations. 
Exo1 mRNA expression appeared to be influenced by PTTG and radiation. The effect was similar to 
Rad51, Chek1 and Brca1 on Taqman validation studies. 
 
7.5 CONCLUSION 
Given the time constraints on the above investigation, we managed to shortlist the 7 genes of Brca1, 
Chek1, Exo1, Mgmt, Tdg, Trp53 and Rad51 for further investigation. Western blot was performed on 
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the Rad51 and Trp53 because it was felt at the time that these genes could likely explain the 
differences between the genomic stability expressed in various genotypes with and without irradiation. 
However, the microarray has identified numerous genes of potential interest and numerous lines of 
investigation could be pursued. Overall, this study has opened up new areas which could define the 
mechanistic role of PTTG and PBF in genetic instability. 
    
8 Final Conclusions and Future Studies 
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The work in this thesis investigated some of the roles of PTTG and its binding factor, PBF in 
maintaining genomic stability in thyroid cells. Our hypothesis was that PTTG and PBF both affected 
genomic stability in the thyroid. In-vivo investigations were facilitated by the generation of a 
transgenic murine model of PBF and PTTG overexpression in the thyroid gland. The tool used for 
measuring genetic instability (GI), fluoresecent inter-simple sequence repeat-PCR (FISSR-PCR), was 
modified for work with murine thyroids. Further investigation to establish the molecular mechanism 
by which PBF and PTTG affected genomic stability was studied using microarrays.   
 
 
8.1 The interaction between PBF and PTTG overexpression in transgenic 
murine thyroid gland 
PTTG is known to bind to PBF for its transport to the nucleus and hence, its transcription function 
(Chien and Pei, 2000). Murine models of PTTG overexpression in the thyroid gland do not develop 
neoplasms but have small thyroids instead (Lewy et al., 2013). Transgenic murine models of PBF 
overexpression develop goitres and hyperplastic nodules (Read et al., 2011). Our transgenic murine 
model of PBF and PTTG overexpression in the thyroid gland (BI-Trans) all developed goitres and 
have partial penetrance for the development of thyroid adenomas (50 % at 18 months with a female 
gender preponderance), which was not driven by thyroid stimulating hormone. The finding in our BI-
Trans model is similar to the observed thyroid phenotype of PBF transgenic mice. This suggests that 
although PTTG and PBF should hypothetically be synergistic with each other, in vivo work in the 
thyroid gland has demonstrated otherwise. The molecular mechanism behind this phenotype was 
investigated further by looking at the expression of genes intimately involved in DNA damage and 
DNA repair pathways. The establishment of this exciting murine model of thyroid cancer could 
provide a base for further experimentation involving known pathways such as MAPK and the 
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PI3K/Akt pathways involved in thyroid cancer. Additionally, little is known about goitrogenesis and 
this murine model could be used for investigations into goitre formation. See Figure 8-1. 
Finally, the BI-Trans murine model had reduced fertility and survival. Hence, future use of this model 
will have to adapt breeding strategies to maintain perpetuity of this line and to be aware of the survival 
of this model for long term observations. 
 
 
Figure 8-1 Thyroid changes in the various murine models and potential for future studies. 
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8.2 Use of FISSR-PCR for measuring genetic instability 
Genetic instability is a hallmark feature of human cancers but the relationship between genetic 
instability in tumourigenesis is not fully understood. A validated technique used by others in 
measuring genetic instability and established in our group is fluorescent inter-simple sequence repeat 
PCR (FISSR-PCR) (Kim et al., 2005). FISSR-PCR provides a unique fingerprint of the genome from 
which the index of genetic instability (GI)  can be derived. We found that murine thyroids 
overexpressing PBF or PTTG on its own did not exhibit significant GI. BI-trans thyroids which 
overexpressed both PBF and PTTG did have increased genetic instability, in keeping with the 
synergistic effect of both PBF and PTTG. 
Primary murine thyroid cultures (PMTCs) were used to study the effects of ionising radiation in a 
background of PBF and PTTG overexpression. The relationship between thyroid cancer and ionising 
radiation has been extensively published (Bounacer et al., 1997, Holm, 1985, Kaplan et al., 2009, 
Nikiforov et al., 1997, Ricarte-Filho et al., 2013). Ionising radiation induces DNA damage and the 
most severe variety of damage caused is double-strand breaks (DSB). This type of damage is difficult 
to repair with high fidelity. PTTG has been shown to inhibit Ku70 which is involved in non-
homologous end-joining in DSBs (Kim et al., 2007b). Not surprisingly, PTTG PMTCs showed most 
genetic instability following exposure to ionising radiation. Unexpected was the finding of reduced 
genetic instability in PBF and BI-Trans PMTCs which suggests PBF had a thyroid protective role 
following radiation-induced damage. If this observation holds true, this will be an intriguing area for 
further investigation. 
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8.3 The expression of genes associated with PBF, PTTG and ionising 
radiation in the thyroid gland 
The use of microarrays to screen for the regulation of genes involved in the DNA damage and DNA 
repair response pathways in the context of PBF, PTTG and ionising radiation was carried out to 
investigate the molecular mechanisms for the above findings. We found that PTTG appeared to 
upregulate the mRNA expression genes constituting the 9-1-1 complex, involved in the activation of 
the critical gene ATR. The ATR gene is involved in a variety of cellular functions including DNA 
replication, repair, recombination and cell cycle checkpoint. This investigation was limited to studying 
gene expression at an mRNA level and further studies at a protein level could prove to be insightful in 
establishing an alternative means by which PTTG affects genomic stability. See Figure 8-2. 
  
 
Figure 8-2  Diagram of key findings. 
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Introduction
The sodium iodide symporter (NIS) is an integral membrane
glycoprotein located in the basolateral plasma membrane of thyroid
follicular epithelial cells. NIS is responsible for mediating iodide
uptake and is consequently essential for thyroid hormone synthesis
in thyroid cells. The ability of the thyroid to accumulate radioiodine
has long been used to image and treat tumours of the thyroid and
their metastases, distinguishing NIS as both a diagnostic and a
therapeutic tool (Boelaert and Franklyn, 2003).
Thyroid carcinomas are the most common endocrine neoplasm
and their annual incidence is rising (Ries et al., 2008). Although
most differentiated thyroid carcinomas have a good prognosis, up
to 35% recur (Mazzaferri and Kloos, 2001). Crucially, many
thyroid cancers and their metastases demonstrate reduced iodide
uptake in comparison to normal thyroid tissue and, even after
thyrotrophin (thyroid-stimulating hormone, TSH) stimulation, 10-
20% of these tumours are unable to concentrate enough radioiodine
for effective therapy (Kogai et al., 2006). Tumours with reduced
NIS activity are therefore generally associated with a poor prognosis.
An understanding of the factors repressing NIS activity is thus
important for improvement of radioiodine delivery to tumours that
fail to uptake radioiodine effectively. Furthermore, such advances
might have profound implications for the treatment of breast cancer
and other nonthyroidal cancers currently being assessed for potential
NIS-mediated radioiodine therapy (Boelaert and Franklyn, 2003).
Pituitary tumor transforming gene (PTTG) produces a
multifunctional protein, that can transactivate basic fibroblast
growth factor (FGF-2), an action that is dependent on PTTG-binding
factor (PBF) (Chien and Pei, 2000). PBF, also known as PTTG1IP
or c21orf3 (Yaspo et al., 1998), promotes transformation in vitro
and is tumourigenic in vivo (Stratford et al., 2005). However, its
exact function is not known. Heaney and colleagues initially
implicated PTTG and FGF-2 in the downregulation of NIS activity
(Heaney et al., 2001). Subsequently, an association between PTTG
overexpression in differentiated thyroid cancers and decreased
radioiodine uptake during follow-up was reported (Saez et al., 2006).
PTTG and PBF are both overexpressed in thyroid and other
tumours, and we have shown that high expression of each gene in
thyroid cancer is independently associated with aggressive tumour
behaviour (Boelaert et al., 2003; Stratford et al., 2005). We recently
examined the influence of PTTG and PBF on human NIS activity
and found that both inhibited iodide uptake and NIS expression in
vitro. Furthermore, we used promoter studies to map the elements
responsible for this transcriptional repression (Boelaert et al.,
2007).
Although PTTG and PBF repressed iodide uptake in primary
thyroid cells by ~70%, inhibition of NIS promoter activity
approximated 40-50% (Boelaert et al., 2007). This led us to
speculate that other mechanisms might exist by which PTTG and
PBF regulate NIS in thyroid cells. Our data implied that PTTG
repression of NIS activity is at least partially dependent on FGF-
2, but that an alternative pathway exists for PBF, given that PBF
also independently inhibited NIS activity, despite being unable to
stimulate FGF-2 (our unpublished data). For active iodide uptake
Differentiated thyroid cancers and their metastases frequently
exhibit reduced iodide uptake, impacting on the efficacy of
radioiodine ablation therapy. PTTG binding factor (PBF) is a
proto-oncogene implicated in the pathogenesis of thyroid cancer.
We recently reported that PBF inhibits iodide uptake, and have
now elucidated a mechanism by which PBF directly modulates
sodium iodide symporter (NIS) activity in vitro. In subcellular
localisation studies, PBF overexpression resulted in the
redistribution of NIS from the plasma membrane into
intracellular vesicles, where it colocalised with the tetraspanin
CD63. Cell-surface biotinylation assays confirmed a reduction
in plasma membrane NIS expression following PBF transfection
compared with vector-only treatment. Coimmunoprecipitation
and GST-pull-down experiments demonstrated a direct
interaction between NIS and PBF, the functional consequence
of which was assessed using iodide-uptake studies in rat thyroid
FRTL-5 cells. PBF repressed iodide uptake, whereas three
deletion mutants, which did not localise within intracellular
vesicles, lost the ability to inhibit NIS activity. In summary, we
present an entirely novel mechanism by which the proto-
oncogene PBF binds NIS and alters its subcellular localisation,
thereby regulating its ability to uptake iodide. Given that PBF
is overexpressed in thyroid cancer, these findings have profound
implications for thyroid cancer ablation using radioiodine.
Supplementary material available online at
http://jcs.biologists.org/cgi/content/full/122/18/3393/DC1
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to occur, NIS must be expressed, targeted and retained at the
basolateral plasma membrane of polarised thyroid follicular
epithelial cells (Dohan et al., 2001). A number of studies have noted
that some thyroid cancers show increased intracellular expression
of NIS (Castro et al., 1999b; Dohan et al., 2001; Wapnir et al., 2003).
Clearly, altered post-translational regulation of NIS could contribute
to a reduction in iodide uptake in thyroid cancers by influencing
its subcellular localisation.
In the current investigation, we examined the subcellular
localisation of NIS in relation to that of the relatively uncharacterised
protein PBF. Our data suggest an entirely novel mechanism by which
PBF binds to NIS and alters its subcellular localisation, thereby
regulating its ability to uptake iodide.
Results
NIS colocalises with PBF
In fluorescent immunocytochemistry experiments, we determined
the localisation of transiently transfected HA-tagged NIS (NIS-HA)
and Myc-tagged NIS (NIS-MYC) in monkey kidney COS-7 cells.
Both NIS-HA (Fig. 1Ai) and NIS-MYC (Fig. 1Aii) were expressed
predominantly at the plasma membrane, but were also apparent in
the cytoplasm, where they appeared to reside within intracellular
vesicles. To confirm NIS plasma membrane expression, CD8
(cluster of differentiation 8) cDNA was cotransfected with NIS-
HA. This encodes a co-receptor involved in antigen recognition,
used as a marker for localisation to the plasma membrane (James
et al., 2008). A good degree of colocalisation between NIS-HA and
CD8 verified the presence of NIS at the cell membrane (Fig. 1B).
To determine whether transfected NIS was functional in COS-7
cells, we assessed iodide uptake. NIS-HA transfection resulted in
a significant induction of uptake compared with untransfected cells
(3425±501 c.p.m. vs 391±95 c.p.m.; P<0.001; n=5). This confirmed
the functionality of exogenous NIS in COS-7 cells, as has been
demonstrated previously in a number of publications (Castro et al.,
1999a; De la Vieja et al., 2004; De la Vieja et al., 2005; Smanik et
al., 1996; Smanik et al., 1997; Van Sande et al., 2003; Zhang et al.,
2005). Furthermore, the level of uptake was very similar to that
demonstrated by Zhang and colleagues (Zhang et al., 2005).
Journal of Cell Science 122 (18)
Fig. 1. NIS and PBF localisation in COS-7 and
FRTL-5 cells. (A) Following transfection into COS-7
cells and detection by immunofluorescence analysis,
NIS-HA (i) and NIS-MYC (ii) demonstrated a
similar pattern of expression. Both proteins were
located predominantly within the plasma membrane,
with partial staining within intracellular vesicles.
(B) Coexpression of NIS-HA (red) with the plasma
membrane marker CD8 (green) resulted in a high
degree of colocalisation as seen in the merged image
(yellow). (C) Representative fluorescence
immunocytochemistry experiments examining
staining of PBF (red) and NIS-HA (green) following
transient transfection in COS-7 (i) and FRTL-5 (ii)
cells. PBF is predominantly expressed within
cytoplasmic vesicles. Merged images demonstrate
strong colocalisation between PBF and NIS (yellow)
(arrows). (D) Enlarged merged confocal image of
PBF (red) and NIS-HA (green) colocalisation
(yellow) at the cell surface (arrowed) of a COS-7
cell. (E) Confocal microscopy of NIS and PBF
localisation in representative COS-7 and FRTL-5
cells. Colocalisation of PBF and NIS was confirmed
by yellow staining in the merged images. Nuclei are
visualised in blue with Hoechst 33342 stain in the
merged images. Scale bars: 20 μM. 
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
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We then assessed the localisation of transiently transfected PBF
and NIS-HA in COS-7 cells and rat-thyroid-derived FRTL-5 cells.
In COS-7 cells, PBF was expressed at relatively low levels in the
nucleus, whereas the majority of PBF protein was concentrated
within intracellular vesicles in the cytoplasm (Fig. 1Ci, arrows).
Merged images demonstrated strong colocalisation between PBF
and NIS, particularly within vesicles. Colocalisation of NIS and
PBF was also apparent in the thyroid cell model of FRTL-5 cells
(Fig. 1Cii), which demonstrate endogenous NIS expression and
iodide uptake (Kogai et al., 1997; Riedel et al., 2001; Schmutzler
et al., 1997; Spitzweg et al., 1999). Sites of coincident PBF and
NIS staining at the cell membrane were also observed in COS-7
cells (Fig. 1D). Confocal microscopy further delineated the marked
overlap between NIS and PBF localisation within COS-7 and FRTL-
5 cells (Fig. 1E).
PBF binds NIS in vitro
Having observed strong evidence of PBF and NIS colocalisation
in both thyroid and non-thyroidal cell lines, we next investigated
whether the two proteins were able to bind in vitro. We performed
pull-down assays with in vitro translated L-α-[35S]methionine-
labelled NIS and glutathione-S-transferase (GST)-tagged PBF.
Binding reactions consistently demonstrated the interaction of
labelled NIS with GST-PBF but not with the GST control (Fig.
2A).
Subsequently, coimmunoprecipitation assays were used to assess
this interaction in a cellular environment. Following the transient
transfection of HA-tagged PBF (PBF-HA) and NIS-MYC into COS-
7 cells, NIS was precipitated with an anti-Myc antibody.
Coprecipitation of PBF-HA with NIS-MYC was observed by
probing with an anti-HA antibody following western blotting (Fig.
2B). By contrast, PBF was not detected in controls in which NIS-
MYC and vector-only (VO) or PBF-HA and VO were transfected
(Fig. 2B). The reciprocal coimmunoprecipitation was performed
using the anti-HA antibody for precipitation of PBF-HA and
immunoblotting for NIS-MYC, which similarly resulted in
successful coimmunoprecipitation (Fig. 2C, arrows). These results
confirm that NIS and PBF not only colocalise, but also interact
within these cells.
PBF alters the subcellular localisation of NIS
In COS-7 cells transfected with NIS-HA (Fig. 3Ai), NIS-HA was
localised predominantly within the plasma membrane, with partial
staining within intracellular vesicles. Endogenous PBF was mainly
localised within cytoplasmic vesicles, with some apparent nuclear
staining. However, when PBF was cotransfected with NIS-HA, there
was an increase of NIS staining within intracellular vesicles and a
concomitant reduction in membrane staining (Fig. 3Aii). Given
that PBF and NIS bound each other in pull-down and
coimmunoprecipitation assays, we therefore investigated by
quantitative means whether PBF overexpression was associated with
diminished NIS localisation at the cell membrane, where NIS is
functional. We transfected COS-7 cells with NIS-HA, and either
VO control or human PBF. Cell surface biotinylation assays
confirmed a reduction in plasma membrane expression of NIS
following PBF transfection compared with VO treatment (32±9%
reduction; P=0.018; n=3) (Fig. 3Bi). By contrast, total NIS-HA
expression was not significantly altered by PBF overexpression
compared with VO (2±3% reduction; P=0.529; n=3) (Fig. 3Bii).
Hence, when PBF expression is increased in COS-7 cells, plasma
membrane expression of NIS decreases.
Colocalisation of PBF, NIS and CD63
Detailed examination of our patterns of intracellular staining for
PBF and NIS (as shown in Figs 1 and 3) raised the possibility that
these proteins were localised to late endosomes. To assess this
hypothesis, we examined expression of the late endosome marker
CD63, a member of the tetraspanin family commonly associated
with clathrin-dependent trafficking. We transfected COS-7 cells with
NIS-HA, and examined its relationship to endogenous CD63.
Merged images revealed a high degree of colocalisation (Fig. 4Ai).
We performed analogous studies with PBF and CD63, which
revealed similar patterns of colocalisation within late endosomes
(Fig. 4Aii). Finally, we assessed staining of caveolin-1, the main
constituent of caveolae which acts as a regulator of caveolae-
Fig. 2. PBF binds NIS in vitro. (A) Pull-down assay showing in vitro
translated L-α- [35S]methionine-labelled NIS binding GST-tagged PBF versus
a GST-only control. (B) Coimmunoprecipitation assays in COS-7 cells
transfected with NIS-MYC and VO, PBF-HA and VO, or NIS-MYC and PBF-
HA. A band corresponding to PBF (arrowed) was observed at approximately
30 kDa when NIS-MYC and PBF-HA were cotransfected but was not present
when either NIS-MYC or PBF-HA were transfected with VO. Analysis of
total protein cell lysate shown below demonstrates the presence of NIS-MYC
or PBF-HA in each sample along with a β-actin loading control.
(C) Reciprocal assay following transfection of NIS-MYC and VO or NIS-
MYC and PBF-HA. NIS-MYC was coprecipitated along with PBF-HA and
detected as a band at approximately 100 kDa (arrow).
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dependent lipid trafficking and endocytosis. When we examined
caveolin-1 localisation in COS-7 cells, we found no overlap with
either PBF or NIS expression (Fig. 4Aiii). Confocal microscopy
confirmed the strong colocalisation apparent between NIS, PBF and
CD63 (Fig. 4Bi), and the lack of association between NIS, PBF
and caveolin-1 (Fig. 4Bii). Thus, NIS and PBF colocalise with CD63
but not with caveolin-1, suggesting that clathrin-dependent rather
than caveolin-dependent endocytosis is responsible for the
internalisation of these proteins.
Localisation of PBF deletion mutants
To investigate the relationship between PBF and NIS further, we
constructed three deletion mutants of PBF. The PBF protein is
extremely poorly characterised, and has no significant homology
to other human proteins. A putative signal peptide lies at the N-
terminus, followed by a putative PSI domain (a cysteine-rich
region common to plexins, semaphorins and integrins) between
amino acids 39 and 92, and a potential transmembrane region
between residues 95 and 122 (Fig. 5A). At the C-terminus,
predicted nuclear localisation and tyrosine-based sorting signals
lie between amino acids 149 and 174. Given the lack of functional
data on PBF, we therefore created three HA-tagged deletion
mutants. Mutant 1 (M1) lacked the C-terminal 30 amino acids
(149-180), which have previously been shown to mediate its
binding to PTTG (Chien and Pei, 2000). Mutant 2 (M2) had a
deletion of residues 29-93, which encompassed part of the signal
peptide and the putative PSI domain, and Mutant 3 (M3) lacked
amino acids 94-149, containing the potential transmembrane
domain (Fig. 5A).
The localisation of each of the mutants in comparison to HA-
tagged wild-type (WT) PBF was initially assessed following
transient transfection into COS-7 cells. Confocal images once
more identified WT PBF predominantly within intracellular
vesicles (Fig. 5Bi). By contrast, M1 was located almost exclusively
in the plasma membrane. M2 and M3 appeared to be expressed
predominantly in the endoplasmic reticulum (Fig. 5Bi). Strong
colocalisation of M1 was observed with the CD8 plasma
membrane marker whereas no significant colocalisation was seen
with WT PBF, M2 or M3 (Fig. 5Bii). Similarly, M2 and M3
demonstrated a high degree of colocalisation with endogenous
protein disulphide isomerase (PDI), a marker for the endoplasmic
reticulum, whereas WT PBF and M1 showed minimal costaining
Journal of Cell Science 122 (18)
Fig. 3. PBF alters the subcellular localisation of NIS.
(A) (i) Immunofluorescent detection of NIS-HA and
endogenous PBF in cells transfected with NIS-HA
and VO control. (ii) PBF overexpression is associated
with an increase in NIS staining within intracellular
vesicles. Scale bars: 20 μM. (B) Cell-surface
biotinylation assay in COS-7 cells transfected with a
VO control or with human PBF. (i) Representative
immunoblot analysis of surface-biotinylated
polypeptides precipitated with streptavidin-agarose
beads and probed with anti-HA antibody, which
revealed HA-tagged human NIS detection at around
100 kDa. Flotillin-1 was used as a marker of
membrane protein expression to determine loading
between samples. (ii) Total NIS-HA protein
expression. Graphs indicate mean differences in cell-
surface and total expression of NIS (n=3 separate
scanning densitometry experiments were performed).
*P<0.05; ns, not significant.
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(Fig. 5Biii). Notably, unlike WT PBF, none of the mutants
colocalised with CD63 (Fig. 5Biv), strongly suggesting they were
not expressed within late endosomes.
PBF, NIS and iodide uptake
We next examined the colocalisation of WT and mutant PBF with
NIS. HA-tagged WT PBF and the three mutants were each
transiently transfected into COS-7 cells along with NIS-MYC.
Localisation of WT PBF and the mutants (Fig. 6Ai) was as
described previously (Fig. 5Ai). Whilst NIS showed intense staining
within intracellular vesicles in the presence of WT PBF, it remained
predominantly membranous when coexpressed with each of the
mutants (Fig. 6Aii). Merged images demonstrated again WT PBF
colocalisation with NIS in intracellular vesicles (Fig. 6Aiii). M1
showed strong colocalisation with NIS at the cell membrane, but
not intracellularly, whereas M2 and M3 failed to significantly
colocalise with NIS (Fig. 6Aiii).
Finally, we investigated the effect of altered PBF localisation upon
endogenous NIS activity. We therefore used FRTL-5 thyroid cells,
which show significant endogenous iodide uptake (Kogai et al., 1997;
Riedel et al., 2001; Schmutzler et al., 1997; Spitzweg et al., 1999)
and show colocalisation of NIS and PBF (Fig. 1). We first confirmed
that FRTL-5 cells express endogenous PBF (supplementary material
Fig. S1). Subsequently, we manipulated PBF expression through
transient transfection of WT and mutant PBF constructs.
Immunofluorescence analyses established that the localisation of WT
and mutant PBF was consistent with that observed in COS-7 cells
(Fig. 6B): WT PBF was apparent in intracellular vesicles, M1 localised
to the membrane, and M2 and M3 localised to the ER. Iodide-uptake
experiments were then performed. Data from FRTL-5 cells were
normalised to iodide uptake in VO controls, which gave a mean count
of 1029 c.p.m. after incubation with 0.05 μCi 125I for 1 hour. WT
PBF repressed iodide uptake into FRTL-5 cells by 39.4±5% (P<0.001;
n=10) compared with VO control (Fig. 6C). By contrast, all three
deletion mutants of PBF, which do not localise within intracellular
vesicles in COS-7 or FRTL-5 cells, lost the ability to inhibit NIS
activity (M1, 104.3±13%; M2, 89.2±11%; M3, 109.6±14%; P=NS
compared with VO control) (Fig. 6C).
Fig. 4. Colocalisation studies of NIS, CD63, PBF and caveolin.
(A) Cellular expression of transiently transfected NIS-HA (i) and
PBF-HA (ii) (both red) with endogenous CD63 (green), a
tetraspanin and a marker of late endosomes, in COS-7 cells.
Endogenous CD63 staining in late endosomes is coincident with
that of both NIS and PBF, as indicated by yellow staining in merged
images. (iii) Relationship between PBF-HA (green), NIS-HA
(green) and caveolin-1 (red), a marker of caveolae-dependent lipid
trafficking and endocytosis. Neither PBF nor NIS colocalises with
caveolin in COS-7 cells. (B) (i) Confocal microscopy was used to
confirm the colocalisation of NIS and PBF with CD63, shown in
yellow. (ii) Confocal images of NIS, PBF and caveolin in COS-7
cells. Nuclei are visualised in blue with Hoechst 33342 stain in the
merged images. Scale bars: 20 μM.
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Taken together, these data support the hypothesis that PBF and
NIS colocalise within late endosomes, and that upregulation of PBF
redistributes NIS away from the plasma membrane into these
organelles, a mechanism that significantly represses cellular iodide
uptake.
Discussion
The regulation of membrane transport proteins is an intricate
process, and NIS regulation is characteristically complex. As an
integral membrane glycoprotein which mediates active iodide
transport into thyroid cells, NIS acts as the crucial first step in thyroid
hormone biosynthesis (Boelaert and Franklyn, 2003; Dohan et al.,
2003). The ability of the thyroid to accumulate iodide has provided
an effective means for therapeutic doses of radioiodine to target
and destroy iodide-transporting differentiated thyroid cancers and
their metastases. However, most thyroid tumours exhibit reduced
iodide uptake and a number of mRNA (Lazar et al., 1999; Park et
al., 2000; Ringel et al., 2001; Ryu et al., 1999; Smanik et al., 1997;
Ward et al., 2003) and protein (Caillou et al., 1998; Faggiano et al.,
2007; Gerard et al., 2003; Jhiang et al., 1998; Trouttet-Masson et
al., 2004) studies have reported decreased NIS expression in
thyroid cancers, suggesting that the reduction in iodide uptake is
due to a transcriptional effect.
By contrast, several other studies have shown either normal, or
even increased levels of NIS mRNA (Arturi et al., 1998; Luciani
et al., 2003; Saito et al., 1998; Tanaka et al., 2000) or protein (Dohan
et al., 2001; Saito et al., 1998; Wapnir et al., 2003) expression in
thyroid cancer. However, immunohistochemical analyses have
detected NIS protein that was not located predominantly in the
basolateral membrane, as found in normal thyroid tissue, but was
principally in the cytoplasm (Castro et al., 1999b; Dohan et al.,
2001; Wapnir et al., 2003). This suggests that the reduction in iodide
uptake in thyroid cancer is at least partially attributable to altered
NIS trafficking and subcellular localisation, which might therefore
be more relevant than expression levels per se. Understanding the
factors regulating NIS localisation and activity in thyroid tumours
is thus important in improving radioiodine delivery to those tumours
that fail to uptake radioiodine effectively.
At present, little is known about the regulation of NIS
trafficking. In addition to stimulating cAMP-mediated NIS
expression, TSH is also required for post-translational regulation
of NIS (Riedel et al., 2001). Studies using FRTL-5 cells have
Journal of Cell Science 122 (18)
Fig. 5. Localisation of PBF deletion
mutants. (A) Putative functional domains of
WT PBF, as well as three deletion mutants
M1, M2 and M3. NLS, nuclear localisation
signal. Site-directed mutagenesis was used
to delete the C-terminal 30 amino acids
(149-180) for M1. M2 had a deletion of
amino acids 29-93 and M3 lacked amino
acids 94-149, containing the potential
transmembrane domain. (B) (i) Confocal
images demonstrating the localisation of
each of the mutant PBF proteins compared
with wild-type PBF in COS-7 cells. M1 is
predominantly in the cell membrane
whereas M2 and M3 appear to be in the
endoplasmic reticulum. (ii) Coexpression of
CD8 confirmed the presence of M1 in the
plasma membrane. (iii) Endogenous PDI
staining verified endoplasmic reticulum
expression of M2 and M3. (iv) Intracellular
expression of WT and mutated PBF with
CD63 in COS-7 cells. Unlike the WT, none
of the mutants show significant
colocalisation with CD63. Scale bars:
20 μM.
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alluded to a mechanism by which NIS is located in the plasma
membrane of thyroid cells in the presence of TSH, but is
redistributed into intracellular vesicles upon TSH withdrawal. TSH
is thus required for either the targeting of NIS to the plasma
membrane or its retention there (Kaminsky et al., 1994; Kogai et
al., 1997; Riedel et al., 2001). NIS is a phosphoprotein that has
demonstrated different patterns of phosphorylation in FRTL-5 cells
maintained in the presence or absence of TSH (Riedel et al., 2001).
Phosphorylation of the C-terminus has been proposed to influence
plasma membrane targeting of NIS (Dohan et al., 2005). However,
although a number of phosphorylated residues have been
confirmed, none has been shown to affect NIS cell membrane
trafficking (Vadysirisack et al., 2007). A recent study assessing
NIS regulation in breast cancer demonstrated that
phosphatidylinositol-3 kinase (PI3K) activation interferes with
cell-surface trafficking and function of all-trans retinoic acid and
hydrocortisone (tRAH)-induced endogenous NIS, as well as
transiently expressed exogenous NIS, in the MCF-7 human
mammary carcinoma cell line (Knostman et al., 2007).
In the present study, we have assessed a potential role for PBF
in the post-translational regulation of NIS activity, given its ability
to repress iodide uptake. Although NIS was expressed at the cell
surface, it was also present in intracellular vesicles reminiscent of
those previously described (Kaminsky et al., 1994; Riedel et al.,
2001). Similarly to NIS, PBF is also a predicted integral membrane
glycoprotein (Yaspo et al., 1998). PBF was predominantly located
in similar vesicular structures to NIS, and was also apparent at the
plasma membrane. Our description of PBF localisation differs from
a previous report (Chien and Pei, 2000), which did not describe
vesicular staining. In common with this earlier study, we did observe
a degree of nuclear localisation. However, our current and previous
(Stratford et al., 2005) investigations into PBF suggest that the
Fig. 6. The effect of PBF on NIS function.
(A) Examination of the subcellular
localisation of WT and mutated HA-
tagged PBF in COS-7 cells (i), Myc-
tagged NIS (ii) and colocalisation (iii). WT
PBF predominantly colocalises with NIS
within late endosomes. M1 colocalises
with NIS at the cell membrane, whereas
M2 and M3 fail to show any significant
colocalisation with NIS. (B) Confocal
images demonstrating the localisation of
WT and mutant PBF in FRTL-5 cells.
Scale bars: 20 μM. (C) Iodide-uptake
studies in rat thyroid FRTL-5 cells
transfected with WT PBF and mutants M1,
M2 and M3. Graph shows c.p.m. values
normalised to that of the VO control.
***P<0.001. 
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protein is highly expressed in the cytoplasm. Validation of our
antibody assessment of PBF localisation within intracellular vesicles
is provided in supplementary material Fig. S2.
Given that PBF and NIS demonstrated strong colocalisation
within such vesicles, we investigated whether PBF could bind NIS
in vitro using pull-down and coimmunoprecipitation assays. GST-
tagged PBF consistently pulled down [35S]-labelled NIS, and PBF-
HA coprecipitated with NIS-MYC in COS-7 cells, indicating that
the proteins can interact. Critically, increased expression of PBF in
COS-7 cells was accompanied by reduced plasma membrane
expression of NIS, as determined through cell-surface biotinylation
assays. This was in agreement with our immunofluorescent
microscopy studies, which suggested an increased vesicular
localisation of NIS in response to augmented PBF expression. Thus,
NIS and PBF colocalise, bind each other, and PBF is able to alter
the subcellular localisation of NIS. The physiological relevance of
this phenomenon is a direct one. PBF is overexpressed in
differentiated thyroid cancers (Stratford et al., 2005), which as a
consequence would be expected to have a lower ability to uptake
iodide, and hence a poorer response to radioiodine treatment. To
test this hypothesis, it would therefore be interesting in future studies
to assess PBF and NIS expression and localisation in a large series
of differentiated thyroid tumours and to relate this to clinical
outcome.
To investigate the vesicles in which PBF and NIS colocalised,
we assessed CD63 staining. CD63 is a tetraspanin involved in
protein trafficking and is located in a number of intracellular
structures, including late endosomes and lysosomes, in addition
to the cell membrane. At the C-terminus, CD63 has a Yxxmotif,
a tyrosine-based sorting signal, which has been shown to interact
with adaptor protein (AP) complexes, thereby linking trafficking
of CD63 to clathrin-dependent pathways (Berditchevski and
Odintsova, 2007). We determined that both PBF and NIS showed
a strong degree of colocalisation with CD63. Based on these
findings, the presence of a Yxx motif at the C-terminus of PBF,
and the fact that neither PBF nor NIS colocalises with caveolin-
1, a regulator of caveolae-dependent lipid trafficking and
endocytosis, we propose that PBF and NIS are indeed enriched
within late endosomes, and use a clathrin-pit-mediated mechanism
of internalisation.
NIS has a long half-life, estimated at 3-5 days (Riedel et al.,
2001), and a hence a mechanism of post-translational regulation of
activity would allow cells to respond to, and regulate their need
for, iodide uptake over a much shorter timeframe. Indeed, we
observed significant internalisation of NIS within 48 hours of PBF
transfection. Membrane vesicles, which have been reported to
contain NIS, were enriched for plasma membrane content,
suggesting an endocytosis-mediated pathway of NIS regulation
(Kaminsky et al., 1994). Our data shed new light on this mechanism,
in that we have identified a protein that appears to significantly
modulate this process.
A final strand of supporting evidence that supports our hypothesis
came from iodide uptake studies in rat thyroid FRTL-5 cells. The
protein structure of PBF is very poorly understood, and hence we
constructed three PBF mutants, lacking the C-terminal Yxxmotif
(M1), a putative signal peptide and the putative PSI domain (M2),
and the potential transmembrane region (M3). All three mutants
lost vesicular enrichment, and failed to colocalise significantly with
CD63 or with NIS. Iodide-uptake assays in FRTL-5 cells
complemented our previous finding in human primary thyroid cells
that PBF represses iodide uptake (Boelaert et al., 2007). The
magnitude of effect was ~40%, which contrasts with our
conservative estimate of transfection efficiency of 15-25%. This
suggests either that we might be underestimating transfection
efficiency by focusing only on strongly fluorescent GFP expression,
or that other mechanisms exist (e.g. paracrine regulation of
surrounding cell function). However, this is beyond the scope of
the present investigation. In contrast to WT PBF, all three mutants
failed to significantly influence iodide uptake compared with the
control. This suggests that PBF requires endosomal entry to
modulate NIS localisation and function. When the protein structure
of PBF is resolved, it will be important to perform more subtle
mutation analysis, investigating point mutations targeting specific
and characterised domains, allowing us to elucidate this mechanism
further.
One caveat to these studies is that because it is not known what
regulates PBF, we are unable to manipulate its endogenous
expression, and hence have used a largely exogenous system in
COS-7 cells. Furthermore, immunofluorescence for native NIS
expression is technically challenging in FRTL-5 cells. For this
reason, most studies of NIS in the literature have focused on COS-
7 cell manipulations. Indeed, in our hands, NIS was entirely
functional in COS-7 cells, yielding extremely similar iodide uptake
to that previously reported by Zhang and co-workers (Zhang et al.,
2005).
Overall, the clinical relevance of PBF repression of NIS activity
relates to its likely influence upon the efficacy of radioiodine therapy.
The ability of the thyroid to accumulate iodide provides the basis
for radioiodine ablation of iodide-transporting differentiated thyroid
cancers and their metastases. Taken together, we propose that
through downregulation of NIS via alteration of its subcellular
localisation, increased PBF could fundamentally influence the
prognosis of differentiated thyroid cancers, at least in part, through
affecting their sensitivity to ablative radioiodine therapy.
Materials and Methods
Plasmids and mutagenesis
The full-length human NIS cDNA was kindly provided by John Morris (Mayo
Graduate School of Medicine, Mayo Clinic, Rochester, MN) (Castro et al., 1999a).
This was inserted into the EcoRI and XhoI restriction sites of the pcDNA3.1+ vector
(Invitrogen, Carlsbad, CA) and simultaneously tagged on the 3 end with either the
HA epitope using the forward primer, 5-GCC GAA TTC CCA CCA TGG AGG
CCG TGG AGA CC-3 and reverse primer, 5-CGG CTC GAG TCA AGC GTA
GTC TGG GAC GTC GTA TGG GTA GAG GTT TGT CTC CTG CTG G-3 (NIS-
HA), or the Myc epitope using the same forward primer, and the reverse primer, 5-
CGG CTC GAG TCA GGA TCC CAG GTC CTC CTC GGA AAT CAG CTT CTG
CTC AAG GTT TGT CTC CTG CTG G-3 (NIS-MYC).
Plasmids containing the full-length PBF cDNA with (PBF-HA) and without (PBF)
a HA tag have previously been described (Stratford et al., 2005). Three deletion
mutants of PBF were created by mutating the PBF-HA plasmid using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene, Cambridge, UK) using the following
primers: M1_forward, 5-GAGAGGCGGATACGGCAGGAGGAATACCCATAC-
GACGTCCCAGACTAC-3; M1_reverse, 5-GTAGTCTGGGACGTCGTATG -
GGTATTCCTCCTGCCGTATCCGCCTCTC-3; M2_forward, 5-CTCCTGCT-
GCTCATCCCGAACTTTGAGGCGCTGATC-3; M2_reverse, 5-GATCAGCGC-
CTCAAAGTTCGGGATGAGCAGCAGGAG-3; M3_forward, 5-GCTGGG -
GAGTTTGTTGGGTGCGGAGAGCAGAGATGAAGAC-3; M3_reverse, 5-
GTCTTCATCTCTGCTCTCCGCACCCAACAAACTCCCCAGC-3.
Additionally, cDNA encoding CD8 was kindly provided by Barbara Reaves
(Department of Biology and Biochemistry, University of Bath, UK) (James et al.,
2008).
Cell lines and transient transfection
FRTL-5 cells are a nontransformed rat thyroid cell line, which were grown in modified
Coon’s F-12 medium as described (Ambesi-Impiombato et al., 1980) (Gibco, Paisley,
Scotland). The medium was supplemented with TSH (300 mU/l), insulin (100 μg/l),
penicillin (105 U/l), streptomycin (100 mg/l) and 5% fetal bovine serum (FBS).
The COS-7 African Green monkey kidney epithelial cell line was maintained in
DMEM medium (Gibco) supplemented with 10% FBS, penicillin (105 U/l) and
Journal of Cell Science 122 (18)
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streptomycin (100 mg/l). The H1299 non-small cell lung carcinoma cell line was
maintained in RPMI 1640 medium (Gibco) supplemented with 10% FBS, sodium
pyruvate (1 mM), glucose (3.5 g/l), HEPES (10 mM), penicillin (105 U/l) and
streptomycin (100 mg/l).
Cells were transfected using Fugene 6 reagent (Roche, Indianapolis, IN) following
the manufacturer’s instructions at a 3:1 reagent:DNA ratio. For iodide-uptake assays,
immunofluorescence staining, coimmunoprecipitation assays and cell-surface
biotinylation assays, cells were seeded in 24-well plates, six-well plates with sterile
coverslips, T25 flasks or T75 flasks, respectively, and transfected with 0.5 μg, 2 μg,
5 μg or 15 μg DNA after 24 hours.
The pMax-GFP plasmid (Amaxa, Cologne, Germany) was used to determine the
transfection efficiency of FRTL-5 cells. Routinely, transfection efficiency was
between 15 and 25% in FRTL-5 cells (see supplementary material Fig. S3).
Immunofluorescence staining
Medium was removed 48 hours after transfection, and cells were washed with
phosphate-buffered saline (PBS). Cells were fixed for 20 minutes at room temperature
in 0.1 M phosphate buffer (pH 7.4) containing 2% paraformaldehyde, 2% glucose
and 0.02% sodium azide. After rinsing twice in PBS, cells were permeabilised in
100% chilled methanol for 10 minutes and then blocked with 10% newborn calf
serum (NCS) in PBS for 30 minutes at room temperature.
Incubation with primary antibody was performed at room temperature for 1 hour
in 1% BSA. The following antibodies were used: rabbit polyclonal anti-HA (Y-11)
antibody (Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal anti-HA.11
antibody (Covance Research Products, Emeryville, CA), rabbit polyclonal anti-PBF
antibody (made by Eurogentec, Seraing, Belgium) for our laboratory using the full-
length PBF protein as an epitope), mouse monoclonal anti-human CD8 antibody
(UCHT4; Ancell Corporation, Bayport, MN), mouse monoclonal anti-protein
disulphide isomerase (PDI) antibody (Stressgen, San Diego, CA), mouse monoclonal
anti-CD63 antibody (kindly provided by Fedor Berditchevski, School of Cancer
Sciences, University of Birmingham, Birmingham, UK), mouse monoclonal anti-
Myc-Tag (9B11) antibody (Cell Signaling Technology, Danvers, MA), and rabbit
anti-caveolin (kindly provided by Melissa Westwood, University of Manchester, UK).
Cells were rinsed three times with PBS before a further 1 hour incubation with
the secondary antibodies, Alexa-Fluor 488-conjugated goat anti-mouse IgG and Alexa-
Fluor-594-conjugated goat anti-rabbit IgG (Invitrogen) at 1:250 in 1% BSA, with
1% NCS and Hoechst 33342 stain for nuclei (1:1000). Finally, cells were rinsed with
PBS three times and coverslips mounted onto slides using Dako Fluorescent
Mounting Solution (Dako, Glostrup, Denmark).
Conventional microscopy was performed using a 100 objective on a Zeiss
Axioplan fluorescent microscope (Zeiss, Germany). A Zeiss confocal LSM 510
microscope with a 63 objective was used to perform confocal microscopy.
In vitro transcription: translation and glutathione-S-transferase
(GST) pull-down assays
The TNT Coupled Reticulocyte Lysate System (Promega, Madison, WI) was used
to express protein from the NIS-HA plasmid following the manufacturer’s instructions.
The following reaction components were assembled: 50 μl TNT Rabbit Reticulocyte
Lysate, 4 μl TNT Reaction Buffer, 2 μl amino acid mixture (minus methionine; 1 mM),
4 μl L-α-[35S]methionine, 1 μl RNasin Ribonuclease Inhibitor (40 U/μl), 2 μg plasmid
DNA, 2 μl TNT RNA Polymerase (T7) and 29 μl nuclease-free water. The reaction
was incubated at 30°C for 2 hours.
PBF was expressed as a fusion protein with glutathione-S-transferase (GST) from
a pGEX plasmid (Amersham) as described previously (Turnell et al., 2000). Along
with a GST-only control, 20 μg GST-tagged PBF protein were combined with 10 μl
L-α-[35S]methionine-labelled NIS protein and incubated for 1 hour on ice. Following
the addition of 400 μl low-salt buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1%
NP-40), 40 μl of packed glutathione agarose beads were added to each reaction, which
was subsequently incubated with end-over-end mixing using a rotator for 90 minutes
at 4°C. After washing with the low-salt buffer, bound GST-PBF protein was eluted
with 40 μl of 25 mM glutathione in 50 mM Tris-HCl, pH 8, on ice for 1 hour. The
protein samples were then analysed by SDS-PAGE, using a 12% acrylamide gel,
along with 1 μl L-α-[35S]methionine-labelled NIS protein in 20 μl Laemmli sample
buffer with 5% (v/v) β-mercaptoethanol, used as a control demonstrating 10% input.
Following electrophoresis, the gel was fixed and stained. The gel was then immersed
in Amplify Fluorographic Reagent (Amersham Biosciences, Little Chalfont,
Buckinghamshire, UK) to increase the sensitivity of signal detection, dried at 65°C
for 2 hours and, finally exposed to autoradiographic film at –20°C.
Coimmunoprecipitation assays
COS-7 cells in T25 flasks were transiently transfected with either NIS-MYC and
pCI-neo (VO), PBF-HA and pcDNA3.1+ (VO) or NIS-MYC and PBF-HA. Cells
were harvested in 500 μl RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1%
v/v Igepal CA-630, 6 mM sodium deoxycholate, 1 mM EDTA) containing protease
inhibitor cocktail (Sigma, Poole, Dorset, UK). After a brief sonication step, cell lysates
were centrifuged at 15,700 g for 20 minutes and transferred to a clean Eppendorf.
Each lysate was incubated with 12.5 μl mouse monoclonal anti-Myc-Tag (9B11)
antibody at 4°C overnight with end-over-end rotation. Following the addition of 25 μl
packed beads prepared from Protein-G-Sepharose 4 Fast Flow (Amersham), the
samples were incubated for a further 2 hours at 4°C with end-over-end rotation. An
antibody-only control consisting of 12.5 μl anti-Myc antibody and 25 μl packed beads
in 500 μl RIPA buffer was also established. Protein-G-Sepharose beads were
centrifuged and, following the removal of any unbound protein, washed four times
with 500 μl RIPA buffer. Bound protein was eluted in 50 μl Laemmli Sample Buffer
(Bio-Rad Laboratories, Hercules, CA) containing 5% (v/v) β-mercaptoethanol and
1% (w/v) SDS at 37°C for 30 minutes.
Proteins were separated by SDS-PAGE using a 15% acrylamide gel and transferred
to polyvinylidene difluoride membrane. The membrane was blocked with 5% milk
in TBS containing 0.025% Tween 80 and PBF-HA protein was probed with rabbit
polyclonal anti-HA (Y-11) antibody at a concentration of 1:1000 in blocking buffer.
Following incubation with Protein-G-HRP (Bio-Rad), the antigen-antibody complexes
were detected using the ECL-Plus chemiluminescence detection system (Amersham).
Total protein cell lysate (20 μg) taken before the coimmunoprecipitation steps was
also separated by SDS-PAGE using 7.5% and 15% acrylamide gels to probe for NIS-
MYC and PBF-HA, respectively. PBF-HA was probed in the same way as the
coimmunoprecipitation samples and NIS-MYC detected with mouse anti-Myc
antibody at a concentration of 1:1000 with 650 ng/ml HRP-conjugated polyclonal
rabbit anti-mouse immunoglobulins (Dako) as secondary antibody. β-actin expression
was assessed as a loading control for each protein.
The reciprocal experiment was performed in the same way by precipitating PBF-
HA with 12.5 μl mouse monoclonal anti-HA.11 antibody (Covance Research
Products) and probing for coimmunoprecipitated NIS-MYC with mouse monoclonal
anti-Myc-Tag (9B11) antibody.
Cell-surface biotinylation
In each of four T75 flasks, NIS-HA and either pCI-neo (VO) or PBF plasmids were
transiently transfected into COS-7 cells. 48 hours after transfection, the Cell Surface
Protein Isolation Kit (Pierce, Rockford, IL) was used as recommended to biotinylate
and isolate membrane-associated proteins. Briefly, cells were rinsed with PBS and
exposed to EZ-Link Sulfo-NHS-SS-Biotin for 30 minutes at 4°C. This biotinylation
reagent labels primary amines in extracellular regions of membrane-bound proteins.
A quenching solution was added to prevent further biotinylation and the cells from
each set of four flasks were scraped into solution and combined. Cells were rinsed
with Tris-buffered saline (TBS) and lysed in buffer containing protease inhibitor
cocktail (Sigma). Cells were disrupted by intermittent sonication and vortexing during
a 30 minute incubation on ice. The lysate was centrifuged and 100 μl of the supernatant
was retained as whole cell lysate.
Immobilised Neutravidin gel was applied to a column and washed with wash buffer.
The remaining cell lysate was transferred to the column and incubated with end-
over-end mixing using a rotator for 1 hour at room temperature to allow the
biotinylated proteins within the lysate to bind the avidin-coated beads. Any unbound
proteins were removed from the column by centrifugation, and the beads were rinsed
thoroughly with wash buffer containing protease inhibitors. SDS-PAGE sample buffer
(62.5 mM Tris-HCl, pH 6.8, 1% SDS, 10% glycerol) containing 50 mM DTT was
added to the column and incubated for 1 hour at room temperature with end-over-
end mixing to release protein bound to the avidin beads. The isolated membrane
proteins were then eluted from the column by centrifugation.
The membrane protein fractions were analysed by immunoblotting. Trace
amounts of bromophenol blue were added to 40 μl of each fraction which were
denatured through incubation at 37°C for 30 minutes. Proteins were separated by
SDS-PAGE using a 12% acrylamide gel and NIS protein was probed with mouse
monoclonal anti-HA.11 antibody at a concentration of 1:1000, followed by
secondary antibody, 650 ng/ml HRP-conjugated polyclonal rabbit anti-mouse
immunoglobulins (Dako). Membranes were subsequently re-probed with mouse
monoclonal anti-flotillin-1 antibody (BD Biosciences, Franklin Lakes, NJ) at 1:1000
to determine equal protein loading. Experiments were carried out on three separate
occasions, and scanning densitometry used to quantify mean changes in expression
versus flotillin controls.
Iodide-uptake assays
Iodide-uptake assays were undertaken to assess endogenous NIS function. 24 hours
after transfection with either VO, PBF, M1, M2 or M3 plasmids, NaI with a final
concentration of 10–6 moles/l and 0.05 μCi 125I was added directly to FRTL-5 cell
medium in each well. After 1 hour of incubation at 37°C to allow uptake of 125I into
the cells, medium was removed and cells were washed rapidly with Hank’s balanced
salt solution (HBSS) to remove unincorporated iodide. Cells were lysed in 200 μl of
2% SDS and the radioactivity of the lysate was counted for 1 minute in a gamma
counter.
Exogenous NIS function in COS-7 cells was also assessed following the transient
transfection of NIS-HA cDNA. 48 hours after transfection, cells were incubated with
NaI with a final concentration of 10–5 moles/l and 0.15 μCi 125I and iodide uptake
determined in a similar manner to the FRTL-5 cells.
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